<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>393</serviceExecutionTime><Trial id="109272"><TitleDisplay>A double-blind, multicenter, placebo-controlled, randomized study to determine the efficacy and safety of once-daily versus twice-daily dosing with fluvastatin in primary hypercholesterolemia</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="174">Hypercholesterolemia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fluvastatin</Name><Drug id="3160">fluvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3160">fluvastatin</Drug><IndicationsPioneer/><Companies><Company><Company id="20534">Baylor College of Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3160" type="Drug"><TargetEntity id="129568" type="siDrug">Fluvastatin sodium</TargetEntity></SourceEntity><SourceEntity id="20534" type="Company"><TargetEntity id="5035456284" type="organizationId">Baylor College of Medicine</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"/><TargetEntity id="D006937" type="MeSH"/><TargetEntity id="-1478187279" type="omicsDisease"/><TargetEntity id="969" type="siCondition"/></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20534">Baylor College of Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="71">Antihypercholesterolemic agent</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>207</PatientCountEnrollment><PatientCountEvaluable>207</PatientCountEvaluable><DateStart>1994-11-14T00:00:00Z</DateStart><DateChangeLast>2013-02-12T03:42:27Z</DateChangeLast><DateAdded>2013-02-12T03:42:27Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with primary hypercholesterolemia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a double-blind, multicenter, placebo-controlled, randomized study to determine the efficacy and safety of once-daily versus twice-daily dosing with &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; in primary hypercholesterolemia [&lt;ulink linkType="Reference" linkID="1359294"&gt;1359294&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 1994, results showed that &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt; was effective and well tolerated at 20 mg/d given in either one or two doses  [&lt;ulink linkType="Reference" linkID="1359294"&gt;1359294&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt;  20 mg p.o. o.d. x 6 weeks (n = 70); &lt;ulink linkType="Drug" linkID="3160"&gt;fluvastatin&lt;/ulink&gt;, 10 mg p.o. b.i.d. x 6 weeks (n = 69); placebo (n = 68)  [&lt;ulink linkType="Reference" linkID="1359294"&gt;1359294&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-12T03:42:27Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="110623"><TitleDisplay>Efficacy of Albuterol Spiromax in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)</TitleDisplay><TitleOfficial>A Single-Dose Study to Assess the Efficacy of Albuterol Spiromax in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ABS-AS-302</Identifier><Identifier type="NCT">NCT01791972</Identifier></Identifiers><Indications><Indication id="559">Bronchus disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1905" role="Toxic effect marker" type="Physiological">Peak expiratory flow rate</BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>salbutamol MDI, IVAX Corp</Name><Drug id="48938">salbutamol MDI, IVAX Corp</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="48938">salbutamol MDI, IVAX Corp</Drug><IndicationsPioneer><Indication id="559">Bronchus disease</Indication></IndicationsPioneer><Companies><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20348" type="Company"><TargetEntity id="4295875158" type="organizationId">Teva Pharmaceutical Industries Ltd</TargetEntity></SourceEntity><SourceEntity id="559" type="ciIndication"><TargetEntity id="10064913" type="MEDDRA"/><TargetEntity id="D001982" type="MeSH"/></SourceEntity><SourceEntity id="40" type="Action"><TargetEntity id="60" type="Mechanism">beta2-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="20348">Teva Pharmaceutical Industries Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="40">Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="646">Bronchodilator</Class></Class><Technologies><Technology id="616">Inhalant formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="618">Powder formulation inhalant</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>38</PatientCountEnrollment><PatientCountEvaluable>38</PatientCountEvaluable><DateStart>2013-03-31T00:00:00Z</DateStart><DateEnd type="actual">2013-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-12T11:11:13Z</DateChangeLast><DateAdded>2013-02-20T09:30:46Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Informed consent/assent: for patients age between 18 and 50 years, inclusive, written             informed consent signed and dated by the patient before conducting any study related             procedures and review of health insurance portability and accountability Act of 1996             (HIPAA) authorization; for patients age between 12 and 17 years, inclusive, written             informed consent signed and dated by the parent/legal guardian and written assent             signed and dated by the patient before conducting any study related procedure and             review of HIPAA authorization&lt;/li&gt;&lt;li&gt;Male or female patients 12 to 50 years of age, inclusive, as of screening visit 1 (SV1)&lt;/li&gt;&lt;li&gt;If female, is currently not pregnant, breastfeeding, or attempting to become             pregnant, has a negative serum pregnancy test, and is of non-childbearing potential&lt;/li&gt;&lt;li&gt;Documented history of Exercise-Induced Bronchoconstriction (EIB; &gt;/= 20% fall from pre-exercise challenge FEV1), with or without underlying asthma. The underlying asthma             must be well-controlled (in the investigators judgment) as per the National Asthma             Education and Prevention Program, Expert Panel Report (NAEPP, EPR-3)&lt;/li&gt;&lt;li&gt;Other criteria apply&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Requires a rescue bronchodilator following the exercise challenge at SV1 for a             decrease in FEV1 that does not return to within 20% of their pre-exercise challenge             FEV1 within 30 min after administration of the rescue medication&lt;/li&gt;&lt;li&gt;Pregnant, nursing, or plans to become pregnant or donate gametes (ova or sperm) for             in vitro fertilization during the study period or for 30 days after the patients             last study related visit (for eligible patients only-if applicable)&lt;/li&gt;&lt;li&gt;Participation in any investigational drug trial within the 30 days preceding SV1 or             planned participation in another investigational drug trial at any time during this             trial&lt;/li&gt;&lt;li&gt;A known hypersensitivity to albuterol or any of the excipients in the formulation&lt;/li&gt;&lt;li&gt;History of severe milk protein allergy&lt;/li&gt;&lt;li&gt;History of a respiratory infection or disorder (including, but not limited to             bronchitis, pneumonia, otitis media, acute or chronic sinusitis, influenza, etc) that             has not resolved within the 2 weeks preceding SV1&lt;/li&gt;&lt;li&gt;Other criteria apply&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum percentage fall from baseline in forced expiratory volume in 1 s (FEV1) up to 60 min after the exercise challenge: A centralized spirometry data collection system was used to reduce FEV1 variability between and within patients and between each participating study center. The percentage fall was defined as 100*(baseline-post baseline)/baseline. The baseline FEV1 is the test day FEV1 measured 5 minutes before the exercise challenge (30 minutes postdose). FEV1 post exercise challenge were measured 5 (±5), 10 (±5), 15 (±5), 30 (±5), and 60 (±10) minutes after completion of the exercise challenge. The exercise challenge consisted of the participant running on a motor-driven treadmill (with adjustable speed and incline). The treadmill was set at a speed and incline sufficient to increase the participant's heart rate to ≥80% of the maximum rate for age (220 bpm-age in years) for a period of either 6, 7, or 8 min</Description><Timeframe>Days 1 and 7: up to 60 min post-exercise challenge</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Percentage of patients whose maximum percentage decrease from the baseline FEV1 post-exercise challenge is &lt; 10%: Participants were classified as protected if the maximum percentage decrease from baseline FEV1 after exercise was less than 10%. Data represents the percentage of participants who were classified as protected</Description><Timeframe>Days 1 and 7: up to 60 min post-exercise challenge</Timeframe></Measure><Measure><Description>Percentage of patients whose maximum percentage decrease from the baseline FEV1 post-exercise challenge is &gt; 20%: Participants were classified as unprotected if the maximum percentage decrease from baseline FEV1 after exercise was more than 20%. Data represents the number of participants who were classified as unprotected</Description><Timeframe>Days 1 and 7: up to 60 min post-exercise challenge</Timeframe></Measure><Measure><Description>Safety parameters: safety will be monitored throughout the study by obtaining physical examinations, vital signs, ECGs, peak expiratory flow rates (PEFs), and the occurrence of adverse events</Description><Timeframe>From signing of the informed consent to the end of study (approximately 5 weeks)</Timeframe></Measure><Measure><Description>Time to recovery from exercise challenge completion to the first measured post-challenge FEV1 within 10% of the pre-challenge baseline FEV1</Description><Timeframe>From exercise challenge completion to the first measured post-challenge FEV1 within 10% of the pre-challenge baseline FEV1</Timeframe></Measure><Measure><Description>FEV1: measured at 30 min post-dose, 5 min before treadmill exercise challenge (baseline) and 5, 10, 15, 30 and 60 min after exercise challenge</Description><Timeframe>At 30 min post-dose, 5 min before treadmill exercise challenge (baseline) and 5, 10, 15, 30 and 60 min after exercise challenge</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In November 2014, results were published. The safety profile of the drug was comparable to both placebo and consistent with the characterized profile of &lt;ulink linkType="Drug" linkID="44310"&gt;salbutamol&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1609861"&gt;1609861&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2014, results were presented. Adverse events included one case of severe migraine in the placebo group and one case of moderate sinus bradycardia in the &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; group; no serious adverse events, discontinuations due to adverse events or deaths were reported in either group [&lt;ulink linkType="Reference" linkID="1617550"&gt;1617550&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, results were published. The treatment with a single dose of Albuterol Spiromax multidose dry powder inhaler (MDPI) was well tolerated [&lt;ulink linkType="Reference" linkID="1716694"&gt;1716694&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study was to evaluate the efficacy of a single dose (two inhalations, 180 microg total) of  &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; (90 microg per inhalation) versus placebo in      patients with Exercise-Induced Bronchoconstriction (EIB). &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2014, results were presented. In the respective groups of &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; and placebo,  the reported  mean maximum percentage decline in FEV1 within 60 min after exercise was 6.21 versus 22.38% (p &amp;lt; 0.0001), with a &amp;lt; 10% decline in 84.2 versus15.8% of patients on &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; versus placebo. &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; provided significant protection (p &amp;lt; 0.001) over placebo within 5 min, which was maintained for 30 min, with a median time to recovery of 5.07 and 30.07 min (p &amp;lt; 0.0001) for &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; and placebo, respectively (both groups recovered within 60 min)  [&lt;ulink linkType="Reference" linkID="1617550"&gt;1617550&lt;/ulink&gt;].  Similar results were published in November 2015 [&lt;ulink linkType="Reference" linkID="1716694"&gt;1716694&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study was a single-dose, randomized, double-blind, placebo-controlled, two-treatment,      two-sequence, two-way crossover, multicenter study in patients with a documented history of Exercise-Induced Bronchoconstriction (EIB),      with or without underlying asthma. Each patient would participate in the study for      approximately 5 weeks. Each patient would complete two screening visits (SV1 and SV2), two      treatment visits (TV1 and TV2), and a follow-up telephone call (FV).&lt;br/&gt;This study would consist of two treatment groups:&lt;br/&gt;Treatment group 1: patients would receive single-dose of 90 microg/inhalation &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; (two inhalatons) during TV1 and placebo  during   TV2.&lt;br/&gt;Treatment group 2: patients would receive placebo  during TV1 and 90 microg/inhalation &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; (single-dose; two inhalatons) during   TV2.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive &lt;ulink linkType="Drug" linkID="48938"&gt;Albuterol Spiromax&lt;/ulink&gt; (180 microg) followed by placebo, or the reverse sequence (n = 19 in each group) [&lt;ulink linkType="Reference" linkID="1617550"&gt;1617550&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1716694"&gt;1716694&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>salbutamol MDI, IVAX Corp</Name><Drug id="48938">salbutamol MDI, IVAX Corp</Drug><Dose unit="microgram dose">180.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="412">Bradycardia</Indication><CountPatientsTotal>38</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="266615">salbutamol MDI, IVAX Corp</Intervention><Treatments><Treatment><Dose>180 microgram</Dose><Route>Inhalant</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Teva Investigational Site 10555</Name><Address1>Denver</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 10556</Name><Address1>Raleigh</Address1><Address2>North Carolina</Address2><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 10557</Name><Address1>San Diego</Address1><Address2>California</Address2><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 10558</Name><Address1>Denver</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 10559</Name><Address1>Wheaton</Address1><Address2>Maryland</Address2><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Teva Investigational Site 10560</Name><Address1>North Dartmouth</Address1><Address2>Massachusetts</Address2><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Asthma</Disease><PatientSegments><PatientSegment><PatientSegment id="3310">Subjects with Levels of Asthma Control</PatientSegment><SubSegments><SubSegment id="3311">Subjects with controlled asthma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="23861">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="3301">Subjects with Exercise Induced Asthma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01791972</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="5939"><Endpoint>Assessment of Forced Expiratory Volume in One Second (FEV1)</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5941">Change from baseline in FEV1</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Asthma" id="5933"><Endpoint>Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="5939"><Endpoint>Assessment of Forced Expiratory Volume in One Second (FEV1)</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="5942">Change in FEV1 after challenge test</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6049"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6082"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6083">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6088"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Asthma" id="6093"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="2691"><Criterion>Subjects with Other Specific Type of Asthma</Criterion><SubCriteria><SubCriterion disease="Asthma" id="2695">Subjects with exercise induced asthma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Asthma" id="2717"><Criterion>Subjects with Levels of Asthma Control</Criterion><SubCriteria><SubCriterion disease="Asthma" id="2718">Subjects with controlled asthma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="3839"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Asthma" id="3951"><Criterion>Subjects with Asthma Exacerbations</Criterion></Exclusion><Exclusion disease="Asthma" id="20245"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Asthma" id="20252"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20253">Subjects with contraindication to drugs or its excipients</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-05-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.03 Months</EnrollmentPeriod><EnrollmentRate>18.72 Patients/Month</EnrollmentRate><DateFirstReceived>2013-02-12T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-20T09:30:46Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-11-11T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="114750"><TitleDisplay>An Open-Label Study To Assess Safety And Efficacy Of Temozolomide In Melanoma</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="3257">Stage IV melanoma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>aldesleukin</Name><Drug id="6306">aldesleukin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>interferon alfa-2b</Name><Drug id="45998">interferon alfa-2b</Drug></Intervention><Intervention type="InterventionPrimary"><Name>molgramostim</Name><Drug id="3648">molgramostim</Drug></Intervention><Intervention type="InterventionPrimary"><Name>temozolomide</Name><Drug id="4529">temozolomide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3648">molgramostim</Drug><IndicationsPioneer><Indication id="3257">Stage IV melanoma</Indication></IndicationsPioneer><Companies><Company><Company id="28887">Netherlands Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4529">temozolomide</Drug><IndicationsPioneer/><Companies><Company><Company id="28887">Netherlands Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="45998">interferon alfa-2b</Drug><IndicationsPioneer/><Companies><Company><Company id="28887">Netherlands Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6306">aldesleukin</Drug><IndicationsPioneer/><Companies><Company><Company id="28887">Netherlands Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4529" type="Drug"><TargetEntity id="108485" type="siDrug">Temozolomide</TargetEntity></SourceEntity><SourceEntity id="6306" type="Drug"><TargetEntity id="155417" type="siDrug">Aldesleukin</TargetEntity></SourceEntity><SourceEntity id="45998" type="Drug"><TargetEntity id="165805" type="siDrug">Interferon alfa-2b</TargetEntity></SourceEntity><SourceEntity id="3648" type="Drug"><TargetEntity id="180638" type="siDrug">Molgramostim</TargetEntity></SourceEntity><SourceEntity id="28887" type="Company"><TargetEntity id="5000062150" type="organizationId">Stichting Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis</TargetEntity></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"/><TargetEntity id="708" type="siCondition"/></SourceEntity><SourceEntity id="917" type="Action"><TargetEntity id="1953" type="Mechanism">Interferon alpha Receptor (IFNAR) Ligands</TargetEntity><TargetEntity id="2945" type="Mechanism">IFN-alpha Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="28887">Netherlands Cancer Institute</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="12481">Interleukin-2 ligand</Action><Action id="410">GM-CSF receptor agonist</Action><Action id="420">CSF-1 agonist</Action><Action id="917">Interferon alpha ligand modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15190">Systemic dermatological antiviral product</Class><Class id="1545">Anticancer</Class><Class id="50">Anticancer alkylating agent</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="740">Infusion</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>74</PatientCountEnrollment><PatientCountEvaluable>74</PatientCountEvaluable><DateStart>2003-01-27T00:00:00Z</DateStart><DateChangeLast>2013-03-08T07:29:26Z</DateChangeLast><DateAdded>2013-03-08T07:29:26Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Outpatients with metastatic melanoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this open-label study was to assess safety and efficacy of &lt;ulink linkType="Drug" linkID="4529"&gt;temozolomide&lt;/ulink&gt; in melanoma [&lt;ulink linkType="Reference" linkID="1376696"&gt;1376696&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2003, results were published. Oral &lt;ulink linkType="Drug" linkID="4529"&gt;temozolomide&lt;/ulink&gt; followed by subcutaneous immunotherapy with &lt;ulink linkType="Drug" linkID="6306"&gt;aldesleukin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="45998"&gt;interferon alfa2b&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3648"&gt;molgramostim&lt;/ulink&gt; rescue showed efficacy in advanced, metastatic melamona, and had manageable toxicity in outpatients [&lt;ulink linkType="Reference" linkID="1376696"&gt;1376696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="4529"&gt;temozolomide&lt;/ulink&gt;, 150-250 mg/m2 p.o. x 5 d followed by &lt;ulink linkType="Drug" linkID="6306"&gt;aldesleukin&lt;/ulink&gt;, 4 MIU/m2 s.c. + &lt;ulink linkType="Drug" linkID="3648"&gt;molgramostim&lt;/ulink&gt;, 2.5 microg/kg s.c. + &lt;ulink linkType="Drug" linkID="45998"&gt;Interferon alfa2b&lt;/ulink&gt;, 5 MIU s.c. x 12 d [&lt;ulink linkType="Reference" linkID="1376696"&gt;1376696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-08T07:29:26Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="126393"><TitleDisplay>A randomized, phase III study of docetaxel in combination with sunitinib versus docetaxel in the first-line treatment of advanced breast cancer patients</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UKCRN 2606</Identifier><Identifier type="Trial Acronym">NCRN004</Identifier></Identifiers><Indications><Indication id="3657">Metastatic breast cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sunitinib</Name><Drug id="12973">sunitinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12973">sunitinib</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2953" type="Drug"><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity></SourceEntity><SourceEntity id="12973" type="Drug"><TargetEntity id="309144" type="siDrug">Sunitinib malate</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="48489" type="Action"><TargetEntity id="1650" type="Mechanism">PDGFRalpha Inhibitors</TargetEntity><TargetEntity id="2517" type="Mechanism">Anti-CD140a (PDGFRalpha)</TargetEntity><TargetEntity id="5666" type="Mechanism">PDGFRalpha (Asp842Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18767">Pfizer Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3154">CSF-1 antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="48489">PDGF receptor alpha antagonist</Action><Action id="48492">PDGF receptor beta antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>550</PatientCountEnrollment><DateStart>2007-02-27T00:00:00Z</DateStart><DateChangeLast>2013-09-25T09:37:27Z</DateChangeLast><DateAdded>2013-05-04T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>National Cancer Research Network Coordinating Centre (ncrn) Arthington House Hospital Lane Leeds West Yorkshire Ls16 6qb United Kingdom</Affiliation><Email>industry@ncrn.org.uk ,</Email><Name>David Cameron</Name><Phone>0113 392 4093,</Phone></Contact><Contact type="Public contact"><Affiliation>National Cancer Research Network Coordinating Centre (ncrn) Arthington House Hospital Lane Leeds West Yorkshire Ls16 6qb United Kingdom</Affiliation><Email>industry@ncrn.org.uk</Email><Name>Matthew Cooper</Name><Phone>0113 392 4093</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically/cytologically proven breast cancer with unresectable locally recurrent or metastatic disease&lt;/li&gt;&lt;li&gt;Her-2 negative, measurable disease&lt;/li&gt;&lt;li&gt;Must have received prior adjuvant/neo-adjuvant anthracycline based therapy (if neo-adjuvant included a taxane, relapse must have occurred &gt; 12 months since completion of treatment)&lt;/li&gt;&lt;li&gt;Candidate for treatment with&lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Female, 18 or older&lt;/li&gt;&lt;li&gt;ECOG PS 0 or 1&lt;/li&gt;&lt;li&gt;Resolution of all toxic effects&lt;/li&gt;&lt;li&gt;Adequate organ function, including LVEF by MUGA/ECHO&lt;/li&gt;&lt;li&gt;Signed and dated consent and willingness to comply with visits etc&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Inflammatory carcinoma&lt;/li&gt;&lt;li&gt;Prior chemotherapy in the metastatic setting&lt;/li&gt;&lt;li&gt;Patients for whom&lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; is contraindicated &lt;/li&gt;&lt;li&gt;History of hypersensitivity to drugs formulated with polysorbate 80 -Diagnosis of second malignancy within three years&lt;/li&gt;&lt;li&gt;AST and/or ALT&amp;gt; 1.5 x ULN concomitant with ALP &amp;gt; 2.5 x ULN &lt;/li&gt;&lt;li&gt;Prior radiation to&amp;gt; 25% bone marrow &lt;/li&gt;&lt;li&gt;Major surgery, radiation therapy or systemic therapy within 3 weeks of start of study treatment&lt;/li&gt;&lt;li&gt;Prior high dose chemotherapy requiring stem cell rescue&lt;/li&gt;&lt;li&gt;Brain mets, spinal cord compression, carcinomatous meningitis, leptomeningeal disease&lt;/li&gt;&lt;li&gt;Any of the following within 12 months: MI, severe unstable angina, coronary/peripheral artery bypass, congestive heart failure, CVA inc TIAs, pulmonary embolus&lt;/li&gt;&lt;li&gt;Ongoing cardiac dysrhythmias of&amp;gt; grade 2, or QTc interval of &amp;gt; 470 ms&lt;/li&gt;&lt;li&gt;Known HIV infection&lt;/li&gt;&lt;li&gt;Current treatment with coumadin (&gt; 2 mg daily) -Pregnancy/breastfeeding, unwilling to use contraception&lt;/li&gt;&lt;li&gt;Other severe acute or chronic condition that may affect participation&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>To study the combination of docetaxel with sunitinib versus docetaxel in the first-line treatment of advanced breast cancer patients</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Thepurpose of this trial was to study the combination of &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt; versus &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; in the first-line treatment of advanced breast cancer patients [&lt;ulink linkType="Reference" linkID="1414402"&gt;1414402&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either  combination of &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt; versus &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; alone [&lt;ulink linkType="Reference" linkID="1414402"&gt;1414402&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts/></Site><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3937">Subjects with HER-2 Negative Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3954">Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3956">Subjects with Un-resectable/Non-operable Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3966">Subjects with Relapsed/Recurrent Breast cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries/><OutcomeMeasureTerms/><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4814"><Criterion>Subjects with HER-2 Negative Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4840"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4856"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4879">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Breast tumor" id="4880">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4923"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22416"><Criterion>Subjects with Unresectable Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22517"><Criterion>Subjects with History of/Scheduled for Diagnostic Procedures</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="22523">Subjects scheduled for imaging/mammography</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6272"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6328"><Criterion>Subjects with History of/Scheduled for Anti-neoplastic Therapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6377"><Criterion>Subjects with history of/planned radiotherapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="17557"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26402"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6245">Subjects with Inflammatory Breast cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26891"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20290">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="129601"><TitleDisplay>Evaluation of therapeutic efficacy and therapeutic biomarker in dry eye with rebamipide eye drop treatment</TitleDisplay><TitleOfficial>Study on evaluation of therapeutic efficacy and search for a therapeutic biomarker in dry eye with rebamipide eye drop treatment</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000009371</Identifier></Identifiers><Indications><Indication id="3016">Xerophthalmia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rebamipide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>hyaluronate sodium</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1079455" type="Company"><TargetEntity id="5038074155" type="organizationId">Nihon University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="3016" type="ciIndication"><TargetEntity id="H04.12" type="ICD10"/><TargetEntity id="10048221" type="MEDDRA"/><TargetEntity id="D014985" type="MeSH"/><TargetEntity id="-455555105" type="omicsDisease"/><TargetEntity id="773" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1079455">Nihon University School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>55</PatientCountEnrollment><DateStart>2012-12-01T00:00:00Z</DateStart><DateEnd type="actual">2015-07-01T00:00:00Z</DateEnd><DateChangeLast>2016-11-26T14:11:19Z</DateChangeLast><DateAdded>2013-05-15T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Nihon University School Of Medicine, Division Of Ophthalmology, Department Of Visual Sciences; Oyaguchikamimachi 30-1, Itabashi-ku, Tokyo, Japan</Affiliation><Email>shojig3589eye@athena.ocn.ne.jp</Email><Name>Jun Shoji</Name><Phone>+81-3-3972-8111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with dry eye:&lt;ul&gt;&lt;li&gt;Male or female of age of 20 years or older&lt;/li&gt;&lt;li&gt;Patients who provided written informed consent for participating in this study&lt;/li&gt;&lt;li&gt;Patients who are diagnosed as dry eye according to the Japan dry eye diagnostic criteria in 2006&lt;/li&gt;&lt;li&gt;Patients with VAS score of 50 or greater in at least one item in symptom&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Non-dry eye patients:&lt;ul&gt;&lt;li&gt;Male or female of age of 20 years or older&lt;/li&gt;&lt;li&gt;Patients, who are visiting the hospital for existing ocular disease other than anterior segment disease, do not have abnormal findings in anterior segment, and are not receiving treatment with eye drops or contact lens&lt;/li&gt;&lt;li&gt;Patients with VAS score&amp;lt; 50 in all items for symptom&lt;/li&gt;&lt;li&gt;Patients who understood the purpose of this study and from whom written consent was obtained&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with dry eye:&lt;ul&gt;&lt;li&gt;Patients with anterior segment disease (including blepharitis, lagophthalmos, blepharospasm, iritis and conjunctivochalasis) other than dry eye (History is excluded)&lt;/li&gt;&lt;li&gt;Patients who cannot discontinue eye drops (include all eye drops such as prescribed drug and OTC medicine) except for the study drug or the control drug from the study initiation until the end of study treatment or who expect to use those drugs&lt;/li&gt;&lt;li&gt;Patients with punctal plug or patients whose punctal plug fell off within three months prior to the study drug initiation examination. Patients with a history ofsurgical punctual occlusion are also excluded&lt;/li&gt;&lt;li&gt;Patients with a history of surgery of the ocular surface within 12 months, or patients with a history of intraocular surgery within three months prior to the study drug initiation examination&lt;/li&gt;&lt;li&gt;Patients who have difficulty in sampling&lt;/li&gt;&lt;li&gt;Patients that a study supervisor or a study partaker judged participation in this study to be inappropriate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Non-dry eye patients:&lt;ul&gt;&lt;li&gt;Patients with anterior segment disease&lt;/li&gt;&lt;li&gt;Patients who used eye drops or the contact lens within 2 weeks prior to study initiation&lt;/li&gt;&lt;li&gt;Patients with a history of surgery of the ocular surface within 12 months or patients with a history of intraocular surgery within 3 months prior to the study drug initiation examination&lt;/li&gt;&lt;li&gt;Patients who have difficulty in sampling&lt;/li&gt;&lt;li&gt;Patients that a study supervisor or a study partaker judged participation in this study to be inappropriate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Comparison of therapeutic effect of dry eye between rebamipide eye drop and hyaluronate sodium eye drop using biomarker in tears</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Investigation of biomarker in tears that is useful for dry eye practice by comparing patients with dry eye and non-dry eye patients</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to investigate the usefulness of rebamipide eyedrop in dry eye treatment and utility of biomarker in tears to measure the therapeutic effect in dry eye patients [&lt;ulink linkType="Reference" linkID="1419214"&gt;1419214&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with dry eye (+) would receive rebamipide eye drop (+) sodium hyaluronate eye drop (-) or rebamipide eye drop (-), sodium hyaluronate eye drop (+)or patients with Dry eye (-) would receive rebamipide eye drop (-) sodium hyaluronate eye drop (-)&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>The University of Tokyo Medical School is affiliated to Tohoku Hospital</Name><Address1>oTkyo Metropolitan Government</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Xerophthalmia</Disease><PatientSegments><PatientSegment><PatientSegment id="11383">Subjects with Aqueous Tear Deficient Dry Eye(ADDE)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11386">Subjects with Evaporative Dry Eye(EDE)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000009371</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Xerophthalmia" id="16700"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Xerophthalmia" id="16700"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Xerophthalmia" id="15082"><Criterion>Subjects with Aqueous Tear Deficient Dry Eye(ADDE)</Criterion></Inclusion><Inclusion disease="Xerophthalmia" id="15087"><Criterion>Subjects with Evaporative Dry Eye(EDE)</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Xerophthalmia" id="14017"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Xerophthalmia" id="14030"><Criterion>Subjects with History of/Scheduled for Ocular Therapy</Criterion><SubCriteria><SubCriterion disease="Xerophthalmia" id="14031">Subjects with history of/scheduled for ocular drug</SubCriterion><SubCriterion disease="Xerophthalmia" id="14032">Subjects with history of/scheduled for ocular procedures</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="143783"><TitleDisplay>Multicenter Trial of Treatment of Transient Hypothyroxinemia in Children &lt;/= 1000 g Birth Weight or &lt;/= 28 Weeks Gestation and Psychomotor Development Up to Five Years of Life</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">EUCTR2004-004314-16-ES</Identifier><Identifier type="Secondary Organisational">1 R01 NS45109-01A1</Identifier><Identifier type="Secondary Organisational">1 R01 NS45109-</Identifier></Identifiers><Indications><Indication id="2775">Hypothyroxinemia</Indication></Indications><BiomarkerNames><BiomarkerName id="646" role="Therapeutic effect marker" type="Proteomic">Thyroid-stimulating hormone</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>levothyroxine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>liothyronine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1085750" type="Company"><TargetEntity id="5040055499" type="organizationId">Instituto Nacional de Trastornos Neurologicos y Accidentes Cerebrovasculares</TargetEntity></SourceEntity><SourceEntity id="2775" type="ciIndication"><TargetEntity id="4753" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1085750">NINDS Clinical Research Collaboration</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2005-04-25T00:00:00Z</DateStart><DateChangeLast>2017-07-06T16:14:29Z</DateChangeLast><DateAdded>2013-07-02T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The target population for this treatment is infants born prior to 28 completed weeks of gestation. All neonates admitted to the three clinical study sites (NY, Amsterdam, Madrid) will be screened for eligibility, regardless of ethnicity, race, nationality, religion, creed or gender&lt;/li&gt;&lt;li&gt;Patient eligibility:&lt;ul&gt;&lt;li&gt;All neonates&amp;lt; 28 weeks gestational age are eligible, unless fulfilling one or more exclusion criteria. Gestational age will be based on the best estimate made by the attending neonatologist. Guidelines for study estimation of gestational age will prioritize data in the following order: &lt;ul&gt;&lt;li&gt;Fetal size on obstetrical ultrasound prior to 18 weeks&lt;/li&gt;&lt;li&gt;Maternal history of date of last menses&lt;/li&gt;&lt;li&gt;Fetal size on second trimester ultrasound&lt;/li&gt;&lt;li&gt;Progression of uterine height in pregnancy&lt;/li&gt;&lt;li&gt;Physical exam of the neonate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The study population is any neonate&amp;gt; 24 0/7 to &amp;lt; 27 6/7 weeks gestational age (and in general &amp;lt; 1000 g birth weight) based on the best consensus made by the attending neonatologist utilizing a combination of information from: the obstetrician (sonography, dates, fetal movement, etc) plus their own personal Dubowitz Scoring Physical Exam&lt;/li&gt;&lt;li&gt;Guidelines for study estimation of gestational age will prioritize data in the following order:&lt;ul&gt;&lt;li&gt;Fetal size on obstetrical ultrasound prior to 18 weeks&lt;/li&gt;&lt;li&gt;Maternal history of date of last menses&lt;/li&gt;&lt;li&gt;Fetal size on second trimester ultrasound&lt;/li&gt;&lt;li&gt;Progression of uterine height in pregnancy&lt;/li&gt;&lt;li&gt;Physical exam of the neonate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Absence of parental consent or assent of the treating physician&lt;/li&gt;&lt;li&gt;A concurrent clinical trial with another randomized drug&lt;/li&gt;&lt;li&gt;Other concern by treating physician that either mandates or prohibits study treatment&lt;/li&gt;&lt;li&gt;Gestational age out of target range 24 0/7 weeks through 27 6/7 weeks&lt;/li&gt;&lt;li&gt;Eligibility only based  on gestational age. No prior blood tests required&lt;/li&gt;&lt;li&gt;Death expected within 48 h of birth due to severity of initial cardiopulmonary disease&lt;/li&gt;&lt;li&gt;Mother of potential study subjects is a minor&amp;lt; 18 completed years old&lt;/li&gt;&lt;li&gt;Maternal-neonatal clinical or laboratory exclusions:&lt;ul&gt;&lt;li&gt;Maternal or congenital thyroid disease (if present, refer to endocrinologist at enrollment)&lt;/li&gt;&lt;li&gt;Known disorders of fatty acid metabolism&lt;/li&gt;&lt;li&gt;Congenital brain structural anomalies (eg, hydrocephalus, migration disorders, etc)&lt;/li&gt;&lt;li&gt;Liver failure (eg, enzymes in the thousands)&lt;/li&gt;&lt;li&gt;Proven sepsis at birth (clinical signs, positive body fluid culture, and antibiotic treatment&amp;gt; 5  contiguous days)&lt;/li&gt;&lt;li&gt;Major congenital malformations requiring surgery:&lt;ul&gt;&lt;li&gt;Structural congenital heart disease (eg, cyanotic heart defects&lt;/li&gt;&lt;li&gt;Anomalies of the gastrointestinal tract (eg, gastroschesis)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Known chromosomal anomalies (eg, Trisomy 21, 13  and 18)&lt;/li&gt;&lt;li&gt;Neonatal cardiac arrhythmia's causing output failure&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Exclusions based on milk or medications in breast milk:&lt;ul&gt;&lt;li&gt;Breast milk:&lt;ul&gt;&lt;li&gt;Women taking anti-thyroid medications or supplemental iodine in therapeutic doses&lt;/li&gt;&lt;li&gt;Issues of contraception are not applicable, as women do not typically receive these  medications in the first 6 weeks post-partum&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Formula:&lt;ul&gt;&lt;li&gt;Use of soy based formulas will be avoided since they are associated with prolonged increases in TSH even after treatment for congenital hypothyroidism&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Exclusions based upon drug exposures: since enrollment will be&amp;lt; 24 h postnatal age, only maternal medications are of concern:&lt;ul&gt;&lt;li&gt;Drugs that will be cause for exclusion at enrollment:&lt;ul&gt;&lt;li&gt;Thyroid drugs and iodine products at any time:  no maternal or neonatal thyroid drugs (eg, propylthiouracil, PTU); supplemental iodine from a non-dietary source (ie, table salt) will not be allowed (subjects to be excluded); povidine Iodine (excessive iodine exposure) will be cause for exclusion at enrollment since there are other skin cleansing alternatives (eg, chlorhexidine) that are not absorbed, and have no known organ toxicity&lt;/li&gt;&lt;li&gt;Substance/drug abuse: maternal alcoholism (&amp;gt; 1 ounce daily) or any use of heroin or methadone during the pregnancy are drugs that can interfere with thyroid hormone transport in serum 51&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Dosing schedules needed to achieve the optimal plasma hormone targets in the neonatal period, without increasing measures of neonatal morbidity, mortality or physiological dysfunction</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Avoidance of suppression of thyroid stimulating hormone (TSH) due to administration of thyroid hormone and to determine its effects on endogenous cortisol levels</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study was to establish the dosing schedules needed to achieve the optimal plasma hormone targets in the neonatal period, without increasing measures of neonatal morbidity, mortality or physiological dysfunction.&lt;br/&gt;The secondary objectives were:&lt;br/&gt;To avoid suppression of thyroid stimulating hormone (TSH) due to administration of thyroid hormone and to determine its effects on endogenous cortisol levels. &lt;br/&gt;To determine whether iodine background contributed to variation in thyroid status and could iodine alone produced a euthyroid state in premature infants.&lt;br/&gt;The long term objectives were:&lt;br/&gt;To demonstrate cooperation among an international consortium of five participating institutions before initiating a trial to involve about 20 clinical study sites.&lt;br/&gt;To set the stage for a large multicenter, randomized trial [&lt;ulink linkType="Reference" linkID="1446822"&gt;1446822&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be given levothyroxine or liothyronine [&lt;ulink linkType="Reference" linkID="1446822"&gt;1446822&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hypothyroidism</Disease><PatientSegments><PatientSegment><PatientSegment id="10359">Subjects with Transient Hypothyroidism</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EUCTR2004-004314-16-ES</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Hypothyroidism" id="22816"><Endpoint>Assessment of Thyroid Structure /Function </Endpoint><SubEndpoints><SubEndpoint disease="Hypothyroidism" id="22819">TSH and or thyroxine levels</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hypothyroidism" id="20091"><Criterion>Subjects with Transient Hypothyroidism</Criterion></Inclusion><Inclusion disease="Hypothyroidism" id="20099"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Hypothyroidism" id="20112"><Criterion>Protocol Specified Criteria for Inclusion of Females in Study</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hypothyroidism" id="17767"><Criterion>Subjects with Thyroid Disease</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17774"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17790"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17792"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17796"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17801"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17802"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Hypothyroidism" id="17809">Subjects on/treated with thyroid preparations</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypothyroidism" id="17815"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17819"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="17827"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Hypothyroidism" id="26282"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Hypothyroidism" id="17830">History /Scheduled for surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypothyroidism" id="28252"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Hypothyroidism" id="17817">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-07-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="163175"><TitleDisplay>Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection</TitleDisplay><TitleOfficial>A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the Combination of Gemcitabine and Metformin in Treating Patients With Pancreatic Cancer After Curative Resection</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02005419</Identifier><Identifier type="Organisational Study">MET1310128-2</Identifier></Identifiers><Indications><Indication id="249">Pancreas tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>metformin hydrochloride</Name><Drug id="6050">metformin hydrochloride</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="DOL1000375">Fudan University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="DOL1000375">Fudan University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6050">metformin hydrochloride</Drug><IndicationsPioneer><Indication id="249">Pancreas tumor</Indication></IndicationsPioneer><Companies><Company><Company id="DOL1000375">Fudan University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="6050" type="Drug"><TargetEntity id="220882" type="siDrug">Metformin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="DOL1000375" type="Company"><TargetEntity id="5001229880" type="organizationId">Fudan University</TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="8805" type="Action"><TargetEntity id="2375" type="Mechanism">AMP-Activated Protein Kinase (AMPK) Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000375">Fudan University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="8805">AMP activated protein kinase stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="38206">Biguanide antidiabetic product</Class><Class id="399">Hypoglycemic agent</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>300</PatientCountEnrollment><DateStart>2013-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-06-30T00:00:00Z</DateEnd><DateChangeLast>2016-08-12T02:06:08Z</DateChangeLast><DateAdded>2013-12-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>yuxianjun88@hotmail.com</Email><Name>Xianjun Yu, M.D., Ph.D.</Name><Phone>+86-21-6417-5590</Phone></Contact><Contact type="Scientific contact"><Affiliation>Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute，Fudan University; 270 Dong An Road, Shanghai 200032, China</Affiliation><Name>Xianjun Yu, M.D., Ph.D.</Name></Contact><Contact type="Public contact"><Email>liuliang.zlhospital@gmail.com</Email><Name>Liang Liu, M.D., Ph.D.</Name><Phone>+86-21-6417-5590</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Signed informed content obtained prior to treatment&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years and&amp;lt;/= 80 years&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&lt;/li&gt;&lt;li&gt;Patients must have histologically confirmed pancreatic adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant) after curative resection (R0). The pathological staging does not exceed the stage IIB&lt;/li&gt;&lt;li&gt;No tumor lesions are seen by abdominal and thoracic CT scan 4 to 8 weeks after surgery, and no serious adverse events are occurred during this period&lt;/li&gt;&lt;li&gt;The expected survival after surgery &gt;/= 6 months&lt;/li&gt;&lt;li&gt;White blood cell (WBC) &gt;/= 3 x 10(9)/l; Absolute neutrophil count (ANC) &gt;/= 1.5 x 10(9)/l; Platelets (PLT) &gt;/= 100 x 10(9)/l; Hemoglobin (Hgb) &gt;/= 9 g/dl&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) &amp;lt;/= 2.5 x institutional upper limit of normal (ULN); Total bilirubin (TBIL) &amp;lt;/= ULN; Creatinine (CRE) &amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;li&gt;Prothrombin time (PT) and international normalized ratio (INR)&amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;li&gt;Patients with diabetes (diagnosed after surgery) are eligible for this trial; all diabetic patients who are enrolled on this study should discuss the need to change their diabetes management regimen with their primary care physician or endocrinologist prior to enrollment&lt;/li&gt;&lt;li&gt;Diabetic patients who are on&lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; are eligible as long as they have been on &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; for &amp;lt; 6 months (estimated 6 months or less duration of &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; therapy from start of &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; to enrollment on study)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active second primary malignancy or history of second primary malignancy within the last three years&lt;/li&gt;&lt;li&gt;Patients who have received any form of anti-tumor therapy before surgery, including chemotherapy, radiotherapy, interventional chemoembolization, radiofrequency ablation, and molecular targeted therapy&lt;/li&gt;&lt;li&gt;Use of any other investigational agents&lt;/li&gt;&lt;li&gt;Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, internal hemorrhage, pancreatic leakage, bile leakage, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements&lt;/li&gt;&lt;li&gt;History of allergic reactions attributed to compounds of similar chemical or biological composition to&lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Current use of&lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; for more than 6 months prior to enrollment on study&lt;/li&gt;&lt;li&gt;Metabolic acidosis, acute or chronic, including ketoacidosis&lt;/li&gt;&lt;li&gt;Pregnant or nursing women&lt;/li&gt;&lt;li&gt;Human immunodeficiency virus (HIV)-positive patients&lt;/li&gt;&lt;li&gt;Patients who are unwilling or unable to comply with study procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Recurrence-free survival at one year after curative resection: to evaluate the therapeutic efficacy of gemcitabine chemotherapy with versus without metformin hydrochloride in terms of recurrence-free survival in patients with pancreatic cancer at one year after curative resection. Computed tomography (CT) scan</Description><Timeframe>From date of randomization (after curative resection) until the date of first documented recurrence or date of death from any cause, whichever came first, assessed 2 months during therapy and 3 months thereafter up to 24 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0: to evaluate the occurrence of grade 3 and 4 toxicities according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE; version 4.0) in patients treated with this regimen. The toxicity profile includes but not limits neutropenia, thrombocytopenia, peripheral neuropathy, hypoglycemia, metabolic acidosis (acute or chronic, including ketoacidosis), which will be summarized as the percentage of patients by type and grade according to treatment group. Outpatient visit, laboratory findings</Description><Timeframe>1 week during therapy and 3 months thereafter up to 24 months</Timeframe></Measure><Measure><Description>Overall survival after curative resection: to evaluate the overall survival of patients (after curative resection) treated with this regimen. Outpatient visit, phone interview</Description><Timeframe>From date of randomization (after curative resection) until the date of death from any cause, assessed 1 month during therapy and 3 months thereafter up to 24 months</Timeframe></Measure><Measure><Description>Quality of life score after curative resection: to evaluate the quality of life score of patients (after curative resection) treated with this regimen. Outpatient visit, phone interview</Description><Timeframe>1 month during therapy and 3 months thereafter up to 24 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study intends to investigate the activity and safety of the combination of &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;      and &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; in treating patients with pancreatic cancer that have removed by surgery.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study will  include two arms:&lt;br/&gt;Arm A: &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; plus placebo: patients will receive &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; 1000 mg/m2 (iv, 30 min) on days 1, 8 and 15 for 3 weeks, followed by 1 week without treatment,  along with placebo  (2 g: 500 mg, bid and if well tolerated, the dose will be increased to 1000 mg, bid in the 2 week) on days 1 to 28. &lt;br/&gt;Arm B: &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt;:  patients will receive &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; 1000 mg/m2 (iv, 30 min) on days 1, 8 and 15 for 3 weeks, followed by 1 week without treatment,  along with &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt;  (2 g: 500 mg, bid and if well tolerated, the dose will be increased to 1000 mg, bid in the 2 week) on days 1 to 28. &lt;br/&gt;Treatment will be repeated every 4 weeks for up to six circles in the absence of disease recurrence or unacceptable toxicity.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University</Name><Address1>Shanghai</Address1><Address3>200032</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>yuxianjun88@hotmail.com</Email><Name>Xianjun Yu, M.D., Ph.D.</Name><Phone>+86-21-6417-5590</Phone></Contact><Contact type="Facility contact backup"><Email>liuliang.zlhospital@gmail.com</Email><Name>Liang Liu, M.D., Ph.D.</Name><Phone>+86-21-6417-5590</Phone></Contact><Contact type="Facility investigator"><Name>Xianjun Yu, M.D., Ph.D.</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8071">Subjects with Localized Pancreatic Cancer</PatientSegment><SubSegments><SubSegment id="8082">TNM Stage I pancreatic cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8072">Subjects with Locally Advanced Pancreatic Cancer</PatientSegment><SubSegments><SubSegment id="8083">TNM Stage II pancreatic cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8074">Subjects with Resectable Pancreatic Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11424">Subjects with Adenocarcinoma of Pancreas</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02005419</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pancreas tumor" id="44888"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13350">Assessment of Relapse/Recurrence Free Survival</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13372"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pancreas tumor" id="8812"><Criterion>TNM Stage I pancreatic cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8813"><Criterion>TNM Stage II pancreatic cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8826"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8827"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8833">Subjects with life expectancy of six months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8834"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8835">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Pancreas tumor" id="8836">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Pancreas tumor" id="8837">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8843"><Criterion>Subjects with Resectable Pancreatic Cancer  </Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8854"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8855">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Pancreas tumor" id="8856">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="13495"><Criterion>Subjects with Histological Subtypes of Pancreatic Cancer</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="13496">Subjects with Pancreatic adenocarcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="34028"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8857">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pancreas tumor" id="10377"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10378"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10397"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10402">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10405"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10406">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Pancreas tumor" id="10407">Subjects with history of targeted therapy</SubCriterion><SubCriterion disease="Pancreas tumor" id="10409">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Pancreas tumor" id="10411">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10412"><Criterion>Subjects with History of Treatment with Non-anticancer Drugs</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-12-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-12-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-12-27T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="169961"><TitleDisplay>Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children</TitleDisplay><TitleOfficial>Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming on Reducing Anemia Prevalence, and Improving Micronutrient Status, Cognitive Function, and Growth in Vietnamese School Children</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00728273</Identifier><Identifier type="Organisational Study">NEYS-CODE VT 188</Identifier></Identifiers><Indications/><BiomarkerNames><BiomarkerName id="1239" role="Therapeutic effect marker" type="Biochemical">Iron</BiomarkerName><BiomarkerName id="2169" role="Therapeutic effect marker" type="Biochemical">Zinc</BiomarkerName><BiomarkerName id="2170" role="Therapeutic effect marker" type="Biochemical">Vitamin A</BiomarkerName><BiomarkerName id="7586" role="Therapeutic effect marker" type="Anthropomorphic">Body fat percentage</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Vidoca</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>albendazole</Name><Drug id="12132">albendazole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12132">albendazole</Drug><IndicationsPioneer/><Companies><Company><Company id="1092516">Neys-van Hoogstraten Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12132" type="Drug"><TargetEntity id="129625" type="siDrug">Albendazole</TargetEntity></SourceEntity><SourceEntity id="1092516" type="Company"><TargetEntity id="5041068050" type="organizationId">Stichting Neys-van Hoogstraten Fonds</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1092516">Neys-van Hoogstraten Foundation</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="35746">Tubulin beta inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1748">Fungicide</Class><Class id="2638">Antiparasitic</Class><Class id="563">Microtubule modulator</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>510</PatientCountEnrollment><DateStart>2007-01-31T00:00:00Z</DateStart><DateEnd type="actual">2007-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-29T07:31:03Z</DateChangeLast><DateAdded>2014-01-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Institute of Nutrition, Mahidol University, Nakhon Pathom, Thailand</Affiliation><Name>Pattanee Winichagoon, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;School children aged 6 to 8 years  with written informed consent from parents/caregivers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Hemoglobin concentrations&amp;lt; 80 g/l&lt;/li&gt;&lt;li&gt;Chronic disease&lt;/li&gt;&lt;li&gt;Congenital abnormalities&lt;/li&gt;&lt;li&gt;Mental or severe physical handicap&lt;/li&gt;&lt;li&gt;Severe malnutrition&lt;/li&gt;&lt;li&gt;Obesity&lt;/li&gt;&lt;li&gt;Receiving deworming within the previous 6 month&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Prevalence of anemia, micronutrient status (iron, vitamin A, zinc, and iodine), and cognitive function (attention, IQ, concentration, and school achievement)</Description><Timeframe>4 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>growth (especially weight), body composition (body fat)</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Prevalence and incidence of infectious diseases such as diarrhea and respiratory infection over a 4-month period during the school feeding in</Description><Timeframe>4 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to identify the effect of a school-based food fortification      intervention with multi-micronutrients with or without deworming to improve anemia,      micronutrient status, cognitive function, health (morbidity and reinfestation rate) and      growth (ponderal) in Vietnamese primary school children.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized as follows:&lt;br/&gt;Arm 1: subjects would receive a multi-micronutrient-fortified biscuit plus placebo deworming-treatment.&lt;br/&gt;Arm 2: subjects would receive placebo biscuit plus deworming treatment with &lt;ulink linkType="Drug" linkID="12132"&gt;albendazole&lt;/ulink&gt; (400 mg).&lt;br/&gt;Arm 3: subjects would receive multiple micronutrient-fortified biscuits with deworming treatment with &lt;ulink linkType="Drug" linkID="12132"&gt;albendazole&lt;/ulink&gt;.&lt;br/&gt;Arm 4: subjects would receive placebo biscuit (non-fortified) and placebo deworming treatment.&lt;br/&gt;Deworming would be repeated with &lt;ulink linkType="Drug" linkID="12132"&gt;albendazole&lt;/ulink&gt; for all children at the end of the study (after 4 months).&lt;br/&gt;The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35 microg iodine, 300 microg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 microg vitamin B12, 120 microg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 microg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 microg vitamin E, 10 microg vitamin K and 18 microg biotin.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Thailand"><Sites><Site><Name>Institute of Nutrition, Mahidol University</Name><Address1>Nakhon Pathom</Address1><Address3>73170</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="7649">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="7651">Infants/children</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00728273</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anemia" id="17197"><Endpoint>Assessment of Incidence/Prevalence of Anemia</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anemia" id="17256"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17353"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17354">Assessment of infections</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anemia" id="14357"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14358">Infants/children</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11816">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11822"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11839"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Anemia" id="11871"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Anemia" id="26321"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11847">Subjects with abnormal/unacceptable hematological functions</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2007-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-07-30T00:00:00Z</DateFirstReceived><FundersType><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="170349"><TitleDisplay>The Impact of Immunostimulating Nutrition on the Outcome of Surgery</TitleDisplay><TitleOfficial>The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00558155</Identifier><Identifier type="Organisational Study">1ST DEPT SURG</Identifier></Identifiers><Indications><Indication id="746">Infectious disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Dipeptiven</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Omegaven</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Parenteral nutrition</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Stresson</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>peptisorb</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1033875" type="Company"><TargetEntity id="4298241599" type="organizationId">Jagiellonian University</TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1033875">Jagiellonian University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>214</PatientCountEnrollment><PatientCountEvaluable>205</PatientCountEvaluable><DateStart>2001-06-30T00:00:00Z</DateStart><DateEnd type="actual">2005-12-31T00:00:00Z</DateEnd><DateChangeLast>2014-03-31T12:51:06Z</DateChangeLast><DateAdded>2014-01-30T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Jagiellonian University 1 Dept Surgery</Affiliation><Name>Stanislaw Klek</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Resectable gastric or pancreatic cancer&lt;/li&gt;&lt;li&gt;Age between 18 and 80 years&lt;/li&gt;&lt;li&gt;Karnofsky performance status score of 80 or more&lt;/li&gt;&lt;li&gt;Adequate organ function&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unresectable gastric or pancreatic cancer&lt;/li&gt;&lt;li&gt;Patients requiring preoperative nutritional support&lt;/li&gt;&lt;li&gt;Disseminated tumor&lt;/li&gt;&lt;li&gt;Serious comorbidities (American Society of Anesthesiologists risk class of 4 or 5)&lt;/li&gt;&lt;li&gt;Renal or liver failure were excluded&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>During the postoperative period, all patients were observed for both surgical and non-surgical complications</Description><Timeframe>52 months</Timeframe></Measure><Measure><Description>Effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay</Description><Timeframe>52 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In August 2008, results were published. Secondary outcome measure which includes mortality rates did not show any significant effect due to immunostimulating formulas or enteral nutrition [&lt;ulink linkType="Reference" linkID="1538943"&gt;1538943&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to assess the clinical effect of immunostimulatory enteral and      parenteral nutrition in patients undergoing resection for gastrointestinal cancer. The study was designed to test the hypothesis that immunonutrition      and enteral nutrition would reduce the incidence of infectious complications following upper      gastrointestinal surgery.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2008, results were published. A total of 33% was observed as the overall morbidity rate and comparing all the groups the incidence of individual complications was comparable.  In standard diet groups 26/102 patients and 22/103 patients who received immunomodulatory formulas showed infectious complications. In patients who received parenteral nutrition and parenteral formulas no significant differences between infectious complications was observed. Secondary outcome measure which includes morbidity and hospital stay  did not show any significant effect due to immunostimulating formulas or enteral nutrition [&lt;ulink linkType="Reference" linkID="1538943"&gt;1538943&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of four arms:&lt;br/&gt;Arm I: subjects would receive standard isocaloric eteral diet (peptisorb)(1 ml = 1 kcal).&lt;br/&gt;Arm II: subjects would receive Stresson immunostimulating enteral nutrition (1 ml=1.25 kcal).&lt;br/&gt;Arm III: subjects would receive standard parenteral nutrition in which protein requirements were covered by 10 and 15% amino acid solutions. Energy requirements were covered by glucose and lipid emulsions.&lt;br/&gt;Arm IV: subjects would receive immunostimulating components  Omegaven  and Dipeptiven.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  were randomly assigned in a 2 x 2 factorial design into four study groups,which includes, standard enteral nutrition (n = 53), immunomodulating enteral nutrition (n = 52), standard parenteral nutrition (n = 49), and immunomodulating enteral nutrition (n = 51)&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Poland"><Sites><Site><Name>1st Department of General Surgery</Name><Address1>Krakow</Address1><Address3>30-798</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="9004">High Risk of Infection due to Cancer Therapy</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9010">Solid tumor subjects for supportive care</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Stomach tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8014">Subjects with Resectable Gastric Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8074">Subjects with Resectable Pancreatic Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00558155</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12229">Assessment of Procedure Related Outcomes</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13463"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13467">Assessment of surgical complication</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19374"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12196"><Endpoint>Pharmacoeconomic Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12209"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12214"><Endpoint>Assessment of Morbidity Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12215"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12216">Assessment of treatment-related mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13445"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13447">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13448"><Endpoint>Assessment of Morbidity Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13450"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19393"><Endpoint>Assessment of hospitalization</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19397"><Endpoint>Assessment of Morbidity Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cancer supportive care" id="19399"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stomach tumor" id="7920"><Criterion>Subjects with Resectable Gastric Cancer</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7934"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7941">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7953"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8834"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8841">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8843"><Criterion>Subjects with Resectable Pancreatic Cancer  </Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8854"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13334"><Criterion>High Risk of Infection due to Cancer Therapy</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13345"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13362"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stomach tumor" id="9480"><Criterion>Subjects with Resectable Tumor</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9484"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10370"><Criterion>Subjects with Advanced/Metastatic/Stage IV Pancreatic Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10375"><Criterion>Subjects with Unresectable Tumor</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10378"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10397"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10400">Subjects with hypersensitivity/contraindication to biological therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10918"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10919">General Cancers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="26358"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9496">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="187406"><TitleDisplay>Food Effect Study of Codeine Sulfate</TitleDisplay><TitleOfficial>A Single-Dose, Two-Period, Two-Treatment, Two-Way Crossover, Bioequivalency Study of Codeine Sulfate Tablets Under Fasting and Fed Conditions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01009892</Identifier><Identifier type="Organisational Study">CODE-T60-PVFS/FD-1</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>codeine sulfate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1003828" type="Company"><TargetEntity id="4295932330" type="organizationId">West-Ward Pharmaceutical Corp</TargetEntity></SourceEntity><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="14881">Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1003828">Hikma Pharmaceuticals USA Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2008-01-31T00:00:00Z</DateStart><DateEnd type="actual">2008-01-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T16:37:09Z</DateChangeLast><DateAdded>2014-05-16T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>CEDRA Clinical Research</Affiliation><Name>Fredrick Bieberdorf</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Positive test for HIV, Hepatitis B, or Hepatitis C&lt;/li&gt;&lt;li&gt;Treatment with known enzyme altering drugs&lt;/li&gt;&lt;li&gt;History of allergic or adverse response to codeine sulfate or any comparable or similar product&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Bioequivalence determined by statistical comparison Cmax</Description><Timeframe>8 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was designed to assess the effect of food on the absorption of codeine from Roxane      Laboratories 60 mg codeine sulfate tablet.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive codeine sulfate  either 30 or  60 or  15 mg po. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>CEDRA Clinical Research</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78217</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01009892</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion></Inclusion><Inclusion disease="Pain" id="22181"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20126">Subjects with hypersensitivity/contraindications to analgesics</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2009-11-06T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="188060"><TitleDisplay>Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer</TitleDisplay><TitleOfficial>Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00953225</Identifier><Identifier type="Organisational Study">CLIN-004-09S</Identifier><Identifier type="Secondary Organisational">MUSC IRB HR#19344</Identifier><Identifier type="Trial Acronym">vit D and PCa</Identifier></Identifiers><Indications><Indication id="276">Prostate tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>vitamin D3</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20675" type="Company"><TargetEntity id="4296717404" type="organizationId">Medical University of South Carolina</TargetEntity></SourceEntity><SourceEntity id="26104" type="Company"><TargetEntity id="8589934520" type="organizationId">US Department of Veterans Affairs</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"/><TargetEntity id="10060862" type="MEDDRA"/><TargetEntity id="D011471" type="MeSH"/><TargetEntity id="-405461207" type="omicsDisease"/><TargetEntity id="5083" type="siCondition"/><TargetEntity id="637" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="26104">US Department of Veterans Affairs</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20675">Medical University of South Carolina</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>83</PatientCountEnrollment><DateStart>2010-01-07T00:00:00Z</DateStart><DateEnd type="actual">2014-10-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:27:27Z</DateChangeLast><DateAdded>2014-05-22T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Ralph H. Johnson VA Medical Center, Charleston, SC</Affiliation><Name>Sebastiano Gattoni-Celli, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Ralph H Johnson VA Medical Center, Charleston</Affiliation><Email>gattonis@musc.edu</Email><Name>Sebastiano Gattoni-Celli, MD</Name><Phone>843-876-5103</Phone></Contact><Contact type="Scientific contact"><Affiliation>Ralph H. Johnson VA Medical Center, Charleston; Charleston; South Carolina</Affiliation><Email>ambrosel@musc.edu</Email><Name>Linda Ambrose</Name><Phone>843) 792-8303</Phone></Contact><Contact type="Scientific contact"><Affiliation>VA Medical Center, Augusta; Augusta; Georgia; 30904; United States</Affiliation><Email>mterris@mcg.edu</Email><Name>Martha Terris</Name><Phone>706-721-2519</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male veterans (&gt;/= 18 years of age) recently diagnosed with low-risk PCa (histologically documented adenocarcinoma of the prostate)&lt;/li&gt;&lt;li&gt;A serum PSA value of up to 10.0 ng/ml, and a&amp;lt;/= Gleason score of  (&amp;lt;/= 3 in either architectural pattern)&lt;/li&gt;&lt;li&gt;For the purpose of eligibility, these additional criteria will be verified:&lt;ul&gt;&lt;li&gt;Serum creatinine 2.0 mg/dl&lt;/li&gt;&lt;li&gt;Serum phosphate (measured as phosphorus) &gt; 2.3 and&amp;lt;/= 4.8 mg/dl&lt;/li&gt;&lt;li&gt;Serum calcium &gt; 8.5 and&amp;lt;/= 10.5 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects with any concurrent malignancy, except non-melanoma skin cancer&lt;/li&gt;&lt;li&gt;Subjects with a history of sarcoidosis&lt;/li&gt;&lt;li&gt;Subjects with a history of high-dose (1000 IU/day) vitamin D supplementation&lt;/li&gt;&lt;li&gt;Subjects with a history of hypercalcemia&lt;/li&gt;&lt;li&gt;Subjects who use lithium as a medication&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>PSA slope (trajectory) or the change in PSA level over time: change in PSA (ng/ml) from baseline to one year visit, which include the baseline through one year follow-up</Description><Timeframe>One year (visits 1 to 8)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of positive biopsy cores (out of twelve) compared to the corresponding values assessed before enrollment: change in the number of positive cores per subject from the pre-study prostate biopsy to the repeat prostate biopsy following study participation</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The propose of this study was  to conduct a      clinical study aimed at measuring the efficacy of vitamin D3 (4000 IU/day) supplementation in      Veterans diagnosed with low-risk, early-stage prostate cancer (PCa), who elect to have their      disease monitored through active surveillance.  &lt;br/&gt;The main objectives of      this proposed clinical study were:&lt;br/&gt;To determine whether a daily supplement of 4000 IU of vitamin D3 taken for 12           months would result in a measurable and significant decrease of serum PSA levels in           vVeterans diagnosed with low-risk, early stage PCa (Gleason score  6, PSA  10, clinical           stage T1C or T2a), who elect to have their disease monitored through active           surveillance for at least one year.&lt;br/&gt;To determine in enrolled Veterans the pathology status of their PCa by analyzing           prostate tissue biopsy specimens at the end of the study (Gleason score and percentage           of positive biopsies), and by comparing them with those obtained before enrollment in           this study, as part of their standard medical care.&lt;/para&gt;&lt;para&gt;Investigators  hypothesize that a daily dose of vitamin D3 (4000 IU) taken for one year by veterans      diagnosed with low-risk, early-stage PCa, who were eligible for active surveillance would: &lt;br/&gt;Result in a measurable decrease of serum PSA levels in a significant number of enrolled      subjects.&lt;br/&gt;Be associated with a stabilization or improvement of their PCa pathology,      as assessed through histological examination of prostate tissue biopsy specimens (Gleason      score and percent of positive biopsies) obtained at the end of the study, as part of their      standard medical care for active surveillance.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized to receive either 4000 IU vitamin D3 or placebo daily for one year.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Medical University of South Carolina</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3>29425</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Ralph H. Johnson VA Medical Center, Charleston, SC</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3>29401-5799</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Ralph H Johnson VA Medical Center</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3> 29401-5799</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Ralph H Johnson Va Medical Center Charleston</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3> 29401-5799</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>VA Medical Center</Name><Address1>Augusta</Address1><Address2>Georgia</Address2><Address3> 30904</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>VA Medical Center, Augusta</Name><Address1>Augusta</Address1><Address2>Georgia</Address2><Address3> 30904</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cataract</Disease><PatientSegments><PatientSegment><PatientSegment id="11773">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="11774">Subjects with history of other ophthalmic conditions</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3559">Subjects with Early Stage/Localized Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3560">Subjects with Stage I Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3562">Subjects with Locally Advanced Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3563">Subjects with Stage III Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3565">Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="17870">Subjects at risk of disease recurrence</PatientSegment><SubSegments><SubSegment id="3566">Subjects with Low Risk of Recurrence</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00953225</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7135">Assessment of PSA failure</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7076"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7081">Assessment of pathological response</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3691"><Criterion>Subjects with Stage I Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3694"><Criterion>Subjects with Stage III Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3695"><Criterion>Subjects with Stage IV Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3697"><Criterion>Subjects with Specified Gleason Grade</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3698">Subjects with grade 2 to 4 (low grade)</SubCriterion><SubCriterion disease="Prostate tumor" id="3699">Subjects with grade 5-7 (intermediate grade)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3701"><Criterion>Subjects with Low Risk Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3719">Subjects with specified PSA levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3723"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3725">Subjects with acceptable blood chemistry</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="7089"><Criterion>Subjects with Early/Localized Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7090"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Cataract" id="21935"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Cataract" id="21936">Subjects with history of other ophthalmic conditions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cataract" id="21942"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="34007"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3727">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4894"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4899">Subjects with Auto-immune/Inflammatory diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4929"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4975"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-12-15T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>36.81 Months</EnrollmentPeriod><EnrollmentRate>2.25 Patients/Month</EnrollmentRate><DateFirstReceived>2009-08-04T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-11-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="190225"><TitleDisplay>Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin</TitleDisplay><TitleOfficial>Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00973986</Identifier><Identifier type="Organisational Study">YWLCSY-0900328</Identifier><Identifier type="Secondary Organisational">08110831</Identifier><Identifier type="Secondary Organisational">GZJQZYY-003</Identifier><Identifier type="Secondary Organisational">ATR-01</Identifier><Identifier type="Secondary Organisational">GD080625</Identifier><Identifier type="Secondary Organisational">20081001</Identifier><Identifier type="Trial Acronym">ECGPPA</Identifier></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1664" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytochrome P450 3A4</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atorvastatin</Name><Drug id="2807">atorvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2807">atorvastatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1044419">Liu Hua Qiao Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1073571">Guangdong Science and Technology Department</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2807" type="Drug"><TargetEntity id="180072" type="siDrug">Atorvastatin calcium</TargetEntity></SourceEntity><SourceEntity id="1044419" type="Company"><TargetEntity id="5035544952" type="organizationId">Liu Hua Qiao Hospital</TargetEntity></SourceEntity><SourceEntity id="1073571" type="Company"><TargetEntity id="5037852964" type="organizationId">Department of Science and Technology of Guangdong Province</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"/><TargetEntity id="D003327" type="MeSH"/><TargetEntity id="-1572475765" type="omicsDisease"/><TargetEntity id="221" type="siCondition"/></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1044419">Liu Hua Qiao Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1073571">Guangdong Science and Technology Department</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2667">Antiarteriosclerotic</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2009-06-30T00:00:00Z</DateStart><DateEnd type="actual">2011-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-03-29T09:13:46Z</DateChangeLast><DateAdded>2014-05-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Guangzhou General Hospital of Guangzhou Military Command</Affiliation><Name>Zhao Shujin, PhD</Name></Contact><Contact type="Public contact"><Affiliation>Guangzhou General Hospital of Guangzhou Military Command</Affiliation><Email>hbxberry@yahoo.com.cn</Email><Name>He Baoxia</Name><Phone>86-20-36653435</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent&lt;/li&gt;&lt;li&gt;Subjects must be &gt;/=35 years and&amp;lt;/=70 years of age&lt;/li&gt;&lt;li&gt;Subjects must have an LDL-C concentration &gt;/= 2.6 mmol/l and TC concentration &gt;/= 4.14 mmol/l&lt;/li&gt;&lt;li&gt;Body mass index (BMI) must be within the range of 19 to 30 for patients&lt;/li&gt;&lt;li&gt;Subjects must have documented coronary heart disease with one or more of the following features:&lt;ul&gt;&lt;li&gt;Documented stable angina (with evidence of ischemia on exercise testing)&lt;/li&gt;&lt;li&gt;History of myocardial infarction&lt;/li&gt;&lt;li&gt;History of percutaneous coronary intervention (with or without stent placement)&lt;/li&gt;&lt;li&gt;Documented history of unstable angina or non-Q wave myocardial infarction&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diabetes and endocrine or metabolic disease&lt;/li&gt;&lt;li&gt;Congestive heart failure defined by New York Heart Association (NYHA) as class III or IV&lt;/li&gt;&lt;li&gt;Uncontrolled cardiac arrhythmia&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension (systolic BP &gt; 160 mmHg and/or diastolic BP &gt; 100 mmHg on two consecutive measurements)&lt;/li&gt;&lt;li&gt;Liver or kidney disease confirmed by abnormal lab values or function&lt;/li&gt;&lt;li&gt;Smokers who report cigarette use of &gt; 10 cigarette/day&lt;/li&gt;&lt;li&gt;Subjects who consume &gt; 2 alcoholic drinks a day. (A drink is: a can of beer, glass of wine, or single measure of spirits)&lt;/li&gt;&lt;li&gt;Known human immunodeficiency virus (HIV) positive&lt;/li&gt;&lt;li&gt;Cancer&lt;/li&gt;&lt;li&gt;Subjects who are on any of the following concomitant medications:&lt;ul&gt;&lt;li&gt;Medications that are potent inhibitors of CYP3A, including cyclosporine, itraconazole, fluconazole, and ketoconazole, erythromycin or clarithromycin, nefazodone, protease inhibitors,mibefradil and large amounts of grapefruit juice (&gt; 1 quart/day)&lt;/li&gt;&lt;li&gt;Lipid-lowering agent: niacin (&gt; 200 mg/day) taken within 5 weeks, fibric acid derivatives taken within 8 weeks&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Compare the area under the plasma concentration versus time curve (AUC) and Area under the plasma concentration versus time curve (AUC) of atorvastatin with different CYP3A41G genotypes</Description><Timeframe>48 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The pharmacokinetics of atorvastatin in Chinese with coronary heart disease</Description><Timeframe>48 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to investigate the effects of CYP3A polymorphisms on the      pharmacokinetics of &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; (Lipitor) in Chinese subjects with coronary heart disease.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration to study the effects of CYP3A polymorphisms (CYP3A41/1 or CYP3A41/1G or CYP3A41G/1G) on pharmacokinetics of &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt;.  &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Guangzhou General Hospital of Guangzhou Military Command</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510010</Address3><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>Department of Pharmacy, Guangzhou General Hospital of Guangzhou Military Command</Name><Address1>Guangzhou</Address1><Address3> 510010</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="173">Subjects with Unstable Coronary Artery Disease</PatientSegment><SubSegments><SubSegment id="174">Acute onset/new onset myocardial infarction (MI)</SubSegment><SubSegment id="177">Prior history of myocardial infarction (MI)</SubSegment><SubSegment id="179">UA-Braunwald classification B&amp;C, I-II-III</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="182">Subjects with Angina</PatientSegment><SubSegments><SubSegment id="188">Subjects with Stable Angina</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><SubSegments><SubSegment id="204">Subjects with history of coronary intervention</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="224">Subjects with High Cardiovascular Risk Profile</PatientSegment><SubSegments><SubSegment id="226">Hyperlipidemia/dyslipidemia</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="368">Subjects with Myocardial Ischemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="13650">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1968633361" id="22529">CYP3A4_HUMAN_rs2242480(A)</SubSegment><SubSegment genevariantId="-324671919" id="22530">CYP3A4_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00973986</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2753"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="46671"><Endpoint>Gene variants involved in outcome measures</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="52539">CYP3A4_HUMAN_rs2242480(A)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2753"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1076"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3879">Hyperlipidemia/dyslipidemia</SubCriterion><SubCriterion disease="Coronary artery disease" id="3880">Subjects with high LDL cholesterol levels as a risk factor</SubCriterion><SubCriterion disease="Coronary artery disease" id="3882">Subjects with hypercholesterolemia as a risk factor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1078"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1080">New or recent onset/Acute MI</SubCriterion><SubCriterion disease="Coronary artery disease" id="1084">Prior history of myocardial infarction</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1085"><Criterion>Subjects with angina</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1091">Subjects with stable angina / angina pectoris / exertional angina</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1171">PTCA (percutaneous transluminal coronary angioplasty)/Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1180"><Criterion>Subjects with Abnormal ECG/ Echocardiographic Findings</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="3873"><Criterion>Subjects with Ischemic Heart Diseases</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="3875">Subjects with symptomatic ischemia</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1662">Subjects co-morbid with congestive heart failure (Killip class II-IV/NYHA Class II-IV)/Failure of the right ventricle/Decompensated heart failure</SubCriterion><SubCriterion disease="Coronary artery disease" id="5585">Subjects co-morbid with arterial hypertension</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1668"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1677">Uncontrolled cardiac arrhythmia/unstable arrhythmia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1696"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1760"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1766"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1820"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1857"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1861">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="25865"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5589">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2009-09-04T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="192785"><TitleDisplay>Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects</TitleDisplay><TitleOfficial>Pilot Study on the Influence of a Synbiotic Formulation (ProSynbiotic) on Gut Microbiota Composition, Adiposity and Selected Markers of Cardiometabolic Health in Overweight or Moderately Obese Individuals</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02151825</Identifier><Identifier type="Organisational Study">2011F7611</Identifier><Identifier type="Secondary Organisational">110021</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="172" role="Therapeutic effect marker" type="Genomic;Proteomic">Adiponectin</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="1069" role="Therapeutic effect marker" type="Genomic;Proteomic">Peroxisome proliferator-activated receptor gamma</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2141" role="Therapeutic effect marker" type="Genomic;Proteomic">Transcription factor p65</BiomarkerName><BiomarkerName id="2880" role="Therapeutic effect marker" type="Genomic">Angiopoietin-related protein 4</BiomarkerName><BiomarkerName id="20205" role="Therapeutic effect marker" type="Genomic;Proteomic">Free fatty acid receptor 2</BiomarkerName><BiomarkerName id="31179" role="Therapeutic effect marker" type="Genomic;Proteomic">Free fatty acid receptor 3</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ProSynbiotic</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1075085" type="Company"><TargetEntity id="4296170629" type="organizationId">Standard Process Inc</TargetEntity></SourceEntity><SourceEntity id="21864" type="Company"><TargetEntity id="4296333708" type="organizationId">University of Texas System</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21864">University of Texas System</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1075085">Standard Process, Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>54</PatientCountEnrollment><DateStart>2011-09-30T00:00:00Z</DateStart><DateEnd type="actual">2012-10-31T00:00:00Z</DateEnd><DateChangeLast>2015-12-11T08:21:58Z</DateChangeLast><DateAdded>2014-06-02T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Texas State University</Affiliation><Name>Vatsala Maitin, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age between 18 to 64 years&lt;/li&gt;&lt;li&gt;BMI of 25 to 34.9 and/or a waist circumference &gt; 35 inches for women and &gt; 40 inches for men&lt;/li&gt;&lt;li&gt;Generally healthy except for overweight or moderately obese&lt;/li&gt;&lt;li&gt;A signed consent form&lt;/li&gt;&lt;li&gt;Passed a screening questionnaire and willingness to comply with study procedures&lt;/li&gt;&lt;li&gt;Lipid levels, fasting glucose, liver function and complete blood counts within the normal reference ranges as measured in a screening blood sample&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Persons on a weight-loss regimen&lt;/li&gt;&lt;li&gt;Antibiotic use (&amp;lt; 3 months before the study)&lt;/li&gt;&lt;li&gt;Regular probiotic, prebiotic or synbiotic use (&amp;lt; 1 month before the study)&lt;/li&gt;&lt;li&gt;Regular use of anti-inflammatory drugs, weight-loss medications or supplements (&amp;lt;  1 month prior to the study)&lt;/li&gt;&lt;li&gt;Personal history of cardiovascular disease, hypertension, cancer, type 1 or type 2 diabetes and inflammatory gastrointestinal disorders such as Crohn's disease or colitis&lt;/li&gt;&lt;li&gt;Smoking&lt;/li&gt;&lt;li&gt;Consumption of &gt; 2 U of alcohol per day&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Irregular periods, menopause or hormone replacement therapy&lt;/li&gt;&lt;li&gt;Over 300 min of exercise per week&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Changes to the gut microbiota: the primary objective of this study is to determine the effect of a synbiotic formulation called ProSynbiotic (administered at three capsules per day) containing 4 billion CFU of a probiotic blend of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii, along with 1 g of the prebiotic inulin and 100 mg of galactooligosaccharide (GOS) on the gut microbiota of healthy overweight adult subjects when compared to a placebo of maltodextrin. Changes in the gut microbiota will be determined by measuring specific bacterial population levels in the subjects' fecal  samples,  using 16S rRNA targeted oligonucleotide probes and fluorescence in situ hybridization</Description><Timeframe>0 (baseline), 6 (midpoint of intervention), 12 (end of intervention) and 16 weeks (4 weeks after end of intervention)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adiposity-related metabolic markers: This will be achieved by measuring TNF-α, adiponectin, total cholesterol, LDL-C, HDL-C, triglycerides and glucose levels in fasting blood samples collected from the study subjects at baseline and 12-weeks.</Description><Timeframe>Baseline and 12 weeks</Timeframe></Measure><Measure><Description>Body composition: the effect of Prosynbiotic on the subjects' body composition will be evaluated by BOD POD assessment carried out at baseline, 6 and 12-weeks</Description><Timeframe>Baseline, 6 and 12 weeks</Timeframe></Measure><Measure><Description>Expression of genes mediating dietary energy harvest and adiposity: this will be achieved by measuring the gene expression levels of ANGPTL4, PPAR-gamma and GPR41/43 in colonocytes isolated from stool and that of ANGPTL4, PPAR-gamma, NF-kB, IL-6 and TNFa in PBMCs isolated from blood collected from the subjects at baseline and 12-weeks</Description><Timeframe>Baseline and 12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was  to investigate the effects of a synbiotic (ProSynbiotic) on the      gut microbiota composition, body composition and adiposity-related genes and metabolic      markers in healthy overweight adult subjects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;  The duration of the      study is 18 weeks, including a 2-week run-in period before randomization of subjects into      the synbiotic or placebo group, a 12-week intervention period, and a 4-week follow-up after      the end of the intervention. During the intervention period, subjects will be instructed to      take three capsules of either synbiotic or placebo (maltodextrin) per day and maintain their habitual diet and      physical activity. Subjects would  also be asked to document any unusual symptoms or side effects      as well as keep a bowel diary. Diet and physical activity would  be monitored via 24-h dietary      recalls and the global physical activity questionnaire respectively. Changes in the gut      microbiota composition would  be determined by measuring bacterial population levels in stool      sampled collected at baseline, 6, 12 weeks and the follow up time point. Body      composition would  be measured using the BOD POD at baseline, 6, and 12 weeks. Gene      expression levels would  be assessed at baseline and 12 weeks in colonocytes (isolated from      stool samples) and PBMCs (isolated from blood samples) by qPCR. Metabolic markers would  be      measured at baseline and 12-weeks in plasma or serum using the respective biochemical- or      immuno-assays.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Texas State University</Name><Address1>San Marcos</Address1><Address2>Texas</Address2><Address3>78666</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02151825</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="193537"><TitleDisplay>Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With COPD Exacerbation</TitleDisplay><TitleOfficial>Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With Exacerbations of Chronic Obstructive Pulmonary Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01393015</Identifier><Identifier type="Organisational Study">FREEO2-COPD-5EPC</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1913" role="Therapeutic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Closed-loop system for oxygen delivery (FreeO2)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1096259" type="Company"><TargetEntity id="5042933236" type="organizationId">Institut universitaire de cardiologie et de pneumologie de Quebec</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1096259">Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2011-07-31T00:00:00Z</DateStart><DateEnd type="estimated">2011-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-02-20T13:06:58Z</DateChangeLast><DateAdded>2014-06-05T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Centre de recherche de l institut universitaire de cardiologie et de pneumologie de Quebec</Affiliation><Email>pierre-alexandre.bouchard.1@ulaval.ca</Email><Extension>2712</Extension><Name>Pierre-Alexandre Bouchard, inh</Name><Phone>1 418 656-8711</Phone></Contact><Contact type="Scientific contact"><Affiliation>Institut universitaire de cardiologie et de pneumologie de Québec</Affiliation><Name>François Lellouche, Md</Name></Contact><Contact type="Public contact"><Affiliation>Centre de recherche de l institut universitaire de cardiologie et de pneumologie de Quebec</Affiliation><Email>maude.roberge.1@ulaval.ca</Email><Name>Maude Roberge</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient hospitalized for COPD exacerbation&lt;/li&gt;&lt;li&gt;Age &gt;/=40 years&lt;/li&gt;&lt;li&gt;Former or current smoker &gt;/= 10 pack-years&lt;/li&gt;&lt;li&gt;Suspicion or diagnosis of COPD at the hospitalisation&lt;/li&gt;&lt;li&gt;Acute dyspnea or acute aggravation of dyspnea&lt;/li&gt;&lt;li&gt;Respiratory rate &gt;/= 20 breaths/min&lt;/li&gt;&lt;li&gt;Patient needs an oxygen therapy by nasal cannula with oxygen delivered between 0.5 to 8l/min to hold SpO2 &gt;/= 92%&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Imminent indications for intubation&lt;/li&gt;&lt;li&gt;FreeO2 system is unavailable at the moment of randomization&lt;/li&gt;&lt;li&gt;Patient in isolation (barrier nursing) to the inclusion&lt;/li&gt;&lt;li&gt;Patient participates to another clinical trial without possibility of co-enrollment&lt;/li&gt;&lt;li&gt;Patient with diagnosis of sleep apnea&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Possibility to use a new closed-loop system for oxygen delivery in common practice: the investigators will see if nurses and medical personnel are agree to work with FreeO2 system. The investigators want to know if the new system of automated adjustment of oxygen flow is useful in common practice</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Percentage of time with desaturation during the oxygentherapy</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Percentage of time with hyperoxia during the oxygentherapy</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Time of oxygen weaning between common oxygen delivery and closed-loop automatic titration of oxygen flow based on SpO2</Description><Timeframe>6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to evaluate the use feasibility of Free O2 so as to deliver      automatically oxygen and to enable a remote medical monitoring with a homogeneous patient      population hospitalized for chronic obstructive pulmonary disease (COPD) exacerbation. The principal hypothesis is that Free O2 is possible and well-accepted by nurses      and medical personnel and there are advantages to use this system. In comparison with the      common oxygen delivery (the rotameter), the hypothesis is that Free O2 system will make for a      better control of the oxygen saturation in function of designed target, reducing the      desaturation time and hyperoxia. The investigators think that oxygen weaning will be faster than classical      way if it is automated. In addition, Free O2 could reduce the number of intervention by nurse      personnel and to improve the support with centralized monitoring in the Free O2 group.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Oxygen will be delivered through FreeO2 system  (manual setting) or rotameter (automated setting).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Centre de recherche de l'institut universitaire de cardiologie et de pneumologie de Québec</Name><Address1>Quebec city</Address1><Address2>Quebec</Address2><Address3>G1V 4G5</Address3><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>pierre-alexandre.bouchard.1@ulaval.ca</Email><Extension>2712</Extension><Name>Pierre-Alexandre Bouchard, inh</Name><Phone>1-418-656-8711</Phone></Contact><Contact type="Facility contact backup"><Email>maude.roberge.1@ulaval.ca</Email><Name>Maude Roberge</Name></Contact></Contacts></Site><Site><Name>Centre de recherche de l institut universitaire de cardiologie et de pneumologie de Quebec</Name><Address1>Quebec city</Address1><Address3> G1V 4G5</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="557">Subjects with Symptomatic Disease</PatientSegment><SubSegments><SubSegment id="558">Subjects with dyspnea</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="559">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="3736">Smokers</SubSegment><SubSegment id="3738">Ex-smokers</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="564">Subjects with disease related complications</PatientSegment><SubSegments><SubSegment id="565">Subjects with acute exacerbation of COPD/Infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01393015</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4536"><Endpoint>Oxygen Requirements/Supplementation</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4336"><Endpoint>Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4349">Desaturation index </SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2072"><Criterion>Subjects with Breathlessness</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2099"><Criterion>Subjects with Exacerbations</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2105">Subjects with severe exacerbation requiring hospitalization</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2106"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2114">Subjects with history of/scheduled for oxygen use</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2148"><Criterion>Subjects with Abnormal Physical/Systemic Assessment</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2212">Subjects with increased respiratory rate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="33821"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="4301">Current smokers</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="4302">Non smokers/exsmokers</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="4304">Subjects with smoking history of &gt;= 10 pack years</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3151"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="20268">Subjects with history of/scheduled for ventilatory support</SubCriterion><SubCriterion disease="Chronic obstructive pulmonary disease" id="20269">Subjects with history of/scheduled for COPD drug therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20270"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="3134">Subjects co-morbid with sleep disorder</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2011-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-07-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="194545"><TitleDisplay>Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)</TitleDisplay><TitleOfficial>Relative Bioavailability of Bromhexine for Oral Administration of 16 mg of Bromhexine Hydrochloride Granules Compared to 16 mg of Bromhexine Hydrochloride Syrup in Healthy Male and Female Volunteers (an Open-label, Randomized, Single-dose, Replicate Design Phase I Study with Two Treatments in Four Crossover Periods)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01423721</Identifier><Identifier type="Secondary Organisational">2011-002733-19</Identifier><Identifier type="Organisational Study">65.129</Identifier></Identifiers><Indications><Indication id="1148">Sjoegrens syndrome</Indication><Indication id="1488">Chronic bronchitis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bromhexine hydrochloride granules</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bromhexine hydrochloride syrup</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="1148" type="ciIndication"><TargetEntity id="M35.0" type="ICD10"/><TargetEntity id="710.2" type="ICD9"/><TargetEntity id="10040767" type="MEDDRA"/><TargetEntity id="D012859" type="MeSH"/><TargetEntity id="-459977592" type="omicsDisease"/><TargetEntity id="734" type="siCondition"/></SourceEntity><SourceEntity id="1488" type="ciIndication"><TargetEntity id="10006458" type="MEDDRA"/><TargetEntity id="D029481" type="MeSH"/><TargetEntity id="-1358226401" type="omicsDisease"/><TargetEntity id="280" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="14881">Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioavailability</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>39</PatientCountEnrollment><DateStart>2011-08-31T00:00:00Z</DateStart><DateChangeLast>2018-08-10T10:10:06Z</DateChangeLast><DateAdded>2014-06-09T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Boehringer Ingelheim Pharmaceuticals</Affiliation><Name>Boehringer Ingelheim</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy male and female volunteers&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any relevant deviation from healthy conditions&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>AUC0 to tz (area under the plasma concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</Description><Timeframe>48 h</Timeframe></Measure><Measure><Description>Cmax (maximum measured concentration of the analyte in plasma)</Description><Timeframe>48 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>AUC0  to infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to infinity)</Description><Timeframe>48 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to investigate relative bioavailability  of bromhexine      hydrochloride given as granules and syrup in healthy volunteers. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized to two arms:&lt;br/&gt;Arm 1: subjects would receive 16 mg of bromhexine hydrochloride granules.&lt;br/&gt;Arm 2: subjects would receive 16 mg of bromhexine hydrochloride syrup.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>65.129.1 Boehringer Ingelheim Investigational Site</Name><Address1>Biberach</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01423721</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2011-002733-19</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Sjoegrens syndrome" id="22352"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Sjoegrens syndrome" id="22352"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="estimated">2011-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.03 Months</EnrollmentPeriod><EnrollmentRate>19.21 Patients/Month</EnrollmentRate><DateFirstReceived>2011-08-25T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="196772"><TitleDisplay>Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder</TitleDisplay><TitleOfficial>Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01133301</Identifier><Identifier type="Secondary Organisational">NAL-DISS-BPD</Identifier></Identifiers><Indications><Indication id="1929">Borderline personality disorder</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>naltrexone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1087309" type="Company"><TargetEntity id="5040241345" type="organizationId">Universitaets Augenklinik Freiburg</TargetEntity></SourceEntity><SourceEntity id="1097322" type="Company"><TargetEntity id="5037142530" type="organizationId">Zentralinstitut fuer Seelische Gesundheit ZI</TargetEntity></SourceEntity><SourceEntity id="1929" type="ciIndication"><TargetEntity id="F60.3" type="ICD10"/><TargetEntity id="301.83" type="ICD9"/><TargetEntity id="10006034" type="MEDDRA"/><TargetEntity id="D001883" type="MeSH"/><TargetEntity id="-595070342" type="omicsDisease"/><TargetEntity id="1801" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1097322">Central Institute of Mental Health, Mannheim</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1087309">Universitats-Augenklinik Freiburg</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>1998-08-31T00:00:00Z</DateStart><DateEnd type="actual">2001-10-31T00:00:00Z</DateEnd><DateChangeLast>2014-07-22T05:07:49Z</DateChangeLast><DateAdded>2014-06-17T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Central Institute of Mental Health, Dep. of Psychosomatic and Psychotherapeutic Medicine</Affiliation><Name>Christian Schmahl, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of BPD according to DSM-IV&lt;/li&gt;&lt;li&gt;DES score  &gt;/= 18&lt;/li&gt;&lt;li&gt;Female gender&lt;/li&gt;&lt;li&gt;Age between 18 and 50 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Lifetime diagnosis of schizophrenia, psychotic or delusional disorder&lt;/li&gt;&lt;li&gt;Current major depressive episode&lt;/li&gt;&lt;li&gt;Lifetime diagnosis opioid dependence&lt;/li&gt;&lt;li&gt;Current diagnosis opioid abuse&lt;/li&gt;&lt;li&gt;Liver insufficiency or hepatitis&lt;/li&gt;&lt;li&gt;Other major medical or neurological medical condition&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Psychotropic medication within 2 weeks before and during the trial (fluoxetine 4 weeks, lithium 8 weeks)&lt;/li&gt;&lt;li&gt;Concomitant treatment with opioid analgetics&lt;/li&gt;&lt;li&gt;Hypersensitivity to naltrexone&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Dissociation Tension Scale (DSS), a reliable and valid self-rating instrument to assess dissociative experiences and inner tension during the last 24 h (Stiglmayr et al. 2001)</Description><Timeframe>Oct. 1998-Oct 2001</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number and intensity of flashbacks during the last week: the number and intensity of flashbacks are documented at the end of each week</Description></Measure><Measure><Description>The number, the method, and the severity of non-suicidal self-injurious acts during the last week: the number, method and the severity of non-suicidal self-injurious acts are documented at the end of each week</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Investigators study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy      as an antidissociative agent by using a double-blind, randomized, controlled trial.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were randomized into two groups starting with either 3 weeks of 50 mg/d naltrexone      or with 3 weeks of placebo. In either case the active treatment phases (weeks 1 to 6) were      followed by one week of placebo. &lt;br/&gt;The major purpose of weeks 1 to 2 and 4 to 5, respectively, was      to achieve a steady state during the active treatment. The primary comparisons of      psychopathology under naltrexone and placebo refer to the weeks following the intended      achievement of a steady state (weeks 3 and 6, respectively).&lt;/para&gt;&lt;para&gt;The treatment for       6 weeks  were split into two phases: &lt;br/&gt;Initially 3 weeks of pharmacologically active      treatment with naltrexone &lt;br/&gt;Then 3 weeks of pharmacologically inactive treatment with      placebo (cross-over design). &lt;br/&gt;      The primary outcome was based on the DSS, a reliable and valid self-rating instrument to      assess dissociative experiences and inner tension during the last 24 h; mean scores for intensity (ranging from 0 = 'no' to 9 = 'very strong') and for duration      (average time during which a particular symptom was present during the last 24 h (in %))      were calculated for   dissociation (calculated from 21 Likert type items) and of aversive inner tension (one item).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Department of Psychiatry and Psychotherapy, University of Freiburg</Name><Address1>Freiburg</Address1><Address2>Baden Württemberg</Address2><Address3>79104</Address3><CountrySubDivision>Baden Württemberg</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01133301</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2001-08-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="208383"><TitleDisplay>The OneFreeze Study</TitleDisplay><TitleOfficial>A Prospective, Multicenter, Randomized, Controlled Trial To Assess The Safety And Efficacy Of One Versus Two Cryoablations Per Pulmonary Vein For The Treatment Of Atrial Fibrillationia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02217254</Identifier><Identifier type="Organisational Study">UC-OF01</Identifier><Identifier type="Trial Acronym">OneFreeze</Identifier></Identifiers><Indications><Indication id="1542">Atrial fibrillation</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Cryoballoon catheter ablation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Medtronic Arctic Front Ablation System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1097361" type="Company"><TargetEntity id="5043331632" type="organizationId">Medtronic PLC</TargetEntity></SourceEntity><SourceEntity id="24773" type="Company"><TargetEntity id="4298366404" type="organizationId">University of California San Francisco</TargetEntity></SourceEntity><SourceEntity id="1542" type="ciIndication"><TargetEntity id="10003658" type="MEDDRA"/><TargetEntity id="D001281" type="MeSH"/><TargetEntity id="-1073626038" type="omicsDisease"/><TargetEntity id="194" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="24773">University of California San Francisco</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1097361">Medtronic plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>90</PatientCountEnrollment><DateStart>2014-10-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-10-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-16T13:26:08Z</DateChangeLast><DateAdded>2014-08-22T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of California, San Francisco</Affiliation><Name>Byron K Lee, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Paroxysmal atrial fibrillation&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Life expectancy  of &gt;/= 1 year&lt;/li&gt;&lt;li&gt;Willing and able to return to and comply with scheduled follow-up visits&lt;/li&gt;&lt;li&gt;Willing and able to provide written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of  &gt; 5 electric cardioversions&lt;/li&gt;&lt;li&gt;History of previous pulmonary vein isolation ablation for atrial fibrillation&lt;/li&gt;&lt;li&gt;History of MAZE procedure&lt;/li&gt;&lt;li&gt;Left ventricular EF&amp;lt;/= 35% within the past 12 months&lt;/li&gt;&lt;li&gt;Mechanical mitral valve&lt;/li&gt;&lt;li&gt;Single PV &gt; 30 mm in diameter, unless deemed appropriate by the site PI&lt;/li&gt;&lt;li&gt;Stroke/TIA within the past 6 months&lt;/li&gt;&lt;li&gt;Creatinine &gt; 2.0 mg/dl within the past 6 months&lt;/li&gt;&lt;li&gt;Pregnancy or desire to get pregnant within the next 12 months&lt;/li&gt;&lt;li&gt;Current enrollment in an investigation or study of a cardiovascular device or investigational drug that would interfere with this study&lt;/li&gt;&lt;li&gt;Mental impairment or other conditions, which may not allow the patient to understand the nature, significance and scope of the study&lt;/li&gt;&lt;li&gt;Any other condition or circumstance that in the judgment of the Clinical Site investigator that makes the patient unsuitable for the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Composite score of adverse events: composite score of adverse events (range 0 to 20 points) will be calculated after the patient has completed follow-up. Higher scores indicate greater severity. Luminal Esophageal Temperature (LET) (0 to 2 points): 1-point if  &lt;/= 20 degC, 2-points if &lt;/= 5 degC. Phrenic nerve injury (0 to 3 points): 1-point if  &gt;/= 30% decrease in compound muscle action potential (CMAP) or loss of phrenic nerve capture resulting in cessation of freeze (without movement of pacing catheter), 2-points if Phrenic nerve palsy lasting &gt; 1 min resolving on table, 3-points if Phrenic nerve palsy not resolving on the table. Pulmonary (0 to 4 points): 1-point if persistent dry cough &gt; 1 week post ablation, 4-points points if Hemoptysis. Gastrointestinal (GI) (0 to 6 points): 1-point if Gastroparesis symptoms, 3-points if Esophageal ulceration, 6-points if left atrial-esophageal fistula.</Description><Timeframe>12 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Acute success of the Pulmonary Vein Isolation (PVI): percentage of pulmonary veins isolated during the catheter ablation procedure</Description><Timeframe>4 to 8 h</Timeframe></Measure><Measure><Description>Atrial Fibrillation (AF) burden: AF burden is defined as the overall percentage of AF during the 14-day observed period on Holter monitoring</Description><Timeframe>6 and 12 months</Timeframe></Measure><Measure><Description>Fluoroscopy Time: the amount of time in minutes (and milligray [mGy]/millisievert [mSv] dosage) of fluoroscopy used during the procedure</Description><Timeframe>4 to 8 h</Timeframe></Measure><Measure><Description>Individual adverse events: number and severity of adverse events following the PVI procedure during the 12-month follow-up window</Description><Timeframe>wWthin 12 months after the Pulmonary Vein Isolation (PVI)</Timeframe></Measure><Measure><Description>Left atrial access time: time it takes to gain transseptal access during the catheter ablation procedure</Description><Timeframe>4 to 8 h</Timeframe></Measure><Measure><Description>Number of cryoablations needed to isolate each vein: number of cryoablations needed to isolate each vein</Description><Timeframe>4 to 8 h</Timeframe></Measure><Measure><Description>Number of re-isolations required: number of pulmonary veins requiring touch up for re-isolation after initial isolation was achieved</Description><Timeframe>4 to 8 h</Timeframe></Measure><Measure><Description>Patients free from symptomatic atrial fibrillation (AF): patients experiencing no episodes of AF &gt; 30 s, excluding episodes documented in the blanking period (6 weeks post-ablation for paroxysmal AF patients)</Description><Timeframe>6 and 12 months</Timeframe></Measure><Measure><Description>Procedure time: the duration of the pulmonary vein Isolation procedure from first leg puncture to removal of ablation catheter</Description><Timeframe>4 to 8 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The One Freeze study is a prospective, multicenter, randomized, controlled trial to assess the safety and efficacy of one versus two cryoablations per pulmonary vein for the treatment of atrial fibrillation. The One Freeze Trial is an investigator-initiated trial that has been developed by the Principals at the &lt;ulink linkType="Company" linkID="20547"&gt;University of California, San Francisco&lt;/ulink&gt; (UCSF) and with full participation of the Steering Committee.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The trial   goal is to enroll and randomize a minimum of 90 study participants. Participants will be randomized in a 1 : 1 ratio to either PVI with a single freeze per pulmonary vein (1F Group) or to PVI with at least two freezes per pulmonary vein (2F Group). The One Freeze study's primary aim is to determine if one 3-min cryoablation per pulmonary vein results in a lower composite adverse event score as compared to the traditional method of using two 3-min cryoablations per pulmonary vein.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Montreal Heart Institute</Name><Address1>Québec</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>University of California, San Francisco</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94122</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Mason Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98101</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Atrial fibrillation</Disease><PatientSegments><PatientSegment><PatientSegment id="18900">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="7193">Subjects with Paroxysmal Atrial Fibrillation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02217254</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Atrial fibrillation" id="9444"><Endpoint>Assessments of Composite Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Atrial fibrillation" id="9646"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Atrial fibrillation" id="9469"><Endpoint>Assessment of Incidence of Atrial Fibrillation</Endpoint><SubEndpoints><SubEndpoint disease="Atrial fibrillation" id="9470">Assessment of incidence of symptomatic AF episodes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Atrial fibrillation" id="9480"><Endpoint>Assessment of Atrial Tachyarrhythmia Burden</Endpoint><SubEndpoints><SubEndpoint disease="Atrial fibrillation" id="9481">Assessment of atrial fibrillation burden</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Atrial fibrillation" id="9533"><Endpoint>Assessment of Atrial Structure/Dimension/Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Atrial fibrillation" id="9636"><Endpoint>Assessment of Device/Procedure Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Atrial fibrillation" id="9638">Assessment of fluoroscopy time</SubEndpoint><SubEndpoint disease="Atrial fibrillation" id="9641">Assessment of cryoablation procedure events (CPEs)</SubEndpoint><SubEndpoint disease="Atrial fibrillation" id="9642">Assessment of procedure time</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Atrial fibrillation" id="5628"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="5630">Subjects with life expectancy of one year or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atrial fibrillation" id="5634"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="5640">History of/Scheduled for cardiac ablation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atrial fibrillation" id="34997"><Criterion>Subjects with Atrial Fibrillation</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="5568">Subjects with Paroxysmal Atrial Fibrillation</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Atrial fibrillation" id="7152"><Criterion>Subjects with Poor Left Ventricular Ejection Fraction(LVEF)</Criterion></Exclusion><Exclusion disease="Atrial fibrillation" id="7201"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Atrial fibrillation" id="7202"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Atrial fibrillation" id="7249"><Criterion>Subjects Indicated/Scheduled for Cardiac Intervention</Criterion></Exclusion><Exclusion disease="Atrial fibrillation" id="7256"><Criterion>Subjects with Prior Cardiac Intervention</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7259">Subjects with prior mechanical valve repair</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atrial fibrillation" id="26675"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7401">Subjects co-morbid with transient ischemic attack</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atrial fibrillation" id="27029"><Criterion>Subjects with History of Cerebrovascular Events</Criterion><SubCriteria><SubCriterion disease="Atrial fibrillation" id="7402">Subjects with history of stroke</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-05-13T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>54.45 Months</EnrollmentPeriod><EnrollmentRate>1.65 Patients/Month</EnrollmentRate><DateFirstReceived>2014-08-08T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-11-19T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-17T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-17T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-17T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-05-17T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change><Change type="added"><Date>2019-05-17T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change></ChangeHistory></Trial><Trial id="214169"><TitleDisplay>Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene</TitleDisplay><TitleOfficial>Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02237937</Identifier><Identifier type="Organisational Study">2011-003190-29</Identifier><Identifier type="Other">HMNC-101</Identifier><Identifier type="Trial Acronym">ABCB1 Clinical Study</Identifier></Identifiers><Indications><Indication id="4898">Major depressive disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="785" role="Disease marker" type="Genomic;Proteomic">Multidrug resistance protein 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>amitriptyline</Name></Intervention><Intervention type="InterventionPrimary"><Name>amitriptylinoxide</Name></Intervention><Intervention type="InterventionPrimary"><Name>citalopram hydrobromide</Name><Drug id="2822">citalopram hydrobromide</Drug></Intervention><Intervention type="InterventionPrimary"><Name>escitalopram</Name><Drug id="17518">escitalopram</Drug></Intervention><Intervention type="InterventionPrimary"><Name>nortriptyline</Name></Intervention><Intervention type="InterventionPrimary"><Name>paroxetine hydrochloride hemihydrate</Name><Drug id="8956">paroxetine hydrochloride hemihydrate</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sertraline</Name><Drug id="15183">sertraline</Drug></Intervention><Intervention type="InterventionPrimary"><Name>trimipramine</Name></Intervention><Intervention type="InterventionPrimary"><Name>venlafaxine hydrochloride</Name><Drug id="4648">venlafaxine hydrochloride</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15183">sertraline</Drug><IndicationsPioneer/><Companies><Company><Company id="1040839">Max-Planck-Institute of Psychiatry</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1070641">HolsboerMaschmeyer NeuroChemie GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17518">escitalopram</Drug><IndicationsPioneer/><Companies><Company><Company id="1040839">Max-Planck-Institute of Psychiatry</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1070641">HolsboerMaschmeyer NeuroChemie GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2822">citalopram hydrobromide</Drug><IndicationsPioneer/><Companies><Company><Company id="1040839">Max-Planck-Institute of Psychiatry</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1070641">HolsboerMaschmeyer NeuroChemie GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4648">venlafaxine hydrochloride</Drug><IndicationsPioneer/><Companies><Company><Company id="1040839">Max-Planck-Institute of Psychiatry</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1070641">HolsboerMaschmeyer NeuroChemie GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8956">paroxetine hydrochloride hemihydrate</Drug><IndicationsPioneer/><Companies><Company><Company id="1040839">Max-Planck-Institute of Psychiatry</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1070641">HolsboerMaschmeyer NeuroChemie GmbH</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4648" type="Drug"><TargetEntity id="100721" type="siDrug">Venlafaxine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="8956" type="Drug"><TargetEntity id="107860" type="siDrug">Paroxetine</TargetEntity><TargetEntity id="170534" type="siDrug">Paroxetine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="17518" type="Drug"><TargetEntity id="157449" type="siDrug">Escitalopram oxalate</TargetEntity></SourceEntity><SourceEntity id="15183" type="Drug"><TargetEntity id="167978" type="siDrug">Sertraline hydrochloride</TargetEntity></SourceEntity><SourceEntity id="2822" type="Drug"><TargetEntity id="90241" type="siDrug">Citalopram hydrobromide</TargetEntity></SourceEntity><SourceEntity id="1040839" type="Company"><TargetEntity id="5001338580" type="organizationId">Max Planck Institut fuer Psychiatrie</TargetEntity></SourceEntity><SourceEntity id="1070641" type="Company"><TargetEntity id="5037613087" type="organizationId">Hmnc Brain Health</TargetEntity></SourceEntity><SourceEntity id="4898" type="ciIndication"><TargetEntity id="F33" type="ICD10"/><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="-1357758656" type="omicsDisease"/><TargetEntity id="54" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1070641">HolsboerMaschmeyer NeuroChemie GmbH</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1040839">Max-Planck-Institute of Psychiatry</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="285">Norepinephrine uptake inhibitor</Class><Class id="2939">CNS modulator</Class><Class id="2941">Antidepressant</Class><Class id="2942">Anxiolytic</Class><Class id="3">5-HT uptake inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="630">Stereochemistry</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>80</PatientCountEnrollment><DateStart>2011-09-30T00:00:00Z</DateStart><DateEnd type="estimated">2014-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-04-27T05:07:46Z</DateChangeLast><DateAdded>2014-10-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>barbara_breitenstein@mpipsykl.mpg.de</Email><Extension>244</Extension><Name>Barbara Breitenstein, MSc</Name><Phone>0049 89 30622</Phone></Contact><Contact type="Scientific contact"><Affiliation>Max-Planck-Institute of Psychiatry</Affiliation><Name>Florian Holsboer, MD, PHD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female patients&lt;/li&gt;&lt;li&gt;Age between 18 and 80 years&lt;/li&gt;&lt;li&gt;In-patients with a DSM-IV diagnosis of Major Depression&lt;/li&gt;&lt;li&gt;Single episode or recurrent&lt;/li&gt;&lt;li&gt;Moderate to severe intensity (indicated by a HAM-D score of = 14)&lt;/li&gt;&lt;li&gt;Without psychotic features&lt;/li&gt;&lt;li&gt;Inpatients with a DSM-IV diagnosis of bipolar disorder I or II&lt;/li&gt;&lt;li&gt;Current episode with depressive symptoms&lt;/li&gt;&lt;li&gt;Moderate to severe intensity&lt;/li&gt;&lt;li&gt;Without psychotic features&lt;/li&gt;&lt;li&gt;HAM-D score, at the time of inclusion in the study, of  &gt;/= 14&lt;/li&gt;&lt;li&gt;Patient has already been adjusted to one of the following antidepressants in a dose which is still under the defined normal-dose:&lt;ulink linkType="Drug" linkID="8956"&gt;paroxetine&lt;/ulink&gt;&amp;lt; 40, &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt;&amp;lt; 100, &lt;ulink linkType="Drug" linkID="2822"&gt;citalopram&lt;/ulink&gt;&amp;lt; 40, &lt;ulink linkType="Drug" linkID="17518"&gt;escitalopram&lt;/ulink&gt;&amp;lt; 20, &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt;&amp;lt; 225, amitriptyline  &amp;lt; 150, amitriptylinoxide  &amp;lt; 150, nortriptyline   &amp;lt; 150, trimipramine   &amp;lt; 150 mg/day&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Acute suicidality (HAM-D Item 3 score&amp;gt; 2)&lt;/li&gt;&lt;li&gt;Acute alcohol-, hypnotics-, analgesics- or psychopharmacological intoxication or delirium&lt;/li&gt;&lt;li&gt;Current alcohol dependence, or dependencies from other psychotropic substances&lt;/li&gt;&lt;li&gt;Severe medical, somatic or neurological diseases: patients with severe hepatic (severe impairment of liver function, cirrhosis of the liver), renal (kidney malfunctions), cardiovascular (recent myocardial infarction, instable heart disease), neurological diseases (eg, multiple sclerosis, Parkinson, dementia)&lt;/li&gt;&lt;li&gt;Untreated hypertonia&lt;/li&gt;&lt;li&gt;Patients incapable of giving informed consent&lt;/li&gt;&lt;li&gt;Pregnant or breast-feeding women&lt;/li&gt;&lt;li&gt;Women of reproductive age without effective contraception&lt;/li&gt;&lt;li&gt;Simultaneous participation in other clinical trials or participation in an other clinical trial within 6 weeks before the start of the study&lt;/li&gt;&lt;li&gt;Hypersensitivity to the study medication or to one of the ingredients of the medication&lt;/li&gt;&lt;li&gt;Simultaneous treatment with another antidepressant besides study medication (exception: trazodone up to 75 mg/day, mirtazapine up to 15 mg/day, trimipramine up to 50 mg/d)&lt;/li&gt;&lt;li&gt;Simultaneous treatment with mood stabilizers or neuroleptic drugs (exception: quetiapine up to 50 mg/day, olanzapine up to 5 mg/day)&lt;/li&gt;&lt;li&gt;Exclusion criteria of the study medication&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Improvement in the HAM-D up to 25%: partial response indicated by at least 25% improvement in the Hamilton Rating Scale for Depression (HAM-D)</Description><Timeframe>After 28 days of treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Side effects: UKU side effect scale, AMDP side effect scale</Description><Timeframe>After 28 days of treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation      strategy within 28 days of treatment with approved antidepressants that are known substrates      of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1      gene.&lt;/para&gt;&lt;para&gt;Moreover, the study evaluates ABCB1-genotype dependent side-effects of approved      antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the      blood-brain barrier expressed by the ABCB1 gene.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study will consist of two arms:&lt;br/&gt;Arm 1: subjects will receive P-glycoprotein substrates at normal doses, ie, &amp;lt; 20 mg of &lt;ulink linkType="Drug" linkID="17518"&gt;escitalopram&lt;/ulink&gt;, &amp;lt; 40 mg each of &lt;ulink linkType="Drug" linkID="8956"&gt;paroxetine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2822"&gt;citalopram&lt;/ulink&gt;, &amp;lt; 100 mg of &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt;, &amp;lt; 150 mg each of amitriptyline, amitriptylinoxide, nortriptyline, and trimipramine, and &amp;lt; 225 mg of &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; for a single day.&lt;br/&gt;Arm 2: subjects will receive P-glycoprotein substrates at high doses, ie, &amp;lt; 40 mg of &lt;ulink linkType="Drug" linkID="17518"&gt;escitalopram&lt;/ulink&gt;, &amp;lt; 80 mg each of &lt;ulink linkType="Drug" linkID="8956"&gt;paroxetine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2822"&gt;citalopram&lt;/ulink&gt;, &amp;lt; 200 mg of &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt;, &amp;lt; 300 mg each of amitriptyline, amitriptylinoxide, nortriptyline, and trimipramine, and &amp;lt; 450 mg of &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt; for a single day.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Max Planck Institute of Psychiatry</Name><Address1>Munich</Address1><Address2>Bavaria</Address2><Address3>80804</Address3><CountrySubDivision>Bavaria</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Barbara Breitenstein, MSc</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Depression</Disease><PatientSegments><PatientSegment><PatientSegment id="7449">Subjects with Major Depressive Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7453">Subjects Based on Severity of Depression</PatientSegment><SubSegments><SubSegment id="7455">Subjects with moderate depression</SubSegment><SubSegment id="7456">Subjects with severe depression</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7457">Subjects with Relapse/Recurrent Depression</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02237937</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Organisational Study">2011-003190-29</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Depression" id="10739"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10741">Assessment by Hamilton Depression Rating Scale (HDRS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="10811"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Depression" id="10805"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Depression" id="34517"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Depression" id="10802"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Depression" id="6402"><Criterion>Subjects with Major Depressive Disorder</Criterion><SubCriteria><SubCriterion disease="Depression" id="6404">Subjects with major depressive disorder without psychotic features</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6416"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Depression" id="6418">Subjects with moderate depression</SubCriterion><SubCriterion disease="Depression" id="6419">Subjects with severe depression</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6420"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Depression" id="6421">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6432"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Depression" id="6436">Subjects with specified Hamilton depression rating score (HDRS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6443"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Depression" id="6446">Subjects with bipolar disorder</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6474"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Depression" id="6477">Subjects with history of tricyclic antidepressants (TCAs)/heterocyclics</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6506"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Depression" id="34715"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="6509">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Depression" id="8069"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Depression" id="8075">Subjects with suicidal ideation/suicide attempts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8086"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Depression" id="8093"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Depression" id="8094">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8095"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Depression" id="8099"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Depression" id="8118"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Depression" id="8119">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8126"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Depression" id="8133">Subjects with history /scheduled to receive antipsychotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8138"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Depression" id="8148"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Depression" id="8151">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="25477"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Depression" id="8149">Subjects unable to provide informed consent</SubCriterion><SubCriterion disease="Depression" id="8159">Subjects who have previously participated (completed/withdrawn) in the trial</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="26079"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Depression" id="8098">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2014-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2013-08-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-10-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="222633"><TitleDisplay>Endoscopic Stenting Versus Surgery for the Treatment of Bile Duct Stricture in Chronic Pancreatitis</TitleDisplay><TitleOfficial>Phase III, Prospective, Multicentric, Randomized Study of Endoscopic Versus Surgical Treatment of Bile Duct Stricture in Chronic Pancreatitis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02366988</Identifier><Identifier type="Organisational Study">2012_43</Identifier><Identifier type="Secondary Organisational">2013-A01671-44</Identifier><Identifier type="Trial Acronym">PASTEC</Identifier></Identifiers><Indications><Indication id="250">Pancreatitis</Indication></Indications><BiomarkerNames><BiomarkerName id="8458" role="Therapeutic effect marker" type="Genomic;Proteomic">gamma-Glutamyltransferase</BiomarkerName><BiomarkerName id="28899" role="Therapeutic effect marker" type="Genomic;Proteomic">Alkaline phosphatase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>endoscopic biliary stenting</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgical treatment bilio-enteric anastomosis</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="28811" type="Company"><TargetEntity id="5035530491" type="organizationId">Centre Hospitalier Universitaire de Lille</TargetEntity></SourceEntity><SourceEntity id="250" type="ciIndication"><TargetEntity id="10033645" type="MEDDRA"/><TargetEntity id="D010195" type="MeSH"/><TargetEntity id="-883850659" type="omicsDisease"/><TargetEntity id="398" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><NumberOfSites>7</NumberOfSites><CompaniesSponsor><Company id="28811">Centre Hospitalier Regional Universitaire de Lille</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>7</PatientCountEnrollment><DateStart>2015-02-28T00:00:00Z</DateStart><DateEnd type="actual">2018-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:02:05Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University Hospital, Lille</Affiliation><Name>Philippe ZERBIB, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Clinical symptomatic chronic pancreatitis-related biliary duct stricture (pain or jaundice or pale stool/dark urine)&lt;/li&gt;&lt;li&gt;Biological symptomatic chronic pancreatitis-related biliary duct stricture (elevation of serum alkaline phosphatase (&amp;gt; 2 or 3 times the upper limit of normal values) and/or of serum bilirubin for &gt; 1 month)&lt;/li&gt;&lt;li&gt;Isolated biliary stricture or biliary stricture associated to main pancreatic duct stricture&lt;/li&gt;&lt;li&gt;Secondary biliary cirrhosis&lt;/li&gt;&lt;li&gt;Progression of biliary stricture&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pancreatic malignancy&lt;/li&gt;&lt;li&gt;Cirrhosis&lt;/li&gt;&lt;li&gt;Portal vein thrombosis, portal cavernoma&lt;/li&gt;&lt;li&gt;Primary sclerosing cholangitis&lt;/li&gt;&lt;li&gt;Recent acute pancreatitis (ie, in the previous 3 weeks)&lt;/li&gt;&lt;li&gt;Acute hepatitis&lt;/li&gt;&lt;li&gt;Post-surgical biliary stricture&lt;/li&gt;&lt;li&gt;Biliary stones or pseudocyst-related biliary duct stricture&lt;/li&gt;&lt;li&gt;Previous pancreatic surgery or endoscopic sphincterotomy&lt;/li&gt;&lt;li&gt;Score IV or V on the American Society of Anesthesiologists scale&lt;/li&gt;&lt;li&gt;Pregnancy or breastfeeding&lt;/li&gt;&lt;li&gt;Patient aged under 18 years&lt;/li&gt;&lt;li&gt;Emergency clinical situations (ie, angiocholitis with septicemia)&lt;/li&gt;&lt;li&gt;Non-compliant patients or suffering from legal incapacity&lt;/li&gt;&lt;li&gt;Contra-indication for endoscopic or surgical treatment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Normalization of serum alkaline phosphatase (considered as &lt; 130 UI/l): a normal value of serum alkaline phosphatase will be considered as &lt; 130 UI/l</Description><Timeframe>18 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Bili-MRI: morphological assessment by Bili-MRI, Pseudocyst, main pancreatic duct &gt; 3 mm, inflammatory cephalic mass &gt; 4 cm, biliary duct stricture, pancreatic calcifications</Description><Timeframe>At 6 and 18 months after the procedure</Timeframe></Measure><Measure><Description>CT-Scan (Morphological assessment): morphological assessment  by CT-Scan, Pseudocyst, main pancreatic duct &gt; 3 mm, inflammatory cephalic mass &gt; 4 cm, biliary duct stricture, pancreatic calcifications</Description><Timeframe>At 6 and 18 months after the procedure</Timeframe></Measure><Measure><Description>Cholestasis: biological measures Cholestasis Bilirubinemia &lt; 1,2 mg/dl (norms : 0,1 and 1,2 mg/dl) Gamma GT &lt; 50 UI/l</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Cytolysis: biological measures Cytolysis TGO &lt; 40 UI/l (norms : 15 and 40 UI/l) TGP &lt; 40 UI/l (norms : 10 and 40 UI/l)</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Hospital length of stay</Description><Timeframe>At 1, 3, 6, 12, 18 months</Timeframe></Measure><Measure><Description>Liver failure: biological measures Liver failure TP &gt; 60% (norms : 60 and 120%) Facteur V &gt; 60% (norms : 60 and 120%)</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Quality of Life (EORTC health surveys): EORTC health surveys will administered to assess quality of life</Description><Timeframe>At 18 months</Timeframe></Measure><Measure><Description>Abdominal pain (Clinical symptoms assessed by Izbicki's score): clinical symptoms assessed by Izbicki's score</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Dark urine (Clinical symptoms assessed): clinical symptoms assessed</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Jaundice (Clinical symptoms assessed): clinical symptoms assessed</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Number of re-hospitalization</Description><Timeframe>At 1, 3, 6, 12, 18 months</Timeframe></Measure><Measure><Description>Pale stool (Clinical symptoms assessed): clinical symptoms assessed</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure><Measure><Description>Presence of surgical complications (dindo and Clavien )</Description><Timeframe>At 1, 3, 6, 12, 18 months</Timeframe></Measure><Measure><Description>Pruritus (Clinical symptoms assessed): clinical symptoms assessed</Description><Timeframe>At 1, 3, 6, 12, 18 months after the procedure</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to assess  the effectiveness of      surgical and endoscopic interventions in the management of bile duct stricture for chronic      pancreatitis.&lt;br/&gt;The primary end point was 18-months normalization of serum alkaline phosphatase. Secondary      end points were morbid-mortality rate, quality of life, numbers of endoscopic or surgical      procedures and length of stay.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized into two groups.&lt;br/&gt;Group A: patients would receive temporary self-expandable metallic covered stent&lt;br/&gt;Group B: patients would receive surgical treatment which includes bilio-enteric anastomosis including whipple, frey or beger procedure, double or triple derivation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial was terminated due to sponsor decision: not enough inclusion.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Centre Hospitalier Dr Schaffner</Name><Address1>Lens</Address1><Contacts/></Site><Site><Name>Centre hospitalier</Name><Address1>Béthune</Address1><Contacts/></Site><Site><Name>Centre hospitalier</Name><Address1>Dunkerque</Address1><Contacts/></Site><Site><Name>Centre hospitalier</Name><Address1>Roubaix</Address1><Contacts/></Site><Site><Name>Centre hospitalier</Name><Address1>Valencienne</Address1><Contacts/></Site><Site><Name>Clinique de la Louvière</Name><Address1>Lille</Address1><Contacts/></Site><Site><Name>Hôpital St Philibert</Name><Address1>Lomme</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02366988</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2018-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-09-24T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-03-10T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-06-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="238383"><TitleDisplay>Bacterial Contamination: Iodine Versus Saline Irrigation in Pediatric Spine Surgery</TitleDisplay><TitleOfficial>Bacterial Wound Contamination Prior to Closure: Povidone-Iodine Versus Saline Irrigation in Pediatric Spine Fusion Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02527512</Identifier><Identifier type="Organisational Study">IRB-P00015085</Identifier></Identifiers><Indications><Indication id="40">Bacterial infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>povidone-iodine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>sodium chloride</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="24334" type="Company"><TargetEntity id="4295982344" type="organizationId">Boston Children's Hospital</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="24334">Boston Children's Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Hospital solutions</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>174</PatientCountEnrollment><DateStart>2017-07-13T00:00:00Z</DateStart><DateEnd type="estimated">2019-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-05-10T02:08:33Z</DateChangeLast><DateAdded>2015-09-15T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Boston Children’s Hospital</Affiliation><Name>Michael Glotzbecker, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 3 to 18 years on day of surgery&lt;/li&gt;&lt;li&gt;Diagnosis of spinal deformity&lt;/li&gt;&lt;li&gt;Undergoing elective posterior spine multi-level instrumentation surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Documented renal failure&lt;/li&gt;&lt;li&gt;Documented allergy to iodine or shellfish&lt;/li&gt;&lt;li&gt;Previous spine fusion surgery&lt;/li&gt;&lt;li&gt;Undergoing elective posterior spine single-level instrumentation surgery&lt;/li&gt;&lt;li&gt;Undergoing anterior spine multi-level instrumentation surgery&lt;/li&gt;&lt;li&gt;Current antibiotic use&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Establish safety of use of dilute povidone-iodine irrigation: number of patients with an initial positive bacterial culture prior to irrigation as assessed by identification of infection at 30 or 90 day</Description><Timeframe>Preoperative to postoperative visit (30 or 90 day post surgery)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Establish population (ie idiopathic vs neuromuscular) specific differences in tissue colonization prior to closure: evaluate bacteriology of tissue contamination as assessed by identification of infection by population status</Description><Timeframe>Surgery</Timeframe></Measure><Measure><Description>Establish estimates for the effect that povidone-iodine/saline have on reducing bacterial contamination: evaluate bacteriology of tissue contamination as assessed by identification of infection</Description><Timeframe>Surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to  evaluate the safety of povidone-iodine irrigation in pediatric spinal      patients by collecting pre- and post-operative safety labwork. Furthermore, the efficacy of      povidone-iodine and normal saline irrigation at reducing bacterial contamination of the      surgical wound will be measured by collecting cultures before and after irrigation.&lt;/para&gt;&lt;para&gt;The investigators hypothesize povidone-iodine is both safe and effective.&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study will determine the safety of using      povidone-iodine irrigation in pediatric spinal patients and how effective it is at reducing      bacterial contamination of the spinal surgical wound prior to closure, compared with normal      saline. Patients will be randomized to receive 0.35% povidone-iodine (Betadine) or sterile 0.90% sodium chloride (NaCl) solution.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Children's Mercy Kansas City</Name><Address1>Kansas City</Address1><Address2>Missouri</Address2><Address3>64114</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>The Children's Hospital of Philadelphia</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02527512</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2019-02-01T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>14.61 Months</EnrollmentPeriod><EnrollmentRate>11.91 Patients/Month</EnrollmentRate><DateFirstReceived>2015-08-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-09-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-07-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-10-03T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="245204"><TitleDisplay>Strategies for Management of Corneal Neovascularisation</TitleDisplay><TitleOfficial>Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02594423</Identifier><Identifier type="Secondary Organisational">2015-003180-11</Identifier><Identifier type="Organisational Study">15070</Identifier></Identifiers><Indications><Indication id="3138">Choroidal neovascularization</Indication></Indications><BiomarkerNames><BiomarkerName id="18315" role="Therapeutic effect marker" type="Physiological">Visual acuity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Fine Needle Diathermy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="20640">University of Nottingham</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8047" type="Drug"><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity></SourceEntity><SourceEntity id="20640" type="Company"><TargetEntity id="4296787527" type="organizationId">University Of Nottingham</TargetEntity></SourceEntity><SourceEntity id="3138" type="ciIndication"><TargetEntity id="10060823" type="MEDDRA"/><TargetEntity id="D020256" type="MeSH"/><TargetEntity id="-246045757" type="omicsDisease"/><TargetEntity id="1167" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20640">University of Nottingham</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="12521">VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="61">Angiogenesis inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2015-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-08-31T00:00:00Z</DateEnd><DateChangeLast>2019-02-07T10:12:32Z</DateChangeLast><DateAdded>2015-11-09T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>harminder.dua@nottingham.ac.uk</Email><Name>Harminder S Dua, Professor</Name><Phone>+44 (0) 115970 9796</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Nottingham</Affiliation><Name>Harminder S Dua, Professor</Name></Contact><Contact type="Public contact"><Email>msxng2@nottingham.ac.uk</Email><Extension>63735</Extension><Name>Noha M Ghoz, Fellow</Name><Phone>+44 (0) 115 9949924</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients  age &gt;  18 years&lt;/li&gt;&lt;li&gt;Able to give informed consent&lt;/li&gt;&lt;li&gt;With corneal neovascularisation non responsive or not suitable for conventional steroid therapy&lt;/li&gt;&lt;li&gt;Use of effective contraception in females of childbearing age&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients&amp;lt; 18 years of age&lt;/li&gt;&lt;li&gt;Patients unable or refusing to provide informed consent&lt;/li&gt;&lt;li&gt;Patients who are needle phobic&lt;/li&gt;&lt;li&gt;Pregnant women, women aiming for conception and breastfeeding women&lt;/li&gt;&lt;li&gt;Patients with hypersensitivity to the active substance or to any of the excipients&lt;/li&gt;&lt;li&gt;Patients with active or suspected ocular or periocular infections&lt;/li&gt;&lt;li&gt;Patients with active severe intraocular inflammation&lt;/li&gt;&lt;li&gt;Patients with raised intraocular pressure or on glaucoma medication&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Decreased corneal neovascularisation: a comparison of total vascularisation of the corneal area as measured by our grading system (Faraj LA et al, 2015) before and after treatment</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Decreased corneal opacity related to lipid deposition: the response to treatment will be judged clinically by biomicroscopy examination and quantitatively by comparison with pre-treatment slit lamp photographs. The comparison of the pre and post treatment slit lamp images will be done by two independent blind reviewers</Description><Timeframe>10 months</Timeframe></Measure><Measure><Description>Improved/maintained Snellen's visual acuity: visual acuity is assessed using Snellen chart and vision is expressed in LOGMAR units</Description><Timeframe>10 months</Timeframe></Measure><Measure><Description>Reduced episodes of graft rejection(in corneal graft patients): number of rejection episodes will be recorded</Description><Timeframe>10 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study deals about management of active and established corneal neovascularisation to prevent visual impairment. The investigators propose to evaluate the efficacy and safety of Fine needle Diathermy(FND) alone and FND combined with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (Avastin)  in treatment of CVas.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study will include two groups:&lt;br/&gt;Group 1 will receive  Fine needle Diathermy.  Fine needle Diathermy(FND) will be applied under topical anesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.&lt;br/&gt;Group 2 will receive  Fine Needle Diathermy and bevacizumab. Fine needle Diathermy(FND) will be applied under topical anesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 to 0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other ocular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17204">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18215">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02594423</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2015-003180-11</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other ocular disease" id="43240"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other ocular disease" id="43437"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Other ocular disease" id="43438">Assessment of corneal neovascularization</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other ocular disease" id="43437"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Other ocular disease" id="43439">Assessment of corneal opacity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other ocular disease" id="43440"><Endpoint>Assessment of Visual Function</Endpoint><SubEndpoints><SubEndpoint disease="Other ocular disease" id="43441">Assessment of visual acuity(VA)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other ocular disease" id="43555"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other ocular disease" id="43003"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other ocular disease" id="32980"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other ocular disease" id="35080"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other ocular disease" id="24053"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="24648">Subjects with infectious diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other ocular disease" id="24306"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="24422"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="24645"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="24964"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="24412">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other ocular disease" id="24993"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="25619"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="27243"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="27920"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-10-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-11-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="262620"><TitleDisplay>Evaluation of Diagnosis of Fever and Biological Inflammatory Syndrome of Unknown Origin</TitleDisplay><TitleOfficial>Evaluation of Diagnosis of Fever and Biological Inflammatory Syndrome of Unknown Origin</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02786693</Identifier><Identifier type="Organisational Study">2015-A01627-42</Identifier><Identifier type="Trial Acronym">FUO</Identifier></Identifiers><Indications><Indication id="1833">Fever</Indication><Indication id="188">Inflammatory disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Disease marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1038962" type="Company"><TargetEntity id="5035542309" type="organizationId">University Hospital  Grenoble</TargetEntity></SourceEntity><SourceEntity id="1833" type="ciIndication"><TargetEntity id="10037660" type="MEDDRA"/><TargetEntity id="D005334" type="MeSH"/><TargetEntity id="-269270090" type="omicsDisease"/><TargetEntity id="24" type="siCondition"/></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1038962">University Hospital, Grenoble</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2015-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-12-31T00:00:00Z</DateEnd><DateChangeLast>2016-12-07T02:05:20Z</DateChangeLast><DateAdded>2016-06-27T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>lbouillet@chu-grenoble.fr</Email><Extension>+33</Extension><Name>Laurence Bouillet, PhD</Name><Phone>04 76 76 55 13</Phone></Contact><Contact type="Scientific contact"><Affiliation>University Hospital, Grenoble</Affiliation><Name>Laurence Bouillet, PhD</Name></Contact><Contact type="Public contact"><Email>cwackenheim@chu-grenoble.fr</Email><Extension>+33</Extension><Name>Chloé Wackenheim, student</Name><Phone>04 76 76 55 13</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients&amp;gt; 18 years old&lt;/li&gt;&lt;li&gt;With fever&amp;gt; 38.5degC and/or CRP &amp;gt; 5 mg/l for &gt; 1 week&lt;/li&gt;&lt;li&gt;With standard check-up that did not allow a causal diagnosis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Immunosuppression : HIV, neutropenia, known cancer with chemotherapy, immunosuppressive treatment or corticotherapy (&amp;gt; 10 mg/l for &amp;gt; 3 weeks)&lt;/li&gt;&lt;li&gt;Nosocomial fever&lt;/li&gt;&lt;li&gt;Pregnant women&lt;/li&gt;&lt;li&gt;Patients who are not able to sign a consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Presence of a final diagnosis after paraclinical explorations: final diagnosis according to the previous classification: infectious disease, inflammatory or auto-immune disease, cancer, or miscellaneous cause</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Medical economic evaluation of the utility of the TEP scan in the diagnostic approach: benefit of TEP Scan in the diagnosis of FUO and SII: the utility is defined as an examination which allows: the direct diagnosis or direct the examination which will allow the diagnosis. The utility will be validated for every examination by two responsible doctors</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Mortality rate of patient with FUO and SII, according to the presence or absence of a final diagnosis: mortality rate</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Causes of FUO/SII: proportion of each causes of FUO/SII, according to the main outcome after final diagnosis: five possible causes : infectious diseases, autoimmune and inflammatory diseases, cancers, miscellaneous causes. Final diagnosis is determined according to the usual criteria, reviewed by two practitioners</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Prevalence of FUO/SII: number of patients with FUO and SII, assessed by inclusion in the present study</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the trial is to evaluate the clinical practices in the diagnosis of fever and biological      inflammatory syndrome of unknown origin, in two units of the University Grenoble Hospital.&lt;/para&gt;&lt;para&gt;Investigators propose to evaluate professional practices in the diagnosis of fever and      biological inflammatory syndrome of unknown origin, and especially the interest of TEP Scan,      in two units of the University Grenoble Hospital.&lt;/para&gt;&lt;para&gt;Investigators will study prevalence of FUO and SII, and of each causes of FUO and SII, and      the prognosis of patients with FUO and SII, according to the presence or the absence of      final diagnosis, as well as the economic impact of the different complementary exams.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with fever &amp;gt; 38.5degC for &amp;gt; 1 week, or CRP &amp;gt; 5 mg/l, without diagnosis after a first step clinical examination and paraclinical exams will be recruited for the study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>CHU Grenoble</Name><Address1>Grenoble</Address1><Address3>38000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>lbouillet@chu-grenoble.fr</Email><Name>Laurence Bouillet, MD</Name><Phone>+33 (0)4 76 76 55 65</Phone></Contact></Contacts></Site><Site><Name>University Hospital</Name><Address1>Grenoble</Address1><Address3>38000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>OEpaulard@chu-grenoble.fr</Email><Name>olivier epaulard, MD, PhD</Name><Phone>+33476765291</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02786693</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other immune disease" id="43089"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other immune disease" id="43089"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other immune disease" id="43109"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other immune disease" id="43111"><Endpoint>Health Economic Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other immune disease" id="45703"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other immune disease" id="32767"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other immune disease" id="24101"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Other immune disease" id="24136">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other immune disease" id="24961"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other immune disease" id="24119">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other immune disease" id="25831"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Other immune disease" id="24126">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other immune disease" id="25890"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Other immune disease" id="24124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-12-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-06-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="275312"><TitleDisplay>Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis</TitleDisplay><TitleOfficial>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02931838</Identifier><Identifier type="Organisational Study">IM011-011</Identifier><Identifier type="Other">2016-002481-31</Identifier><Identifier type="Other">JapicCTI-173522</Identifier></Identifiers><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="252" role="Therapeutic effect marker" type="Genomic;Proteomic">Interferon gamma</BiomarkerName><BiomarkerName id="383" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-17A</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1925" role="Therapeutic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="1950" role="Therapeutic effect marker" type="Genomic;Proteomic">Protein S100-A8</BiomarkerName><BiomarkerName id="1952" role="Therapeutic effect marker" type="Genomic;Proteomic">Protein S100-A9</BiomarkerName><BiomarkerName id="2120" role="Therapeutic effect marker" type="Genomic;Proteomic">Interferon-induced GTP-binding protein Mx1</BiomarkerName><BiomarkerName id="2242" role="Therapeutic effect marker" type="Genomic;Proteomic">C-C motif chemokine 20</BiomarkerName><BiomarkerName id="2266" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-23 subunit alpha</BiomarkerName><BiomarkerName id="2467" role="Therapeutic effect marker" type="Genomic">59 kDa 2'-5'-oligoadenylate synthetase-like protein</BiomarkerName><BiomarkerName id="2706" role="Therapeutic effect marker" type="Cellular">Natural killer cells</BiomarkerName><BiomarkerName id="3390" role="Therapeutic effect marker" type="Cellular">T helper 17 cells</BiomarkerName><BiomarkerName id="3824" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-19</BiomarkerName><BiomarkerName id="4806" role="Therapeutic effect marker" type="Cellular">Lymphocytes</BiomarkerName><BiomarkerName id="6476" role="Therapeutic effect marker" type="Genomic;Proteomic">Keratin, type I cytoskeletal 16</BiomarkerName><BiomarkerName id="6663" role="Therapeutic effect marker" type="Cellular">B-lymphocytes</BiomarkerName><BiomarkerName id="6942" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-17F</BiomarkerName><BiomarkerName id="9094" role="Therapeutic effect marker" type="Genomic">Interleukin-17D</BiomarkerName><BiomarkerName id="29438" role="Therapeutic effect marker" type="Proteomic">beta-Defensins</BiomarkerName><BiomarkerName id="36677" role="Therapeutic effect marker" type="Genomic;Proteomic">Late cornified envelope protein 3E</BiomarkerName><BiomarkerName id="59332" role="Therapeutic effect marker" type="Proteomic">Interleukin-36 cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BMS-986165</Name><Drug id="98856">BMS-986165</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="98856">BMS-986165</Drug><IndicationsPioneer/><Companies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="15134">Bristol-Myers Squibb KK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15134" type="Company"><TargetEntity id="5000271360" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="3568" type="Action"><TargetEntity id="1507" type="Mechanism">Tyk2 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>77</NumberOfSites><CompaniesSponsor><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="15134">Bristol-Myers Squibb KK</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3568">Tyk2 tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>270</PatientCountEnrollment><PatientCountEvaluable>267</PatientCountEvaluable><DateStart>2016-11-15T00:00:00Z</DateStart><DateEnd type="actual">2017-11-16T00:00:00Z</DateEnd><DateChangeLast>2019-05-31T16:25:57Z</DateChangeLast><DateAdded>2016-11-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bristol-Myers Squibb</Affiliation><Name>Bristol-Myers Squibb</Name></Contact><Contact type="Public contact"><Affiliation>Clinical Trials Contact Personnel</Affiliation><Email>mg-jp-clinical_trial@bms.com</Email><Name>Bristol-Myers Squibb K.K.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and female, aged 18 to 70 years&lt;/li&gt;&lt;li&gt;Diagnosis of plaque psoriasis for 6 months&lt;/li&gt;&lt;li&gt;Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy&lt;/li&gt;&lt;li&gt;Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus five half-lives of the study drug plus 90 days&lt;/li&gt;&lt;li&gt;Other protocol defined inclusion criteria could apply&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of non-plaque psoriasis&lt;/li&gt;&lt;li&gt;History or evidence of active infection and/or febrile illness&lt;/li&gt;&lt;li&gt;Any significant acute or chronic medical illness&lt;/li&gt;&lt;li&gt;Blood transfusion within 4 weeks of study drug administration&lt;/li&gt;&lt;li&gt;Inability to tolerate oral medication&lt;/li&gt;&lt;li&gt;Positive hepatitis-B (HBV) surface antigen&lt;/li&gt;&lt;li&gt;Positive hepatitis-C (HCV) antibody&lt;/li&gt;&lt;li&gt;Any history or risk for tuberculosis (TB)&lt;/li&gt;&lt;li&gt;Any major illness/condition or evidence of an unstable clinical condition&lt;/li&gt;&lt;li&gt;Chest X-ray findings suspicious of infection at screening&lt;/li&gt;&lt;li&gt;Has received ustekinumab, secukinumab or ixekizumab within 6 months of first administration of study medication&lt;/li&gt;&lt;li&gt;Has received anti-tumor necrosis factor (TNF) inhibitor(s) within 2 months of first administration of study medication&lt;/li&gt;&lt;li&gt;Has received rituximab within 6 months of first administration of study medication&lt;/li&gt;&lt;li&gt;Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication&lt;/li&gt;&lt;li&gt;Any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication&lt;/li&gt;&lt;li&gt;Other protocol defined exclusion criteria could apply&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportion of subjects reaching a 75% reduction in Psoriasis Area and Severity Index (PASI-75)</Description><Timeframe>Days 1 to  85</Timeframe></Measure><Measure><Description>Number of adverse events (AEs)</Description><Timeframe>Days 1 to 115</Timeframe></Measure><Measure><Description>Safety and tolerability</Description><Timeframe>Day 1 to 115</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Dermatology Life Quality Index score (DLQI)</Description><Timeframe>Days 1 to 85</Timeframe></Measure><Measure><Description>Proportion of subjects at week 12 with PASI-100</Description><Timeframe>Baseline to week 12</Timeframe></Measure><Measure><Description>Proportion of subjects at week 12 with PASI-50</Description><Timeframe>Baseline to week 12</Timeframe></Measure><Measure><Description>Proportion of subjects at week 12 with PASI-75</Description><Timeframe>Baseline to week 12</Timeframe></Measure><Measure><Description>Proportion of subjects at week 12 with PASI-90</Description><Timeframe>Baseline to week 12</Timeframe></Measure><Measure><Description>Trough observed plasma concentration of BMS-986165 (Ctrough)</Description><Timeframe>Days 1 to 85</Timeframe></Measure><Measure><Description>The proportion of subjects reaching '0' and '1' on the static Physician Global Assessment score (sPGA)</Description><Timeframe>Days 1 to 85</Timeframe></Measure><Measure><Description>The proportion of subjects reaching a 50% (PASI-50), 75% (PASI-75), 90% (PASI-90) and 100% (PASI-100) reduction in psoriasis activity and severity index</Description><Timeframe>Day 1 to 85</Timeframe></Measure><Measure><Description>Analysis of IL-23/Th17- and IFN-pathway biomarkers by quantitative real-time polymerase chain reaction, RNA sequencing, and immunohistochemistry</Description></Measure><Measure><Description>To assess dose-dependent effects on the laboratory parameters in the blood indicative of non-selective inhibition of JAKs 1 to 3 (hemoglobin, Lymphocytes, natural killer [NK] cells, or B-cell counts, total cholesterol levels or neutrophil count)</Description></Measure><Measure><Description>RNA expression analysis</Description></Measure><Measure><Description>Immunohistochemistry</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2018, results were published. Subjects receiving the BMS-986165, demonstrated three serious adverse events, as well as one case of malignant melanoma 96 days after the initiation of treatment [&lt;ulink linkType="Reference" linkID="2095973"&gt;2095973&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, results were presented. Adverse events  (generally mild to moderate) were reported in 51, 59, 55, 64, 80 and 77% of subjects in BMS-986165 3 mg qod, 3 mg qd, 3 mg bid, 6 mg bid, 12 mg qd groups respectively. The overall safety profile was acceptable with no abnormalities associated with inhibition of other tyrosine kinases, such as JAKs 1 to 3 [&lt;ulink linkType="Reference" linkID="2112284"&gt;2112284&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, results were presented. In subjects receiving placebo and BMS-986165 (3 mg qod, 3 mg qd, 3 mg bid, 6 mg bid and 12 mg qd), treatment-emergent adverse events (TEAEs) were reported in 53, 59, 57, 64, 80 and 77%, respectively. The serious AEs reported were five and none of which were considered drug-related: two events in one placebo subject (hemorrhagic anemia, hemorrhoidal hemorrhage) and one event in one each in the 3 mg qod (gastroenteritis rotavirus), 3 mg qd (eye injury) and 3 mg bid (dizziness) treatment groups. There were no cases of herpes zoster or tuberculosis. Nasopharyngitis (2 to 16%), headache (4 to 9%), diarrhea (2 to 9%) and upper respiratory tract infections (0 to 9%) were the most common TEAEs across treatment arms, with no clear dose-related trends. Generally, AEs reported were mild to moderate in intensity and resulted in drug discontinuation in 4% of placebo and 2 to 7% of subjects across the active doses. Significant changes in liver enzymes, blood counts or lipid levels were not observed [&lt;ulink linkType="Reference" linkID="2121919"&gt;2121919&lt;/ulink&gt;]. Similar results were presented in March 2019 [&lt;ulink linkType="Reference" linkID="2126191"&gt;2126191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, results were presented. Adverse events were reported in 51, 59, 55, 64, 80 and 77% including nasopharyngitis (4, 2, 9, 11, 16 and 5%), headache (4, 9, 9, 7, 7 and 5%), diarrhea (4, 2, 2, 4, 4 and 9%), nausea (4, 9, 0, 2, 2 and 5%), upper respiratory tract infection (0, 2, 7, 2, 9 and 2%), pruritus (4, 0, 2, 2, 7 and 5%), acne (0, 2, 0, 2, 4 and 4%), toothache (2, 2, 2, 2, 7 and 2%), psoriasis (4, 2, 7, 2, 0 and 0%) and apthous ulcer (0, 0, 0, 7, 0 and 2%) being  the most frequent adverse events reported in subjects treated with placebo and BMS-986165 (3 mg qod, 3 mg qd, 3 mg bid, 6 mg bid and 12 mg qd), respectively [&lt;ulink linkType="Reference" linkID="2126191"&gt;2126191&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the trial was  to evaluate efficacy and safety in subjects with moderate to severe psoriasis      treated with &lt;ulink linkType="Drug" linkID="98856"&gt;BMS-986165&lt;/ulink&gt;.  &lt;br/&gt;Main objective of the trial:&lt;br/&gt;To compare the proportion of subjects with moderate to severe psoriasis experiencing a 75% improvement as measured by reduction in psoriasis area and severity index (PASI-75) score after 12 weeks of treatment between doses of BMS-986165 and placebo.   &lt;br/&gt;To assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis.  &lt;br/&gt;Secondary objectives of the trial were:  &lt;br/&gt;To assess that the proportion of subjects (sbj) experiencing a 75% reduction in psoriasis area and severity index (PASI) score in the most efficacious treatment group.&lt;br/&gt;To compare the proportions of subjects experiencing a 75% reduction in PASI score between treatment groups.&lt;br/&gt;To assess a positive trend btw treatment groups of BMS-986165 and proportion of sbj experiencing a 75% reduction in PASI score aftr 12  weeks of treatment.&lt;br/&gt;To assess clinical efficacy of BMS-986165 as measured by improvement in skin disease area and severity indices PASI50/75/90/100 over time in sbj with moderate to severe psoriasis.&lt;br/&gt;To assess a significantly higher proportion of sbj achieving a static physician's global assessment (sPGA) score of 0=cleared or 1=minimal after 12 wks of treatment with BMS-986165 than after 12 wks of treatment with placebo.&lt;br/&gt;To assess improvement by BMS-986165 in quality of life assessments (DLQI).&lt;br/&gt;To assess the trough concentrations of BMS-986165 in subjects with moderate to severe psoriasis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2018, results were published. At week 12, the percentage of subjects with a PASI score &gt;/= 75% reduction  (PASI 75)  were 7%  with placebo (n = 45), 9%  with 3 mg of BMS-986165 every other day (n = 44; p  = 0.49 versus placebo), 39% with 3 mg daily (n = 44; p &amp;lt; 0.05 versus placebo), 69% with 3 mg bid (n = 45; p &amp;lt; 0.001 versus placebo), 67%  with 6 mg bid (n = 45; p &amp;lt; 0.0001 versus placebo), and 75% with 12 mg daily (n = 44; p &amp;lt; 0.001 versus placebo) [&lt;ulink linkType="Reference" linkID="2095973"&gt;2095973&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2112284"&gt;2112284&lt;/ulink&gt;]. Similar results were presented in September 2018 [&lt;ulink linkType="Reference" linkID="2121919"&gt;2121919&lt;/ulink&gt;]. Similar results were presented in March 2019 [&lt;ulink linkType="Reference" linkID="2126191"&gt;2126191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, further results were presented. At week 12, in placebo and BMS-986165 (3 mg qod, 3 mg qd, 3 mg bid, 6 mg bid, 12 mg qd) groups (n = 45, 44, 44, 45, 45 and 44, respectively), the proportion of subjects with PASI90 was 2, 7, 16, 44 (p &amp;lt; 0.0001 versus placebo), 44 (p &amp;lt; 0.0001 versus placebo) and 43% (p &amp;lt; 0.0001 versus placebo), respectively; PASI100 was 0, 2, 0, 9, 18 (p &amp;lt; 0.05 versus placebo) and 25% (p &amp;lt; 0.05 versus placebo), respectively; sPGA 0/1 was 7, 21, 39 (p &amp;lt; 0.05), 76 (p &amp;lt; 0.0001), 64 (p &amp;lt; 0.0001) and 75% (p &amp;lt; 0.0001), respectively  [&lt;ulink linkType="Reference" linkID="2112284"&gt;2112284&lt;/ulink&gt;]. Similar results were presented in September 2018 [&lt;ulink linkType="Reference" linkID="2121919"&gt;2121919&lt;/ulink&gt;]. Similar results were presented in March 2019 [&lt;ulink linkType="Reference" linkID="2126191"&gt;2126191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, further results were presented. Static Physician Global Assessment [sPGA] 0/1) rate was 7, 20, 41, 76, 66 and 75%, respectively (p &amp;lt; 0.05 for 3 mg qd, p &amp;lt; 0.0001 for higher doses) and Dermatology Life Quality Index 0/1 rate was 6, 18, 17, 44, 68 and 65, respectively (p &amp;lt; 0.05 for 3 mg bid, and p &amp;lt; 0.0001 for higher doses). In both biologic-naive and biologic-experienced subjects, efficacy was observed with a rapid onset of response by day 15  [&lt;ulink linkType="Reference" linkID="2121919"&gt;2121919&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, results of subgroup analysis were presented, which evaluated the influence of baseline disease characteristics (age of onset, Dermatology Life Quality Index [DLQI] score, musculoskeletal symptoms, PASI score, disease duration, static Physician Global Assessment [sPGA] score, previous biologic use) on the efficacy of BMS-986165 in subjects with moderate to severe plaque psoriasis. At week 12, the 75% improvement in Psoriasis Area and Severity Index (PASI) with age groups (&amp;lt; 18, 18 to &amp;lt; 45 and &gt;/= 45 years) were 65.8, 75.0 and 60.0 in combined BMS-986165 treated  group; 76.9, 71.4 and 54.5  in 3 mg bid group; 50, 76.9 and 66.7 in 6 mg bid group; 77.8, 75.9 and 66.7 in 12 mg bid group and 0, 11.1 and 0% in placebo groups, respectively; in Dermatology Life Quality Index (DLI) score (&amp;lt; 10, 10 to &amp;lt; 20 and &gt;/= 20) were 75.0, 66.1 and 70.0 in combined BMS-986165 treated  group; 57.1, 73.1 and 80.0 in 3 mg bid group;   84.2, 50.0 and 75.0 in 6 mg bid group; 78.9, 78.6 and 63.6 in 12 mg bid group; and 0, 8.7 and 12.5% in placebo groups, respectively; and in PASI responders (&amp;lt; 20 and &gt;/= 20) were 71.9 and 65.8  in combined BMS-986165 treated  group; 69.0 and 68.8 in 3 mg bid group; 72.7 and 50.0 in 6 mg bid group; 73.5 and 80.0 in 12 mg bid group; and 0 and 21.4% in placebo groups, respectively. At week 12, the 90 improvement in PASI with age groups (&amp;lt; 18, 18 to &amp;lt; 45 and &gt;/= 45 years) were 36.8, 51.3 and 30.0 in combined BMS-986165 treated  group; 53.8, 42.9 and 36.4 mg in 3 mg bid group; 18.8, 61.5 and 33.3 in 6 mg bid group; 44.4, 48.3 and 16.7 in 12 mg bid group and 0, 3.7 and 0% in placebo groups, respectively; in DLI score (&amp;lt; 10, 10 to &amp;lt; 20 and &gt;/= 20) were 50.0, 38.7 and 45.0 in combined BMS-986165 treated group; 35.7, 50.0 and 40.0 mg in 3 mg bid group; 68.4, 22.7 and 50.0 in 6 mg bid group; 42.1, 42.9 and 45.5 in 12 mg bid group and 0, 0 and 12.5% in placebo groups, respectively; and in PASI responders (&amp;lt; 20 and &gt;/= 20) were 45.8 and 39.5  in combined BMS-986165 treated group; 48.3 and 37.5 in 3 mg bid group; 48.5 and 33.3 in 6 mg bid group; 41.2 and 50.0 in 12 mg bid group; and 0 and 7.1% in placebo groups, respectively. At week 12, the static Physician Global Assessment score (sPGA) of 0 or 1 with age groups (&amp;lt; 18, 18 to &amp;lt; 45 and &gt;/= 45 years) were 71.1, 72.4 and 70.0 in combined BMS-986165 treated group; 84.6, 71.4 and 72.7 in 3 mg bid group; 56.3, 69.2 and 66.7 in 6 mg bid group; 77.8, 75.9 and 66.7 in 12 mg bid group and 0, 11.1 and 0% in placebo groups, respectively; in DLI score (&amp;lt; 10, 10 to &amp;lt; 20 and &gt;/= 20) were 73.1, 71.0 and 70.0 in combined BMS-986165 treated group; 64.3, 80.8 and 80.0 in 3 mg bid group; 78.9, 50.0 and 75.0 in 6 mg bid group; 73.7, 85.7 and 63.6 in 12 mg bid group and 7.1, 8.7 and 0% in placebo groups, respectively; and in PASI responders (&amp;lt; 20 and &gt;/= 20) were 75.0 and 63.2 in combined BMS-986165 treated group; 79.3 and 68.8 in 3 mg bid group; 72.7 and 41.7 in 6 mg bid group; 73.5 and 80.0 in 12 mg bid group; and 3.2 and 14.3% in placebo groups, respectively. At week 12, the PASI 75 score in subgroups including disease duration (&amp;lt; 15 and &gt;/= 15 years) were 68.3 and 71.6; 72.0 and 65.0; 61.5 and 80.6,  in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively; musculoskeletal symptoms (no and yes) were 69.1 and 73.0;  64.7 and 81.8; 67.6 and 63.6;  and 75.9 and 73.3 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively, sPGA score (3 and 4 to 5) were 67.4 and 77.3; 65.5 and 75.0; 65.6 abd 75.0 and 71.4 and 81.3 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively and previous biologic use per IWRS (no and yes) were 75.3 and 63.2, 65.4 and 73.7; 80.0 and 50.0; 80.8 and 66.7 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively; the PASI 90 score in subgroups including disease duration (&amp;lt; 15 and &gt;/= 15 years) were 45.0 and 43.2; 48 and 40; 54.5 and 34.8 and 23.1 and 51.6 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively, musculoskeletal symptoms (no and yes) were 45.4 and 40.5; 47.1 and 36.4; 44.1 and 45.5 and 44.8 and 40.0 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively, sPGA score (3 and 4 to 5) were 41.6 and 50.0; 37.9 and 56.3; 43.8 and 50.5 and 42.9 and 43.8 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively; and previous biologic use per IWRS (no and yes) were 50.6 and 35.1; 50.0 and 36.8; 60 and 25; 42.3 and 44.4, in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groupsrespectively; and in sPGA 0/1 score in subgroups including disease duration (&amp;lt; 15 and &gt;/= 15 years) were 63.3 and 78.4; 68.0 and 85.0; 63.6 and 65.2 and 53.8 and 83.9 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively, musculoskeletal symptoms (no and yes) were 71.1 and 73.0; 70.6 and 90.9; 67.6 and 54.5 and 75.9 and 73.3, in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively, sPGA score (3 and 4 to 5) were 70.8 and 75.0; 75.9 and 75.0; 62.5 and 75.0 and 75.0 and 75.0 in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively, and previous biologic use per IWRS (no and yes) were 71.4 and 71.9; 75.0 and 61.5; 75.0 and 72.0 and 75.0 and 80.8, in combined BMS-986165 group; 3 mg bid; 6 mg bid; and 12 mg qd groups, respectively  [&lt;ulink linkType="Reference" linkID="2126262"&gt;2126262&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, results of subgroup analysis were presented, which  investigated the changes in IL-23/Th17- and IFN-pathway biomarkers associated with BMS-986165 treatment of subjects with moderate to severe psoriasis. BMS-986165 treatment was associated with  reduction in the pathologic hallmarks of psoriasis and markers of the IL-23 pathway, including IL-17A, beta-defensin, S100A9, IL-17F, IL-22, and S100A8 returned to non-lesion levels in a dose-dependent manner; IFN-regulated genes (IFN-induced GTP-binding protein Mx1 and 2'-5'-oligoadenylate synthetase-like) were normalized with doses &gt;3 mg bid; reductions in expression of IL-19 and IL-36A  with doses &gt;3 mg bid and keratinocyte dysregulation markers (keratin-16, chemokine CCL20, and late cornified envelope genes [LCE3E]) returned towards non-lesion levels with effective doses following BMS-986165 treatment. Changes in mean levels of hemoglobin or in mean counts of NK cells, B cells, or lymphocytes were not observed  with BMS-986165 treatment (n =222) and in addtion, the mean total cholesterol levels and  neutrophil count were not changed with BMS-986165 treatment. Relative to placebo, greater proportion of subjects achieved PASI 75 (primary endpoint), PASI 90, and sPGA 0/1 at BMS-986165 doses &gt;/=3 mg qd and  PASI 100 responses were greatest at the highest BMS-986165 doses. It was noted that treatment effects were apparent as early as day 15 and persisted with reduced effect in the 30-day follow-up period after last treatment  [&lt;ulink linkType="Reference" linkID="2126191"&gt;2126191&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, results were presented. This subgroup analysis included patients who received BMS-986165 at the three most efficient doses (&gt;/= 3 mg bid; n = 134). In each subgroup, there was a slight imbalance in the number of patients per treatment  as no stratification by subgroup was performed at randomization. At week 12, the proportion of patients attaining 75% improvement in Psoriasis Area and Severity Index (PASI) 75 in the weight subgroups &amp;lt; 90 and &gt;/= 90 kg was 74.1 and 64.2% in the combined BMS-986165 group and 18.8 and 0% in the placebo group; those attaining PASI 90 was 51.9 and 32.1% in the combined BMS-986165 group and 6.3 and 0% in the placebo group; and those with static Physicians Global Assessment (sPGA) score 0/1 was 71.6 and 71.7% in the combined BMS-986165 group and 12.5 and 3.4% in the placebo group. In BMI subgroups &amp;lt; 25, 25 to &amp;lt; 30 and &gt;/= 30 kg/m2, 80.5, 65.2 and 66% in BMS-986165 treated group and 0, 7.1 and 8.0% in placebo groups attained PASI 75; 65.9, 34.8 and 34% in BMS-986165 treated group and 0, 0 and 4% in placebo group attained PASI 90; and 73.2, 71.7 and 70.2% in BMS-986165 treated group and 0, 7.1 and 8% in placebo groups had sPGA score 0/1, respectively. In the age groups 18 to &amp;lt; 45 and &gt;/= 45 years subgroups, 74.2 and 66.2% in BMS-986165 treated group and 5 and 8% in placebo group reached PASI 75; 3 and 35.3% in BMS-986165 treated group and 0 and 4% in placebo group achieved PASI 90; and 77.3 and 66.2% in BMS-986165 treated group and 5 and 8% in placebo groups had sPGA score 0/1, respectively [&lt;ulink linkType="Reference" linkID="2126321"&gt;2126321&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized to one of six arms and would receive  BMS-986165 dose 1, 2, 3, 4, 5 or placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects were randomized to receive oral BMS-986165, 3 mg  every other day, 3 mg qd, 3 mg bid, 6 mg bid, or 12 mg qd or to receive placebo for 12 weeks [&lt;ulink linkType="Reference" linkID="2095973"&gt;2095973&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2112284"&gt;2112284&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="2121919"&gt;2121919&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2126262"&gt;2126262&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2126191"&gt;2126191&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2126321"&gt;2126321&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>BMS-986165</Name><Drug id="98856">BMS-986165</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="205">Melanoma</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="641655">BMS-986165</Intervention><Treatments><Treatment><Dose>3 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>6 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>12 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>Local Institution</Name><Address1>Kogarah</Address1><Address2>New South Wales</Address2><Address3>2217</Address3><CountrySubDivision>New South Wales</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Melbourne</Address1><Address2>Victoria</Address2><Address3>3053</Address3><CountrySubDivision>Victoria</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Nedlands</Address1><Address2>Western Australia</Address2><Address3>6009</Address3><CountrySubDivision>Western Australia</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Wolloongabba</Address1><Address2>Queensland</Address2><Address3>4151</Address3><CountrySubDivision>Queensland</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>Local Institution</Name><Address1>Calgary</Address1><Address2>Alberta</Address2><Address3>T2S3B3</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Edmonton</Address1><Address2>Alberta</Address2><Address3>T5K 1X3</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><Address3>L8N 1V6</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Markham</Address1><Address2>Ontario</Address2><Address3>L3P 1X2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Mississauga</Address1><Address2>Ontario</Address2><Address3>L5H 1G9</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H3H 1V4</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Peterborough</Address1><Address2>Ontario</Address2><Address3>K9J 5K2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M4W 2N2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V5Z 4E8</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Waterloo</Address1><Address2>Ontario</Address2><Address3>N2J 1C4</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Windsor</Address1><Address2>Ontario</Address2><Address3>N8W 1E6</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Name>Local Institution</Name><Address1>Dresden</Address1><Address3>01097</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Gera</Address1><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Hamburg</Address1><Address3>20253</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Hamburg</Address1><Address3>20354</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Kiel</Address1><Address3>24103</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Kiel</Address1><Address3>24105</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Luebeck</Address1><Address3>23562</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Mahlow</Address1><Address3>15831</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Mainz</Address1><Address3>55131</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Schwerin</Address1><Address3>19055</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Stuttgart</Address1><Address3>70178</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Japan"><Sites><Site><Name>Local Institution</Name><Address1>Fukuoka City</Address1><Address2>Fukuoka</Address2><Address3>814-0180</Address3><CountrySubDivision>Fukuoka</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Kobe</Address1><Address2>Hyogo</Address2><Address3>6500017</Address3><CountrySubDivision>Hyogo</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Kumamoto</Address1><Address3>8608556</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Kyoto</Address1><Address3>6028566</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Minato-ku</Address1><Address2>Tokyo</Address2><Address3>105-8471</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Nagoya</Address1><Address2>Aichi</Address2><Address3>467-8602</Address3><CountrySubDivision>Aichi</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Osaka</Address1><Address3>5500012</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Sapporo</Address1><Address2>Hokkaido</Address2><Address3>060-0063</Address3><CountrySubDivision>Hokkaido</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Shimotsuke-shi</Address1><Address2>Tochigi</Address2><Address3>3290498</Address3><CountrySubDivision>Tochigi</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Shinagawa-Ku</Address1><Address2>Tokyo</Address2><Address3>141-8625</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Shinjuku-ku</Address1><Address2>Tokyo</Address2><Address3>160-0023</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Skinjuku-ku</Address1><Address2>Tokyo</Address2><Address3>1690073</Address3><CountrySubDivision>Tokyo</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Tokyo</Address1><Address3>1738606</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Latvia"><Sites><Site><Name>Local Institution</Name><Address1>Daugavpils</Address1><Address3>LV-5404</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Riga</Address1><Address3>LV-1001</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Riga</Address1><Address3>LV-1003</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Riga</Address1><Address3>LV-1011</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Riga</Address1><Address3>LV-1013</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Ventspils</Address1><Address3>LV3601</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Mexico"><Sites><Site><Name>Local Institution</Name><Address1>Cuautitlan Izcalli</Address1><Address2>Estado DE Mexico</Address2><Address3>54740</Address3><CountrySubDivision>Estado DE Mexico</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Monterey</Address1><Address2>Nuevo LEON</Address2><Address3>64460</Address3><CountrySubDivision>Nuevo LEON</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Monterrey</Address1><Address2>Nuevo LEON</Address2><Address3>64000</Address3><CountrySubDivision>Nuevo LEON</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Zapopan</Address1><Address2>Jalisco</Address2><Address3>45030</Address3><CountrySubDivision>Jalisco</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Name>Local Institution</Name><Address1>Kraksaw</Address1><Address3>31011</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Lodz</Address1><Address3>90-436</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Lublin</Address1><Address3>20-080</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Osielsko</Address1><Address3>86-031</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Siedlce</Address1><Address3>08 - 110</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Skierniewice</Address1><Address3>96-100</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Warsaw</Address1><Address2>Masovian</Address2><Address3>02-758</Address3><CountrySubDivision>Masovian</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Warszawa</Address1><Address3>01-142</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Warszawa</Address1><Address3>01-817</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Warszawa</Address1><Address2>Masovian</Address2><Address3>00-660</Address3><CountrySubDivision>Masovian</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Wroc?aw</Address1><Address3>51-318</Address3><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Wroclaw</Address1><Address3>50-368</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Austin Dermatology Associates</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78705</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Central Sooner Research</Name><Address1>Norman</Address1><Address2>Oklahoma</Address2><Address3>73071</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts/></Site><Site><Name>Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center</Name><Address1>Lebanon</Address1><Address2>New Hampshire</Address2><Address3>03756</Address3><CountrySubDivision code="NH">New Hampshire</CountrySubDivision><Contacts/></Site><Site><Name>Dawes Fretzin Clinical Research Group, LLC</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3>46256</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Dermatologic Surgery Specialists, PC</Name><Address1>Macon</Address1><Address2>Georgia</Address2><Address3>31217</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Health Concepts</Name><Address1>Rapid City</Address1><Address2>South Dakota</Address2><Address3>57702</Address3><CountrySubDivision code="SD">South Dakota</CountrySubDivision><Contacts/></Site><Site><Name>Local Institution</Name><Address1>Knoxville</Address1><Address2>Tennessee</Address2><Address3>37920</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>NorthShore University Health System</Name><Address1>Skokie</Address1><Address2>Illinois</Address2><Address3>60077</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>PMG Research of Christie Clinic, LLC</Name><Address1>Champaign</Address1><Address2>Illinois</Address2><Address3>61820</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>PMG Research of Rocky Mount, LLC</Name><Address1>Rocky Mount</Address1><Address2>North Carolina</Address2><Address3>27804</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>PMG Research of Wilmington, PLC</Name><Address1>Wilmington</Address1><Address2>North Carolina</Address2><Address3>28401</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Piedmont Plastic Surgery &amp; Dermatology - Charlotte/Blakeney Location</Name><Address1>Macon</Address1><Address2>Georgia</Address2><Address3>31217</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Name>Renstar Medical Research</Name><Address1>Ocala</Address1><Address2>Florida</Address2><Address3>34471</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Rivergate Dermatology Clinical Research Center, Pllc</Name><Address1>Goodlettsville</Address1><Address2>Tennessee</Address2><Address3>37072</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>University of California Irvine</Name><Address1>Irvine</Address1><Address2>California</Address2><Address3>92697</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of California San Diego</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92122</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3451">Subjects with Moderate Psoriasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3452">Subjects with Severe Psoriasis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02931838</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2016-002481-31</Identifier></Identifiers></Registry><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier>JapicCTI-173522</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6486"><Endpoint>Disease Severity Assessment by PASI Scores/Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6489">PASI-75 response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Psoriasis" id="6597"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Psoriasis" id="6599"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Psoriasis" id="6486"><Endpoint>Disease Severity Assessment by PASI Scores/Response</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6487">Change in psoriasis area and severity index score (PASI)</SubEndpoint><SubEndpoint disease="Psoriasis" id="6488">PASI-50 response</SubEndpoint><SubEndpoint disease="Psoriasis" id="6489">PASI-75 response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6559"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6563">Assessment by Dermatology Life Quality Index (DLQI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6626"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="46095"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6504">Assessment by Investigator/Physician Global Assessment (PGA) Scale</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="3285"><Criterion>Subjects with Plaque Psoriasis/Psoriasis Vulgaris</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3296"><Criterion>Subjects with Moderate Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3297"><Criterion>Subjects with Severe Psoriasis</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3401"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Psoriasis" id="34142"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="3416">Men with adequate contraception</SubCriterion><SubCriterion disease="Psoriasis" id="3417">Women with adequate contraception/Negative pregnancy test/Non-lactating women</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Psoriasis" id="4532"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4533">Subjects with autoimmune diseases/disorders</SubCriterion><SubCriterion disease="Psoriasis" id="4543">Subjects with HIV infections/immunodeficiency syndrome</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4555"><Criterion>Subjects with History of Tuberculosis</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4564"><Criterion>Subjects with History of/Scheduled for Psoriasis Treatment</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4565">Subjects with history of/scheduled for systemic therapy</SubCriterion><SubCriterion disease="Psoriasis" id="5041">Subjects with history of/scheduled for biologics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Psoriasis" id="27940"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4611">Subjects unable to comply with study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-11-16T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-10-13T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-03-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-02-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-02-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-02-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-02-15T00:00:00Z</Date><Reason id="311">Trial Treatment added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-16T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2019-03-28T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Removed"><Date>2019-03-28T00:00:00Z</Date><Reason id="307">Adverse Event Removed</Reason></Change><Change type="Removed"><Date>2019-03-28T00:00:00Z</Date><Reason id="307">Adverse Event Removed</Reason></Change><Change type="Removed"><Date>2019-03-28T00:00:00Z</Date><Reason id="307">Adverse Event Removed</Reason></Change><Change type="Removed"><Date>2019-03-28T00:00:00Z</Date><Reason id="307">Adverse Event Removed</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="removed"><Date>2019-03-28T00:00:00Z</Date><Reason id="312">Trial Treatment removed</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="279328"><TitleDisplay>Post-Marketinng Surveillance to Evaluate Implant Survivorship and Performance of The Freedom Total Knee System in Total Knee Arthroplasty</TitleDisplay><TitleOfficial>Freedom 400: A Prospective, Single-arm, Multicenter, Observational, Post-Marketing Surveillance To Evaluate Implant Survivorship and Performance of the Freedom Total Knee System in Total Knee Arthroplasty</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2016/11/007455</Identifier></Identifiers><Indications><Indication id="3754">Knee injury</Indication></Indications><BiomarkerNames><BiomarkerName id="46522" role="Therapeutic effect marker" type="Physiological">Knee motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Freedom Total Knee System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1067988" type="Company"><TargetEntity id="5034828876" type="organizationId">Meril Life Sciences Pvt Ltd</TargetEntity></SourceEntity><SourceEntity id="3754" type="ciIndication"><TargetEntity id="5599" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>9</NumberOfSites><CompaniesSponsor><Company id="1067988">Meril Life Sciences Pvt Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>400</PatientCountEnrollment><DateStart>2016-11-15T00:00:00Z</DateStart><DateChangeLast>2016-11-23T13:17:26Z</DateChangeLast><DateAdded>2016-11-21T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Deenanath Mangeshkar Hospital and Research Center</Affiliation><Email>hwakankar@gmail.com</Email><Name>Dr Hemant Wakankar</Name><Phone>09921131122</Phone></Contact><Contact type="Public contact"><Affiliation>Meril Life Sciences Pvt. Ltd.</Affiliation><Email>ashok.thakkar@merillife.com</Email><Name>Dr Ashok Thakkar</Name><Phone>912603063880</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subject is male or non-pregnant female&lt;/li&gt;&lt;li&gt;Aged 18 years or older at the time of study&lt;/li&gt;&lt;li&gt;Subject is willing and able to provide written Informed Consent by signing and dating the IRB or EC approved Informed Consent Form&lt;/li&gt;&lt;li&gt;Subject is a candidate for a total knee arthroplasty&lt;/li&gt;&lt;li&gt;Subject is willing and able to comply with postoperative scheduled clinical and radiographical evaluations&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject with a BMI &gt;/=40&lt;/li&gt;&lt;li&gt;Subject with an active infection within the affected knee joint&lt;/li&gt;&lt;li&gt;Subject with neuromuscular or neurosensory deficiency that may limit ability of the patient to evaluate the safety and efficacy of the device&lt;/li&gt;&lt;li&gt;Subject with a known sensitivity to device materials&lt;/li&gt;&lt;li&gt;Subject is unwilling or unable to sign the Informed Consent Document.&lt;/li&gt;&lt;li&gt;Subject with short Life expectancy&amp;lt; 5 years (eg, Cancer, HIV/AIDS)&lt;/li&gt;&lt;li&gt;Subject with history of deep vein thrombosis or other thrombotic disorders&lt;/li&gt;&lt;li&gt;Subject with conditions such as Parkinsonism, loco motors ataxia, spinal scoliosis or kyphosis, stroke etc. that would affect their loco motors stability and interfere with assessment of range of motion of the target knee&lt;/li&gt;&lt;li&gt;Subject who, in consideration of treating doctor, would not be suitable for compliance of the follow-up&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Implant Survivorship</Description><Timeframe>6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure><Measure><Description>Cumulative Revision Rate</Description><Timeframe>6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Knee Society Score</Description><Timeframe>Pre-operative, 6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure><Measure><Description>WOMAC (Western Ontario and McMaster Universities Osteoarthritis) Pain</Description><Timeframe>Pre-operative, 6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure><Measure><Description>Range of Motion</Description><Timeframe>Pre-operative, 6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure><Measure><Description>SF-36 QuestionnaireShort Form Health Survey questionnaire)</Description><Timeframe>Pre-operative, 6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure><Measure><Description>Radiographical analysis</Description><Timeframe>Pre-operative, 6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure><Measure><Description>Adverse events</Description><Timeframe>Pre-operative, 6 weeks, 6 months, one, three, five, seven and ten years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of the study is to obtain implant survivorship and clinical outcomes data for commercially available Freedom Total Knee Replacement System used in total knee arthroplasty.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects will receive Freedom Total Knee System.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>All India Institute Of Medical Sciences</Name><Address1>New Delhi</Address1><Address2>DELHI</Address2><Address3>110029</Address3><CountrySubDivision>DELHI</CountrySubDivision><Contacts/></Site><Site><Name>Amandeep Hospital</Name><Address1>Amritsar</Address1><Address2>PUNJAB</Address2><Address3>143001</Address3><CountrySubDivision>PUNJAB</CountrySubDivision><Contacts/></Site><Site><Name>Apollo Gleneagles Hospitals</Name><Address1>Kolkata</Address1><Address2>WEST BENGAL</Address2><Address3>700054</Address3><CountrySubDivision>WEST BENGAL</CountrySubDivision><Contacts/></Site><Site><Name>Artemis Health Institute</Name><Address1>Gurgaon</Address1><Address2>HARYANA</Address2><Address3>122018</Address3><CountrySubDivision>HARYANA</CountrySubDivision><Contacts/></Site><Site><Name>Deenanath Mangeshkar Hospital and Research Center</Name><Address1>Pune</Address1><Address2>MAHARASHTRA</Address2><Address3>411004</Address3><CountrySubDivision>MAHARASHTRA</CountrySubDivision><Contacts/></Site><Site><Name>Fortis Hospital</Name><Address1>Ludhiana</Address1><Address2>PUNJAB</Address2><Address3>141015</Address3><CountrySubDivision>PUNJAB</CountrySubDivision><Contacts/></Site><Site><Name>Lakeshore Hospital and Research Centre Ltd</Name><Address1>Ernakulam</Address1><Address2>KERALA</Address2><Address3>682042</Address3><CountrySubDivision>KERALA</CountrySubDivision><Contacts/></Site><Site><Name>Paras Hospital</Name><Address1>Gurgaon</Address1><Address2>HARYANA</Address2><Address3>122002</Address3><CountrySubDivision>HARYANA</CountrySubDivision><Contacts/></Site><Site><Name>Saviour Multispeciality Hospital</Name><Address1>Ahmadabad</Address1><Address2>GUJARAT</Address2><Address3>380014</Address3><CountrySubDivision>GUJARAT</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Osteoarthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="8866">Subjects With History of /Scheduled For Surgical Procedures</PatientSegment><SubSegments><SubSegment id="9327">Subjects with history of/scheduled for total knee arthroplasty</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2016/11/007455</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoarthritis" id="13937"><Endpoint>Assessment of Implant/Prosthesis Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13943">Assessment of implant survival rate</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="13944">Assessment of incidence of revisions and removals</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other musculoskeletal disease" id="45597"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Osteoarthritis" id="13912"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13917">Assessment by SF-36/SF-12</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13937"><Endpoint>Assessment of Implant/Prosthesis Function</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13940">Assessment of range of motion post treatment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13963"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13974"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Osteoarthritis" id="13995"><Endpoint>Assessment of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Osteoarthritis" id="13998">Assessment of Pain by WOMAC Score</SubEndpoint><SubEndpoint disease="Osteoarthritis" id="14011">Assessment of Pain by Knee Society Score</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="42923"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="43038"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="43046">Assessment by Short Form Health Survey (SF-36)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Osteoarthritis" id="14217"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14224">Subjects with history of/scheduled for total knee arthroplasty</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="14227"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="32681"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="32742"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="34307"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32740">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoarthritis" id="34331"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="14231">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Osteoarthritis" id="11602"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11603">Subjects with neurological/CNS disorder</SubCriterion><SubCriterion disease="Osteoarthritis" id="11609">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Osteoarthritis" id="11619">Subjects with muscular disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11614"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11616"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="11645"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11646">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="11649"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11657">Subjects unsuitable for study participation as per investigator's assessment</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24089"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24172"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24183"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Osteoarthritis" id="25601"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11651">Subjects incapable/unwilling to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="25889"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11615">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="25891"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24182">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoarthritis" id="27015"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion><SubCriteria><SubCriterion disease="Osteoarthritis" id="11656">Subjects excluded based on prespecified body weight/BMI</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="285548"><TitleDisplay>Metabolic Rate in Burns</TitleDisplay><TitleOfficial>In Vivo Cellular and Physiological Response to Severe Burns Injuries</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03024931</Identifier><Identifier type="Organisational Study">QW</Identifier><Identifier type="Trial Acronym">MrBurn</Identifier></Identifiers><Indications><Indication id="52">Skin burns</Indication></Indications><BiomarkerNames><BiomarkerName id="435" role="Disease marker" type="Genomic;Proteomic">Glucagon</BiomarkerName><BiomarkerName id="646" role="Disease marker" type="Proteomic">Thyroid-stimulating hormone</BiomarkerName><BiomarkerName id="808" role="Disease marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1904" role="Disease marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="1913" role="Disease marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="1978" role="Disease marker" type="Biochemical">Thyroxine</BiomarkerName><BiomarkerName id="2089" role="Disease marker" type="Physiological">Cardiac Output</BiomarkerName><BiomarkerName id="2534" role="Disease marker" type="Biochemical">Hydrocortisone</BiomarkerName><BiomarkerName id="2586" role="Disease marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="6875" role="Disease marker" type="Biochemical">Triiodothyronine</BiomarkerName><BiomarkerName id="10157" role="Disease marker" type="Structural (imaging)">Lung</BiomarkerName><BiomarkerName id="10169" role="Disease marker" type="Physiological">Oxygen saturation</BiomarkerName><BiomarkerName id="10260" role="Disease marker" type="Physiological">Respiratory frequency</BiomarkerName><BiomarkerName id="11268" role="Disease marker" type="Physiological">Urinary flow</BiomarkerName><BiomarkerName id="17183" role="Disease marker" type="Physiological">Intra abdominal pressure</BiomarkerName><BiomarkerName id="32942" role="Disease marker" type="Physiological">Basal metabolic rate</BiomarkerName><BiomarkerName id="44216" role="Disease marker" type="Physiological">Body temperature</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>indocyanine green</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1012048" type="Company"><TargetEntity id="5035533720" type="organizationId">Chelsea and Westminster Hospital NHS Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="52" type="ciIndication"><TargetEntity id="D002056" type="MeSH"/><TargetEntity id="-672164191" type="omicsDisease"/><TargetEntity id="452" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1012048">Chelsea &amp; Westminster NHS Trust</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2017-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-03-14T05:28:45Z</DateChangeLast><DateAdded>2017-01-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>ashida@imperial.ac.uk</Email><Name>Asako Shida</Name><Phone>07957497542</Phone></Contact><Contact type="Scientific contact"><Affiliation>Chelsea and Westminster NHS trust</Affiliation><Name>Marcela Vizcaychipi</Name></Contact><Contact type="Public contact"><Email>m.vizcaychipi@imperial.ac.uk</Email><Name>Marcela Vizcaychipi</Name><Phone>02087468903</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male or female, aged &gt;/= 16 years&lt;/li&gt;&lt;li&gt;Informed, written consent from patient. If the participant is unable to give consent then assent will be considered&lt;/li&gt;&lt;li&gt;Burns &gt; 15%&lt;/li&gt;&lt;li&gt;Acute presentation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any concern from the clinical team that the application or ongoing presence of the monitoring device would interfere with optimal patient management&lt;/li&gt;&lt;li&gt;Allergy to adhesives used for monitor leads and belts&lt;/li&gt;&lt;li&gt;Participants&amp;lt; 16 years old&lt;/li&gt;&lt;li&gt;Burns&amp;lt; 5%&lt;/li&gt;&lt;li&gt;Conditions that gives an inaccurate calorimetry results&lt;/li&gt;&lt;li&gt;Participants needing oxygen concentration &gt; 60%&lt;/li&gt;&lt;li&gt;Participants who have broncho-alveolar fistula&lt;/li&gt;&lt;li&gt;Participants with chest drains&lt;/li&gt;&lt;li&gt;Airway leak within the ventilated systems&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Monitor the change in resting metabolic rate over period of time after severe burns injury: the resting metabolic rate will be measured using Quark Indirect Calorimetry Machine from Cosmed, Italy. The rested metabolic rate will be measured in kilo calories</Description><Timeframe>Continuous monitoring over 72 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Monitor the cardiac output using Fick principle in severe burns: the cardiac output will be measured in mls</Description><Timeframe>The cardiac output will be measured using the fick principle. The cardiac output will be measured at 12th, 24th, 36th, 48th, 60th 72nd h from the point of the injury. 10 patients will be recruited over a year</Timeframe></Measure><Measure><Description>Monitor the splanchnic circulation by measuring the indocyanine green clearance rate: splanchnic circulation will be measured by using Limon machine from Maquet. The plasma clearance rate of indocyanine green will be measured in percentage per ml.</Description><Timeframe>The splanchnic circulation will be measured at 12th, 24th, 36th, 48th, 60th 72nd h from the point of the injury. 10 patients will be recruited over a year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial is to evaluate the in vivo cellular and physiological response to severe burns injuries. The purpose of this study is to gain a better understanding of the           acute physiological and metabolic changes in severe burns injury. This research will be looking into the acute resting basal metabolic changes in severe           adult burns patients by using Quark RMR (indirect calorimetry). This equipment will           allow the investigator to detect the metabolic switch in severe burns patients. &lt;br/&gt;The primary objective is to identify the 'Ebb' phase and 'flow' phase in acute burns injury. Secondary objectives are:&lt;br/&gt;To establish cardiovascular response to burns in the acute phase: to establish cardiovascular response to hyper-catabolism, using ESCO (estimated cardiac      output).&lt;br/&gt;To asses the relationship between the splanchnic circulation and hyper-catabolism.&lt;br/&gt;To assess the feasibility of performing LiMON test and (Bispectral Index) BIS monitoring      for future (Burns Intensive Care Unit) BICU patients.&lt;br/&gt;To optimize dietary recommendations      for patients who are suffering from hyper-catabolic state. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This will be a prospective, observational study with intensive      monitoring but no experimental intervention. This study will be conducted on the adult Burns Intensive Care      Unit (BICU), Chelsea and Westminster Foundation Trust, London, United Kingdom (UK). This is      a tertiary referral hospital serving an area of North West London. The average annual      admission for severe burns to BICU will vary form 10 to 15 patients. The study will be conducted      from December 2015 to December 2019. The BICU will have facilities for ventilatory support, sedation and surgery of critically ill      patients, with two-bed intensive care unit. Each bed will be isolated with three senior trained      intensive care nurses covering 24 h. Critically ill burns patients will be monitored      continuously by nurses and doctors with the use of non-invasive and invasive monitoring      depending on their clinical needs as per standard clinical care.&lt;/para&gt;&lt;para&gt;General history and examination upon enrolment, full history and examination will be      performed, including detailed assessment of the respiratory system, extent and depth of      burns, neurological examination, cardiovascular examination and excluding other potential      trauma that the patients could have suffered from. The results will be recorded on a designated record form. Patients will be re-assessed      by a physician or nurse for the duration of continuous monitoring to independently assess      blood pressure, heart rate, respiratory rate, oxygen saturation, cardiac output, Glasgow      coma scale, sedation score, ventilator requirement, urine output, intra-abdominal pressure,      splanchnic circulation, BIS, EEG, nitrogen balance, resting metabolic rate and temperature. Daily follow-up will include assessment for any complications of burns including sepsis,      infection, inhalational injury, suspected acute respiratory distress syndrome, and suspected      respiratory distress of uncertain aetiology. The decision to obtain imaging or other      investigations to assess such complications will be made by the clinical team and the      results will be archived as source documents.&lt;/para&gt;&lt;para&gt;In addition to above, venous blood sample will be taken to establish on the daily basis to      monitor inflammatory markers, renal, liver, bone marrow function, electrolyte levels.      Urinary nitrogen levels, plasma hormones including thyroid stimulating hormone, T3, T4,      cortisol levels, insulin, glucagon levels will be taken daily. These tests will be completed by      the clinical team. Regular arterial line gas sample will be taken as guided by the clinical team.&lt;/para&gt;&lt;para&gt;Continuous monitoring: patients will undergo standard electrophysiological monitoring,      cardiovascular monitoring including arterial line blood pressure monitoring, placement of      estimated cardiac output monitoring and intra-abdominal pressure. These devices will be      connected to a portable diagnostic recording system to aid the diagnosis of any      physiological changes that occurs. The system will comprise a central device, with a display      screen, battery pack and memory card. The electrophysiological monitoring device will      consist or three electrodes and wires which feeds into the central device ports. The      electrodes will be attached to the participants' forehead; left central and right. The      intra-abdominal pressure device will consist of a transducer which is located in the urinary      catheter. The wires which are connected to the transducers will then be fed into the central      device ports. The continuous estimated cardiac output monitoring devices will consist of three      cardiac electrodes, pulse oximetry device and wires, which will be connected to the central      device ports. The cardiac electrodes will be placed to the patients' thorax and the pulse      oximetry device will be attached to the patients' digit either in the foot or hand.&lt;/para&gt;&lt;para&gt;The following sensors will be applied:&lt;br/&gt;Electrocardiogram: recording cardiac electrical activity to give three recorded and           three derived traces.&lt;br/&gt;Ventilator: recording airflow inhale and exhalation, flow rate, pressure, tidal volume,           peep, type of ventilator mode.&lt;br/&gt;Pulse oximeter: recording arterial oxygen saturation and pulse rate. The monitoring           system will be applied to the patient once assent is obtained and after the initial           management; drug administration, examination and other investigation will be performed by           the clinical team. The sensors will be applied with the goal of recording continuously           for 72 h.&lt;/para&gt;&lt;para&gt;Intermittent monitoring: patients will undergo indirect calorimetry monitoring and LIMON      test. Resting metabolic rate will be measured every 12 hourly for 72 h using indirect      calorimetry with Quark Resting Metabolic Rate (QUARK RMR) (COSMED, Rome, Italy). This device      will consist of canopy, ventilator tubing, heat and moisture exchange filter, air sample      analyzing tubes, computer, gas analyzing chamber, calibration gas cylinder, air pump to      calibrate the flow sensor, fuel cell, spirometry and Windows 8.0 computer which has COSMED      Quark RMR software installed.  Patients will be either ventilated or awake. Ventilated patients will have a gas      analyzing tubing attached to the heat and moisture exchange filter which is fed unto the gas      analyzing chamber. The flow meter will be attached at the exhaust port at the back of the      ventilator.&lt;/para&gt;&lt;para&gt;The measurement will be taken until a steady resting state is achieved. This will normally vary      from two minutes to 20 min. The results will automatically be recorded onto the Quark RMR      software. In order to achieve steady ventilation with little minimum bias flow the      patients' Bispectral index will be maintained between forty and sixty using medications such      as propofol, fentanyl, midazolam or clonidine.&lt;/para&gt;&lt;para&gt;Liver and splanchnic circulation will be measured every 6 hourly using LIMON Liver Function      Monitor (Liver Monitor, PULSION Medical Systems, Munich, Germany). The device will consist of      sensor, wires and monitor to display the instructions and results. The sensor will be attached to      the patients' earlobe, finger tips in the hand or foot. The indocyanine green dye (ICG)      will be injected into a vein. The results will be displayed onto the monitor. If the recording is suboptimal due to loss of sensors or insufficient recording, it will be      repeated.&lt;/para&gt;&lt;para&gt;All of the above equipments and monitoring system will be cleaned and disinfected according      to the manufacturing advice and microbiology team. The standard operating procedures for the      above equipments are described in the appendix.&lt;/para&gt;&lt;para&gt;Cessation of monitoring: the recording system, or individual sensors will be removed      immediately if it is required for clinical investigations or interventions. However, it is      anticipated that most investigations and interventions will be able to proceed with the      sensors in place. The device will be expected to remain in place during patient re-positioning,      airway management, delivery of oxygen, delivery of oral and intravenous medication and fluids and      most imaging with the exception of magnetic resonance imaging. BIS monitoring will be removed in the event of cardio-respiratory arrest. If study clinician      is not present at the time of cardio-respiratory arrest, the monitor will detach without      difficulty and will not impede or delay resuscitation efforts.&lt;/para&gt;&lt;para&gt;In addition to above data, the investigator be collecting the patients' demographics      including apache II scoring, end organ function including liver function, renal function,      hematological status, ventilator settings, arterial gas, urine output and temperature. Analysis of recording data will be exported from the monitoring devices      after each recording and assessed for adequacy and quality.&lt;/para&gt;&lt;para&gt;All frontal lobe electroencephalogram will be analyzed. If there is any EEG finding that are      consist with seizures it will be reviewed by neurophysiologist. All resting metabolic rate      will be plotted against the physiological parameters including splanchnic circulation,      temperature and intra-abdominal pressure. The ECG will be reviewed to assess heart rate,      rhythm and conduction. Invasive blood pressure monitoring device will assess the blood      pressure. Estimated cardiac output monitoring will assess the cardiac output and the trend      over the seventy two hours. Fick principle will be used to calculate the cardiac output      using the data (CaO2 and CVO2) obtained from the Quark RMR. Any stimulus, airway management, changes in the levels of sedation, return from theatres      will be noted.&lt;/para&gt;&lt;para&gt;In the view of the complexity of data provided by continuous           monitoring, statistical guidance will be sought at all stages of analysis from the           statistician. For the primary end points, the investigator will draw a graph of time           again resting metabolic rate. The precise choice of test will be determined once the           distribution pattern of the data is known. Repeated measure analysis of variance will           be used followed by regression analysis accounted for repeat measures.&lt;/para&gt;&lt;para&gt;In comparing patient specific outcome measures (mortality, requirement for ventilation,           development of complications such as sepsis), patients will be placed into ranked           groups from most to least difference in trend change in resting metabolic rate and           nonparametric analysis will be used to assess the relationship between mortality or           morbidity and resting metabolic rate. Sample Size Justification Primary determinant will be expected number of eligible patients           presenting in the duration of study.&lt;/para&gt;&lt;para&gt;Power calculation will be completed for the primary outcome measures. In order to conclude to      show that there is an increase in metabolic rate by 200 kcal per day with a power of 0.8, investigators will need 8 patients to be able to conclude that there increase in metabolic rate. Estimated cardiac output monitor' will be placed           in conjunction with calculating the Fick principle. Heart rate and pulse oximeter will           be monitored continuously. These adjuncts will allow the investigator to conclude           whether hyper-metabolism is associated with hyper dynamic cardiovascular response to           burns. Splanchnic circulation will be monitored using the LiMON indocyanine green test and           intermittent intra-abdominal pressure will be monitored to assess whether there is a           link between the metabolic rate and splanchnic circulation.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Chelsea and Westminster NHS trust</Name><Contacts/></Site><Site><Name>The Burn Intensive Care Unit (BICU), Chelsea and Westminster Hospital</Name><Address1>London</Address1><Address3>SW10 9NH</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16196">Subjects with Skin Burn</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03024931</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other dermatological disease" id="43231"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other dermatological disease" id="43231"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="33233"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="34310"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="33091">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other dermatological disease" id="23963"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="24589"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="26749"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24354">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-05-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-12-03T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-03-14T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="291455"><TitleDisplay>A phase II, MAD study of ARB-1740 in HBV patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="152">Hepatitis B virus infection</Indication></Indications><BiomarkerNames><BiomarkerName id="5849" role="Therapeutic effect marker" type="Genomic;Proteomic">Hepatitis B large envelope protein</BiomarkerName><BiomarkerName id="30697" role="Therapeutic effect marker" type="Proteomic">Anti-Hepatitis B e antigen antibodies</BiomarkerName><BiomarkerName id="44378" role="Therapeutic effect marker" type="Genomic">Hepatitis B virus DNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ARB-1740</Name><Drug id="100509">ARB-1740</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nucleoside/nucleotide analogs therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>ARB-1740</Name><Drug id="100509">ARB-1740</Drug></Intervention><Intervention type="InterventionPrimary"><Name>interferon alpha-2a</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="100509">ARB-1740</Drug><IndicationsPioneer/><Companies><Company><Company id="1032153">Arbutus Biopharma Corp</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="100509">ARB-1740</Drug><IndicationsPioneer/><Companies><Company><Company id="1032153">Arbutus Biopharma Corp</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1032153" type="Company"><TargetEntity id="4295861697" type="organizationId">Arbutus Biopharma Corp (Pre-Merger)</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"/><TargetEntity id="D019694" type="MeSH"/><TargetEntity id="-1284790527" type="omicsDisease"/><TargetEntity id="429" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1032153">Arbutus Biopharma Corp</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="26035">siRNA agent</Class><Class id="2953">Anti-inflammatory</Class><Class id="59620">Unspecified drug target</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="142">Liposome formulation</Technology><Technology id="599">Nanoparticle formulation injectable</Technology><Technology id="103">Oligonucleotide</Technology></Technologies><TrialCategories><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2017-07-27T16:07:57Z</DateChangeLast><DateAdded>2017-03-24T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Hepatitis B virus infection (HBV) patients&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim was to evaluate the safety and efficacy of ARB-1740 in chronic hepatitis B virus infection (HBV) patients [&lt;ulink linkType="Reference" linkID="1910431"&gt;1910431&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1929993"&gt;1929993&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2017, dosing was begun [&lt;ulink linkType="Reference" linkID="1910431"&gt;1910431&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2017, results were presented. Patients treated with ARB-1740 in combination with nucleoside/nucleotide analogs (NAs) and  interferon alpha-2a (IFN) standard of care had shown either  additive or synergistic effects, suppressing multiple elements of HBV including HBsAg, HBeAg and HBV DNA [&lt;ulink linkType="Reference" linkID="1929993"&gt;1929993&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive ARB-1740 [&lt;ulink linkType="Reference" linkID="1910431"&gt;1910431&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received ARB-1740 in combination with nucleoside/nucleotide analogs (NAs) or interferon alpha-2a (IFN) standard of care  [&lt;ulink linkType="Reference" linkID="1929993"&gt;1929993&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-05-25T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="296762"><TitleDisplay>A longitudinal, prospective, multicenter, cohort study on the effect of geriatric rehabilitation in patients with severe COPD admitted to the hospital with an acute exacerbation</TitleDisplay><TitleOfficial>Geriatric Rehabilitation in Patients with Severe COPD</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">NTR6261</Identifier><Identifier type="Secondary Organisational">P14.248 Commissie Medische Ethiek (CME) LUMC, Leiden</Identifier><Identifier type="Trial Acronym">GR-COPD</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>geriatric rehabilitation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>usual care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1147350" type="Company"><TargetEntity id="5052154265" type="organizationId">Achmea Gezondheidszorg Stg</TargetEntity></SourceEntity><SourceEntity id="27406" type="Company"><TargetEntity id="5001236580" type="organizationId">Academisch Ziekenhuis Leiden</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="27406">Leiden University Medical Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1147350">Zorggroep Solis, Stichting Achmea Gezondheidszorg (SAG)</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>180</PatientCountEnrollment><DateStart>2015-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2018-10-01T00:00:00Z</DateEnd><DateChangeLast>2017-05-10T12:49:09Z</DateChangeLast><DateAdded>2017-05-04T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>E.F.vanDamvanIsselt@lumc.nl</Email><Name>Leonoor van Dam van Isselt</Name></Contact><Contact type="Scientific contact"><Email>E.F.vanDamvanIsselt@lumc.nl</Email><Name>Leonoor van Dam van Isselt</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosed with severe COPD&lt;/li&gt;&lt;li&gt;Admitted to the hospital with an acute exacerbation&lt;/li&gt;&lt;li&gt;Indication for rehabilitation: this is based on the presence of two major, or one major and two minor criteria&lt;/li&gt;&lt;li&gt;Major criteria:&lt;ul&gt;&lt;li&gt;Decline of functional status (ADL, iADL)&lt;/li&gt;&lt;li&gt;Health status is severely impaired, as measured by the Clinical COPD Questionnaire (CCQ), score&amp;gt; 2, 0&lt;/li&gt;&lt;li&gt;Frequent exacerbations; ¡Y 2 in the last 6 months (excluding the present exacerbation)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Minor criteria:&lt;ul&gt;&lt;li&gt;Hypoxaemia (excluding pre-existent long-term oxygen treatment [LTOT])&lt;/li&gt;&lt;li&gt;Impaired nutritional status: body mass index (BMI)&amp;lt; 21 kg/m2 and/or fat-free-mass- index (FFMi) depletion&lt;/li&gt;&lt;li&gt;Patients at risk for clinically relevant anxiety disorder or depression; hospital anxiety and depression score (HADS)&amp;gt; 7 on either subscale&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;End-stage disease&lt;/li&gt;&lt;li&gt;A major psychiatric or cognitive disease&lt;/li&gt;&lt;li&gt;Insufficient mastery of Dutch language&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Health status as measured by the Clinical COPD Questionnaire (CCQ); delta-CCQ during follow-up, compared between GR-COPD intervention group and usual care</Description><Timeframe>Baseline measurements (T0): first week of admission to the hospital. Follow-up 1: 3 months after T0, follow-up 2: 6 months after T0, follow-up 3: 9 months after T0 and follow-up 4: 12 months after T0</Timeframe></Measure><Measure><Description>Functional status as measured by the 6-min walking test (6MWT); delta-6MWT during follow-up, compared between GR-COPD intervention group and usual care</Description><Timeframe>Baseline measurements (T0): first week of admission to the hospital. Follow-up 1: 3 months after T0, follow-up 2: 6 months after T0, follow-up 3: 9 months after T0 and follow-up 4: 12 months after T0</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The following parameters will be compared between GR-COPD intervention and usual care: number of COPD exacerbations and number of hospital admissions and in-hospital-days as a result of COPD exacerbations and mortality rate</Description><Timeframe>Baseline measurements (T0): first week of admission to the hospital. Follow-up 1: 3 months after T0, follow-up 2: 6 months after T0, follow-up 3: 9 months after T0 and follow-up 4: 12 months after T0</Timeframe></Measure><Measure><Description>Process evaluation. In accordance with the theory of Saunders and using a mixed-method approach (self-administered questionnaire and qualitative group interviews), fidelity; completeness; exposure; satisfaction; reach; recruitment and context will be evaluated as part of the process evaluation</Description><Timeframe>Baseline measurements (T0): first week of admission to the hospital. Follow-up 1: 3 months after T0, follow-up 2: 6 months after T0, follow-up 3: 9 months after T0 and follow-up 4: 12 months after T0</Timeframe></Measure><Measure><Description>Economic evaluation. The economic evaluation consists of a cost analysis and a cost-utility analysis, both with a 12 month time horizon after inclusion (during follow-up). Costs will be measured from a healthcare perspective. In the cost-utility analysis, the difference in healthcare costs between the strategies will be compared to the difference in Quality-Adjusted Life Years (QALYs, calculated using the Dutch EQ-5D tariff and the visual analogue scale for health). Estimated healthcare costs will include the costs of the GR-COPD intervention (estimated from the study registration) and other healthcare utilization (estimated using quarterly questionnaires filled out by the patients). Other healthcare utilization will include general practitioners, home care, hospitalization, and residential care. A cost-price analysis will be performed for the GR-COPD; other healthcare will be valued using standard prices</Description><Timeframe>Baseline measurements (T0): first week of admission to the hospital. Follow-up 1: 3 months after T0, follow-up 2: 6 months after T0, follow-up 3: 9 months after T0 and follow-up 4: 12 months after T0</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The hypothesis of this study is that geriatric rehabilitation in patients with severe COPD, admitted to the hospital with an acute exacerbation, will improve health status and decrease the exacerbation frequency and hospital admissions in comparison to patients who do not receive this rehabilitation program. The objective is to  determine the (cost) effectiveness of the GR-COPD program in patients with severe COPD admitted to the hospital with an acute exacerbation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This will be a longitudinal, prospective, multicenter, cohort study. Patients diagnosed with severe COPD and admitted to the hospital with an acute exacerbation will be included. Furthermore, patients will need to have an indication for rehabilitation based on a set of standard major and minor criteria. Patient who suffer from conditions interfering with rehabilitation, such as: end-stage disease, a major psychiatric or cognitive disease or insufficient mastery of Dutch language, will be excluded from participation. This study will be conducted on the pulmonary department of two local hospitals in the Netherlands.&lt;/para&gt;&lt;para&gt;The intervention group will receives the GR-COPD program. The GR-COPD program will consist of a multidisciplinary inpatient rehabilitation program and contains several modules concerning different aspects of rehabilitation: optimizing pulmonary medication use, compliance and inhalation techniques, physiotherapy (endurance, strength and inspiratory muscle training), occupational therapy, support of smoking cessation, nutritional analysis and advise, analysis of speech and breathing techniques, psychosocial intervention, education and peer support contact. The control group will receive care as usual.&lt;/para&gt;&lt;para&gt;Main study parameters/endpoints will include: &lt;br/&gt;Effect evaluation: improvement in health and functional status as measured by the CCQ and the 6MWT, reduction of the number of COPD exacerbations and number of hospital admissions and in-hospital-days as a result of COPD exacerbations.&lt;br/&gt;Process evaluation: within the framework of the process evaluation, fidelity; completeness; exposure; satisfaction; reach; recruitment and context will be evaluated by quantitative and qualitative analysis.&lt;br/&gt;Economic evaluation: cost analysis (from a healthcare perspective) and cost-utility analysis (comparing healthcare costs to Quality-Adjusted Life Years).&lt;/para&gt;&lt;para&gt;To balance potential confounders between treated and untreated patients of this study investigators will estimate the propensity score (PS). Investigators will include the following variables in the PS: age, sex, comorbidity-score, smoking, lung-function, functional status (Barthel Index), nutritional status (BMI, FFMi), symptoms (pain, fatigue, insomnia, anorexia) measured by the NRS, psychosocial functioning (HADS), social status and number of exacerbations in year before admission.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="562">Subjects with GOLD Stage 3/Severe COPD</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="564">Subjects with disease related complications</PatientSegment><SubSegments><SubSegment id="565">Subjects with acute exacerbation of COPD/Infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1015">Netherlands Trial Registry (NTR)</Name><Identifiers><Identifier type="Secondary Organisational">NTR6261</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4448">Clinical COPD Questionnaire (CCQ)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4501"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4502">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="27379">EuroQol (EQ-5D)</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="27778">Treatment satisfaction</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4466"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4467">Assessment of Hospitalization Rates</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4469">Assessment of duration of hospitalization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4473"><Endpoint>Assessment of Exacerbations</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4474">Assessment of exacerbation rate/frequency/number</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4572"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="37248"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="37253">Cost-Utility Analysis (CUA)</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="37254">Assessment by Quality-Adjusted Life Year (QALY)</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="37264">Health Services Utilization</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="43848"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4432"><Endpoint>Assessment of Dyspnea</Endpoint></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4604"><Endpoint>Assessment of Pulmonary Function</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2083"><Criterion>Subjects with Abnormal Arterial Gas Analysis</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2099"><Criterion>Subjects with Exacerbations</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="2171"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="34771"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2067">Subjects with GOLD Stage 3/Severe COPD</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20270"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="298898"><TitleDisplay>Investigation on the Bidirectional Cortical Neuroprosthetic System</TitleDisplay><TitleOfficial>Investigation on the Bidirectional Cortical Neuroprosthetic System</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03161067</Identifier><Identifier type="Organisational Study">IRB00106844</Identifier><Identifier type="Trial Acronym">BiCNS</Identifier></Identifiers><Indications><Indication id="1258">Spinal cord injury</Indication><Indication id="2896">Quadriplegia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Bidirectional Cortical Neuroprosthetic System</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>CereStim R96</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>NeuroPort Electrode Array Systems (Blackrock Microsystems, Inc)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>intracortical microstimulation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20596" type="Company"><TargetEntity id="5000068265" type="organizationId">Johns Hopkins University</TargetEntity></SourceEntity><SourceEntity id="1258" type="ciIndication"><TargetEntity id="10041552" type="MEDDRA"/><TargetEntity id="D013119" type="MeSH"/><TargetEntity id="90058" type="ORPHANET"/><TargetEntity id="-1980782964" type="omicsDisease"/><TargetEntity id="178" type="siCondition"/></SourceEntity><SourceEntity id="2896" type="ciIndication"><TargetEntity id="G82.5" type="ICD10"/><TargetEntity id="10037714" type="MEDDRA"/><TargetEntity id="D011782" type="MeSH"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20596">Johns Hopkins University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>5</PatientCountEnrollment><DateStart>2017-08-01T00:00:00Z</DateStart><DateEnd type="estimated">2020-01-16T00:00:00Z</DateEnd><DateChangeLast>2019-06-07T06:36:39Z</DateChangeLast><DateAdded>2017-05-23T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>pcelnik@jhmi.edu</Email><Name>Pablo A Celnik, MD</Name><Phone>4105022446</Phone></Contact><Contact type="Public contact"><Email>manaya1@jhmi.edu</Email><Name>Manuel Anaya, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participants must meet all inclusion criteria, verified by medical evaluation, psychological evaluation, and review of medical history. Inclusion criteria include:&lt;ul&gt;&lt;li&gt;Participants with C4 to C6 tetraplegia from any etiology except neurodegenerative disease (eg, amyotrophic lateral sclerosis) or active cancer&lt;/li&gt;&lt;li&gt;Complete or incomplete spinal cord injury classified by the American Spinal Injury Association (ASIA) as A or B or C if fewer than three muscle groups in the leg and foot (as identified in the ASIA Impairment Scale) can be contracted&lt;/li&gt;&lt;li&gt;Injury more than one year prior to enrollment&lt;/li&gt;&lt;li&gt;Participant has a life expectancy of &gt; 5 years&lt;/li&gt;&lt;li&gt;Meeting surgical safety criteria, including surgical clearance by the participant's primary healthcare provider, study physicians, and any necessary consultants&lt;/li&gt;&lt;li&gt;Willingness and ability to provide informed consent&lt;/li&gt;&lt;li&gt;Screened by rehabilitation psychologist with a result showing that the participant has a stable psychosocial support system with caregiver capable of monitoring participant throughout the study&lt;/li&gt;&lt;li&gt;Ability and willingness to travel to up to fifty miles to study location up to three days per week for the duration of the study&lt;/li&gt;&lt;li&gt;Ability to understand and comply with study session instructions&lt;/li&gt;&lt;li&gt;Pain well controlled without narcotic medications&lt;/li&gt;&lt;li&gt;No other neurological, orthopedic conditions beyond the spinal cord injury&lt;/li&gt;&lt;li&gt;Participant consents to the study and still wishes to participate at the time of the study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;All interested participants will be reviewed for the presence of exclusion criteria by medical evaluation, review of medical history, self (or assistant) report and evaluation by a psychologist. Presence of any of the following criteria will exclude participants from eligibility to participate. In addition, the medical team has the right to withdraw the participant at any time if any of the exclusion criteria emerge and participants can withdraw at any time for any reason. Withdrawal details are outlined below exclusion criteria:&lt;ul&gt;&lt;li&gt;Neurological conditions: impaired receptive and/or expressive verbal communication skills&lt;/li&gt;&lt;li&gt;Presence of memory impairment on the Rey Auditory Verbal Learning Test&lt;/li&gt;&lt;li&gt;Intellectual impairment: score of&amp;lt;/= 26 on the Mini-Mental State Examination or history of Intelligence Quotient &amp;lt; 80&lt;/li&gt;&lt;li&gt;Chronic psychiatric illness, including psychosis and treatment-resistant major depression, as indicated by a diagnosis of Axis I or Axis II on the Symptom Checklist-90-Revised Test&lt;/li&gt;&lt;li&gt;Ventilator dependent&lt;/li&gt;&lt;li&gt;Implanted devices such as: pacemakers, cardiac defibrillators, spinal cord or vagal nerve stimulators, deep brain stimulators, cochlear implants or any other implantable device incompatible with MRI.&lt;/li&gt;&lt;li&gt;History of drug or alcohol dependence in past 24 months&lt;/li&gt;&lt;li&gt;Cerebral lesions affecting frontal and parietal lobes&lt;/li&gt;&lt;li&gt;Medical conditions contraindicating surgery of a chronically implanted device (eg, osteomyelitis, diabetes, hepatitis, any autoimmune disease/disorder, epilepsy, skin disorders causing excessive skin sloughing or poor wound healing, blood or cardiac disorder requiring chronic anti-coagulation)&lt;/li&gt;&lt;li&gt;Other chronic, unstable medical conditions that could make control unsuitable (such as tremor or spasticity)&lt;/li&gt;&lt;li&gt;Presence of pre-surgical findings in anatomical, functional, and/or vascular neuroimaging that makes achieving implant locations within desired risk levels too challenging (to be decided by neurological and neurosurgical team)&lt;/li&gt;&lt;li&gt;Prior cranioplasty&lt;/li&gt;&lt;li&gt;Inability to undergo MRI or anticipated need for an MRI during the study period&lt;/li&gt;&lt;li&gt;Participants with active infections or unexplained fever&lt;/li&gt;&lt;li&gt;Participants with other morbid conditions making the implantation of the recording elements unsafe; not limited to: significant pulmonary, cardiovascular, or renal impairments making the surgical procedure unsafe&lt;/li&gt;&lt;li&gt;Pregnancy (confirmation through blood test)&lt;/li&gt;&lt;li&gt;Nursing an infant, planning to become pregnant, or not using adequate birth control&lt;/li&gt;&lt;li&gt;Corrected vision no worse than 20/30&lt;/li&gt;&lt;li&gt;HIV or AIDS infection&lt;/li&gt;&lt;li&gt;Existing scalp lesions or skin breakdown&lt;/li&gt;&lt;li&gt;Chronic oral or intravenous use of steroids or immunosuppressive therapy&lt;/li&gt;&lt;li&gt;Active cancer within the past year or requires chemotherapy&lt;/li&gt;&lt;li&gt;Uncontrolled autonomic dysreflexia within the past 3 months&lt;/li&gt;&lt;li&gt;An implanted ventricular shunt&lt;/li&gt;&lt;li&gt;Suicidal ideation within the past 12 months&lt;/li&gt;&lt;li&gt;Medications that affect neuroplasticity: neuroleptics, Benzodiazepines (BDZ), Tricyclic Antidepressants  (TCA)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety of BiCNS: the device is not explanted during 52-week study: this outcome will be considered successful if the device is not explanted during the 52-week period. Explantation of the device prior to the 52-week study period implies that the device is putting the subject at risk (eg, through a serious infection at implantation site) and therefore must be removed</Description><Timeframe>52 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy of BiCNS: control of one end-effector using neural signals acquired by the BiCNS: one or more participants demonstrate successful control of an assistive device using the action research arm test (ARAT). The ARAT's is a 19 item measure divided into 4 sub-tests (grasp, grip, pinch, and gross arm movement). Performance on each item is rated on a 4-point ordinal scale ranging from: 3) Performs test normally 2) Completes test, but takes abnormally long or has great difficulty 1) Performs test partially 0) Can perform no part of test</Description><Timeframe>52 weeks</Timeframe></Measure><Measure><Description>Sensory feedback: the participants can perceive environmental information through delivery of intracortical microstimulation (ICMS): intracortical microstimulation will be delivered to participants through the BiCNS device. The effect of ICMS will be measured based on participants' verbal reporting of what the stimuli feel like (quality of percepts) and where they appear to be coming from (location of percepts)</Description><Timeframe>52 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this early feasibility study consist of safety and      efficacy evaluations of the Bidirectional Cortical Neuroprosthetic System (BiCNS) device.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Electrode arrays will be implanted in the brain in pairs, with a pair comprising a recording array and a stimulating array. A total of six NeuroPort arrays, consisting of three array pairs, will be implanted in each study participant. Each pair will consist of an array implanted in primary motor cortex (M1) for recording and an array implanted in primary sensory cortex (S1) for stimulation and/or recording; both arrays in each pair will be connected to a single percutaneous pedestal as an external interface. In each participant, two such array pairs will be implanted in the hand/arm area of M1 and S1 in the dominant brain hemisphere (eg, the left hemisphere for a right-handed individual). A third pair will be implanted in the hand/arm area of M1 and S1 in non-dominant hemisphere (eg, right hemisphere for a right handed-individual). The recording arrays implanted in M1 will be  the NeuroPort microelectrode arrays with platinum (Pt) tips (K070272), whereas the ICMS arrays implanted in S1 will be  NeuroPort microelectrode arrays with Sputtered Iridium-Oxide Film (SIROF) tips (K110010). The study has Investigational Device Exemption (IDE) approval from &lt;ulink linkType="Company" linkID="28926"&gt;FDA&lt;/ulink&gt; to implant these devices for 52 weeks (plus/minus 2 weeks).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Department of Physical Medicine and Rehabilitation</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21287</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>pcelnik@jhmi.edu</Email><Name>Pablo Celnik, MD</Name><Phone>410-502-2420</Phone></Contact><Contact type="Facility contact backup"><Email>manaya@jhmi.edu</Email><Name>Manuel Anaya</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15871">Subjects with spinal cord injury</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03161067</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="42924"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="46419"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="43056"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="46419"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33192"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="33214">Subjects with spinal cord injury</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other neurological disease" id="33372"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="34308"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="32748">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24397">Subjects with infectious diseases/disorders</SubCriterion><SubCriterion disease="Other neurological disease" id="24399">Subjects co-morbid with other brain diseases</SubCriterion><SubCriterion disease="Other neurological disease" id="24636">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="24386"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24389"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24390">Subjects with abnormal neurological examination</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="24392"><Criterion>Subjects with abnormal/unacceptable neuropsychological assessment</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24402"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24405"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="24408"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24410">Subjects with implanted pacemaker/defibrillator/neurologic stimulation systems</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="24963"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24095">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="26702"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24385">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion><SubCriterion disease="Other neurological disease" id="24637">Subjects with mood disorders</SubCriterion><SubCriterion disease="Other neurological disease" id="24639">Subjects co-morbid with psychosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other neurological disease" id="27919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24149">Subjects unwilling/unable to comply with the study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-03-31T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-03-28T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="updated"><Date>2019-06-07T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="299132"><TitleDisplay>Efficacy of Nasal Irrigation With Respimer Netiflow Versus Saline Among Patients With Cystic Fibrosis and Chronic Rhinosinusitis</TitleDisplay><TitleOfficial>Prospective, Randomized, Crossover, Multicenter Trial Comparing the Efficacy and Tolerability of Nasal Irrigation With Respimer Netiflow Mineral Salts Solution Versus Saline Among Patients With Cystic Fibrosis and Suffering From Chronic Rhinosinusitis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03145051</Identifier><Identifier type="Organisational Study">LABORATOIREDELAMER</Identifier><Identifier type="Trial Acronym">Respire</Identifier></Identifiers><Indications><Indication id="3000">Chronic sinusitis</Indication><Indication id="88">Cystic fibrosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Respimer Netiflow</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Respimer mineral salts solution</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1034267" type="Company"><TargetEntity id="4298093361" type="organizationId">Laboratoire de la Mer SAS</TargetEntity></SourceEntity><SourceEntity id="3000" type="ciIndication"><TargetEntity id="J32" type="ICD10"/><TargetEntity id="10009137" type="MEDDRA"/><TargetEntity id="1297" type="siCondition"/></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"/><TargetEntity id="10011762" type="MEDDRA"/><TargetEntity id="D003550" type="MeSH"/><TargetEntity id="586" type="ORPHANET"/><TargetEntity id="-1447400656" type="omicsDisease"/><TargetEntity id="288" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="1034267">Laboratoire De La Mer</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2015-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:52:58Z</DateChangeLast><DateAdded>2017-05-25T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with cystic fibrosis with or without lung transplant&lt;/li&gt;&lt;li&gt;Patients with allergic chronic rhino sinusitis or no allergic diagnosed by the clinical investigator on the basis of the following signs in variable combination: nasal congestion, headache, sneezing, itchy nose and eyes, runny nose, nosebleeds and nasal crusts, redness and eye discharge present &gt; 3 months per year&lt;/li&gt;&lt;li&gt;Patient treated on an outpatient basis&lt;/li&gt;&lt;li&gt;Patient agreeing not to take sea baths for the duration of the study&lt;/li&gt;&lt;li&gt;Patient agreeing to respect the procedures for conducting the study, in particular the washout period and follow-up visits&lt;/li&gt;&lt;li&gt;Patient capable of understanding and self-completing the questionnaires&lt;/li&gt;&lt;li&gt;For juvenile patients, the holder (s) of parental authority have accepted the participation of the young person (by signing the informed consent after having taken note of the information note)&lt;/li&gt;&lt;li&gt;Member or beneficiary of a social security program&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with significant obstruction of the nasal passages due to:&lt;ul&gt;&lt;li&gt;A mucocele&lt;/li&gt;&lt;li&gt;Polyposis causing nasal obstruction&amp;gt; 90%&lt;/li&gt;&lt;li&gt;Severe malformation of the septum causing a nasal obstruction&amp;gt; 90% in whom surgical treatment is recommended&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with signs of severity that may require hospitalization, such as: severe impairment of general health, dyspnoea with cyanosis, high fever (&amp;gt; 40degC)&lt;/li&gt;&lt;li&gt;Patients requiring corticosteroid therapy during the study, with the exception of patients who received pulmonary transplant and were treated with oral corticosteroids at no &gt; 0.2 mg/kg/day&lt;/li&gt;&lt;li&gt;Patients with known systemic immunodeficiency status with the exception of patients receiving pulmonary transplantation and immunosuppressed&lt;/li&gt;&lt;li&gt;Patient pregnant (urine test) or without effective contraception (birth control pill, contraceptive patch, contraceptive implant, vaginal ring, intrauterine device or intrauterine device, male condom)&lt;/li&gt;&lt;li&gt;Nursing patient&lt;/li&gt;&lt;li&gt;Patient with a contraindication to nasal irrigations as defined in the product leaflet&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in quality of life among subjects undergoing nasal irrigation with Respimer Netiflow mineral salts solution compared to saline solution between inclusion and the end of treatment period: quality of life to be assessed over an 8 weeks period of nasal wash using SNOT-20 questionnaire</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Clinical status evolution among subjects undergoing nasal irrigation with Respimer Netiflow mineral salts solution to saline solution between inclusion and the end of treatment period: clinical status to be assessed after 4 and 8 weeks of nasal wash using Lund-Kennedy Symptomatic Score (LKSS)</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure><Measure><Description>Endoscopic status evolution among subjects undergoing nasal irrigation with Respimer Netiflow mineral salts solution to saline solution between inclusion and the end of treatment period: endoscopic status to be assessed after 4 and 8 weeks of nasal wash using Lund-Kennedy Endoscopic Score (LKES)</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure><Measure><Description>Evolution of nasal bacterial pathogens among subjects undergoing nasal irrigation with Respimer Netiflow mineral salts solution to saline solution between inclusion and the end of treatment period: evolution of nasal bacterial pathogens to be assessed by bacteriologic swab within ethmoid nasal cavities after 4 and 8 weeks of nasal wash</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure><Measure><Description>Mucociliary transport change among subjects undergoing nasal irrigation with Respimer Netiflow mineral salts solution to saline solution between inclusion and the end of treatment period: mucociliary transport to be assessed after 4 and 8 weeks of nasal wash using saccharine test</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure><Measure><Description>Occurrence of adverse events: taste impairment, epistaxis, nasal irritations, nasal burning: adverse events to be assessed based on vigilance tracking during the whole study period</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure><Measure><Description>Patient treatment acceptance of nasal irrigation with Respimer® Netiflow® medical device: patient treatment acceptance to be assessed by Morisky score after 4 and 8 weeks of nasal wash</Description><Timeframe>Over an 8 weeks period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Prospective, randomized, crossover, multicenter  trial comparing the efficacy and      tolerability of nasal irrigation with Respimer mineral salts solution versus saline      solution both administered with Respimer Netiflow medical device among patients aged &gt;/= 11      years and older with cystic fibrosis and suffering from chronic rhinosinusitis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Nasal irrigation will be done with saline or Respimer  mineral salts solution, four times a day during 8 weeks using Respimer Netiflow class I medical device.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Czech Republic"><Sites><Site><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>clinicaltrials@ablynx.com</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>ORL et Chirurgie Cervico-faciale Centre Hospitalier Intercommunal (CHI) de Créteil</Name><Address1>Creteil</Address1><Address3>94010</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Contacts><Contact type="Facility contact"><Name>clinicaltrials@ablynx.com</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cystic fibrosis</Disease><PatientSegments><PatientSegment><PatientSegment id="9555">Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9567">Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis</PatientSegment><SubSegments><SubSegment id="9571">Subjects with H/O or scheduled for lung transplant</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other otorhinolaryngological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18267">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="17752">Subjects with sinusitis/rhinosinusitis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03145051</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cystic fibrosis" id="14105"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other otorhinolaryngological disease" id="43241"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cystic fibrosis" id="14061"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14105"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14130"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Cystic fibrosis" id="14131">Assessment of adverse events/treatment emergent adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14135"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other otorhinolaryngological disease" id="42925"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other otorhinolaryngological disease" id="43241"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other otorhinolaryngological disease" id="43559"><Endpoint>Assessment of Interventional/Surgical Procedures</Endpoint><SubEndpoints><SubEndpoint disease="Other otorhinolaryngological disease" id="43560">Assessment of tympanic membrane graft success rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cystic fibrosis" id="16427"><Criterion>Subjects with Confirmed Diagnosis of Cystic Fibrosis</Criterion></Inclusion><Inclusion disease="Cystic fibrosis" id="16433"><Criterion>Subjects with Sino-Pulmonary Manifestations</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16435">Subjects with other respiratory symptoms</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cystic fibrosis" id="16447"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16453">Subjects history of/requiring lung transplant</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cystic fibrosis" id="16475"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16478">Subjects able/willing to provide informed consent/or from guardian</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other otorhinolaryngological disease" id="33029"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other otorhinolaryngological disease" id="33546"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Other otorhinolaryngological disease" id="33215">Subjects with sinusitis/rhinosinusitis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cystic fibrosis" id="34469"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16483">Subjects included based on discretion of investigator</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cystic fibrosis" id="34872"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16477">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other otorhinolaryngological disease" id="35228"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other otorhinolaryngological disease" id="35229">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cystic fibrosis" id="13614"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Cystic fibrosis" id="13624"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Cystic fibrosis" id="13630"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Cystic fibrosis" id="13637"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13641">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other otorhinolaryngological disease" id="24025"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other otorhinolaryngological disease" id="24492">Subjects co-morbid with respiratory disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other otorhinolaryngological disease" id="24307"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other otorhinolaryngological disease" id="24486"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Other otorhinolaryngological disease" id="24494"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other otorhinolaryngological disease" id="24496"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other otorhinolaryngological disease" id="25224"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other otorhinolaryngological disease" id="25225">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>31.03 Months</EnrollmentPeriod><EnrollmentRate>1.61 Patients/Month</EnrollmentRate><DateFirstReceived>2016-11-15T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-09-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="299199"><TitleDisplay>N-acetyl-cysteine effect in stroke treatment</TitleDisplay><TitleOfficial>Evaluation of the neuroprotective effect of N-Acetyl-Cysteine in patients with cerebrovascular accident in years 95 to 96 in firoozgar hospital</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2017011931229N2</Identifier><Identifier type="Secondary Organisational">IR.IUMS.REC.1395.28001</Identifier></Identifiers><Indications><Indication id="65">Stroke</Indication></Indications><BiomarkerNames><BiomarkerName id="173" role="Therapeutic effect marker" type="Genomic;Proteomic">Matrix metalloproteinase-9</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>N-acetyl-cysteine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>acetyl salicylic acid (ASA)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>clopidogrel</Name><Drug id="2836">clopidogrel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2836">clopidogrel</Drug><IndicationsPioneer/><Companies><Company><Company id="1035896">Iran University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2836" type="Drug"><TargetEntity id="142672" type="siDrug">Clopidogrel bisulfate</TargetEntity></SourceEntity><SourceEntity id="1035896" type="Company"><TargetEntity id="5035541621" type="organizationId">Iran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"/><TargetEntity id="-1815339002" type="omicsDisease"/><TargetEntity id="93" type="siCondition"/></SourceEntity><SourceEntity id="4913" type="Action"><TargetEntity id="613" type="Mechanism">P2Y12 (P2T) Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1035896">Iran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4913">P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2016-03-19T00:00:00Z</DateStart><DateChangeLast>2018-01-08T15:30:30Z</DateChangeLast><DateAdded>2017-05-25T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>Re.ashayeri@gmail.con</Email><Name>Rezan ashayeri</Name><Phone>00982182141728 00989145841910</Phone></Contact><Contact type="Scientific contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>eshraghi.a@iums.ac.ir, Mirzaasgari.z@iums.ac.ir</Email><Name>Azadeh Eshraghi, Zahra Mirza Asgari</Name><Phone>00982182141728 00989133152584, 00989145841910</Phone></Contact><Contact type="Public contact"><Affiliation>Iran University of Medical Sciences</Affiliation><Email>Re.ashayeri@gmail.com</Email><Name>Rezan Ashayeri</Name><Phone>00982182141728 00989145841910</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All admitted patients with first attack of mild to moderate CVA according to NIHSS between 0 to 16&lt;/li&gt;&lt;li&gt;Admitted patients within first 24 h of onset of CVA&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Hemorrhagic stroke&lt;/li&gt;&lt;li&gt;Severe Hepatic or renal failure (creatinine clearance&amp;lt; 30 mg/dl)&lt;/li&gt;&lt;li&gt;History of Vasculitis&lt;/li&gt;&lt;li&gt;Allergy to N- acetyl- cystein&lt;/li&gt;&lt;li&gt;Alzheimer or dementia due to any cause&lt;/li&gt;&lt;li&gt;Coexistent other neurologic disorders&lt;/li&gt;&lt;li&gt;Past history of CVA&lt;/li&gt;&lt;li&gt;Age &gt; 80 years&lt;/li&gt;&lt;li&gt;Diseases that affect on MMP-9 level. eg, neuropsychiatric disorders like schizophrenia and bipolar disorder, epilepsy and mutiple sclerosis&lt;/li&gt;&lt;li&gt;Intravenous or intaarterial r-tPA injection&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>MMP9: ELISA kit</Description><Timeframe>Before and 24 hours after intervention</Timeframe></Measure><Measure><Description>NIHSS: Standard scale</Description><Timeframe>Before intervention, 24 hours, 2 weeks, 1 month and 3 months after intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Side effects: Clinic</Description><Timeframe>24 hours after treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  goal of this single-blind placebo-controlled  study  is evaluation of the neuroprotective effect of N-acetyl-cysteine in patients with cerebrovascular accident (CVA) in years 95 to 96 in firoozgar hospital. &lt;br/&gt;The blood sample for measuring MMP-9 marker will be collected from both groups before and 24 h after receiving N-acetyl-cysteine and standard treatment. NIHSS for the patients in both group will be  calculated before therapy, 24 h, 2 weeks, 1 and 3 months after therapy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Intervention time is first 24 h of CVA onset. Patients will be randomized into the following arms:&lt;br/&gt;Arm  1. Amp N- acetyl- cysteine 100 mg/kg stat in the onset of stroke then 10 mg/kg/h IV infusion for 10 h.&lt;br/&gt;Arm 2.  acetyl salicylic acid (ASA) 325 mg po daily for 14 days then 80 mg po daily lifelong&lt;br/&gt;Arm 3.  &lt;ulink linkType="Drug" linkID="2836"&gt;Plavix&lt;/ulink&gt; 325 mg po stat then 75 mg daily for 90 days&lt;br/&gt;Arm 4:  Plavix 325 mg po stat then 75 mg daily for 90 days&lt;br/&gt;Arm 5:  ASA 325 mg po daily for 14 days then 80 mg po daily lifelong.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Firoozgar hospital</Name><Address1>Tehran</Address1><Address2>Tehran</Address2><CountrySubDivision>Tehran</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Rezan Ashayeri</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stroke</Disease><PatientSegments><PatientSegment><PatientSegment id="11635">Subjects with First Stroke</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19027">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="11642">Subjects with Cerebrovascular Disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2017011931229N2</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="27540">Assessment by National Institute of Health Stroke Scale (NIHSS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stroke" id="24235"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stroke" id="24244"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stroke" id="24180"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Stroke" id="24179"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stroke" id="20941"><Criterion>Subjects with Other Types of Stroke</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20942">Subjects with first stroke</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20949"><Criterion>Subjects with Cerebrovascular Disease</Criterion></Inclusion><Inclusion disease="Stroke" id="20957"><Criterion>Inclusion Based on Time Post Stroke</Criterion></Inclusion><Inclusion disease="Stroke" id="20985"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20988">Inclusion based on NIHSS</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stroke" id="18642"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Stroke" id="18643"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Stroke" id="18667"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Stroke" id="18686"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Stroke" id="18692"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Stroke" id="18693"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Stroke" id="26672"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Stroke" id="24112">Subjects with hemorrhagic stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="26680"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18672">Subjects co-morbid with epilepsy/seizures</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2018-03-20T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>24.06 Months</EnrollmentPeriod><EnrollmentRate>2.49 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="300404"><TitleDisplay>The effect of an anti-VEGF drug on proliferative diabetic retinopathy</TitleDisplay><TitleOfficial>The effect of an anti-VEGF drug on proliferative diabetic retinopathy complicated with diabetic macular edema</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000027618</Identifier></Identifiers><Indications><Indication id="2657">Proliferative diabetic retinopathy</Indication><Indication id="2659">Diabetic macular edema</Indication></Indications><BiomarkerNames><BiomarkerName id="11304" role="Therapeutic effect marker" type="Structural (imaging)">Retina</BiomarkerName><BiomarkerName id="18315" role="Therapeutic effect marker" type="Physiological">Visual acuity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Name><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="53547">aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer</Drug><IndicationsPioneer/><Companies><Company><Company id="14557">Bayer Yakuhin Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="DOL1000683">Tokyo Women's Medical College</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="53547" type="Drug"><TargetEntity id="303153" type="siDrug">Aflibercept</TargetEntity></SourceEntity><SourceEntity id="14557" type="Company"><TargetEntity id="4296353174" type="organizationId">Bayer Yakuhin Ltd</TargetEntity></SourceEntity><SourceEntity id="DOL1000683" type="Company"><TargetEntity id="4298192896" type="organizationId">Tokyo Women's Medical University</TargetEntity></SourceEntity><SourceEntity id="2657" type="ciIndication"><TargetEntity id="4527" type="siCondition"/></SourceEntity><SourceEntity id="2659" type="ciIndication"><TargetEntity id="1781" type="siCondition"/></SourceEntity><SourceEntity id="15904" type="Action"><TargetEntity id="4107" type="Mechanism">Placental Growth Factor (PGF) Inhibitors</TargetEntity><TargetEntity id="4108" type="Mechanism">Anti-PGF</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000683">Tokyo Women's Medical College</Company></CompaniesSponsor><CompaniesCollaborator><Company id="14557">Bayer Yakuhin Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="15904">Placenta growth factor ligand inhibitor</Action><Action id="1689">VEGF-A ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15148">Ocular antineovascularisation agent</Class><Class id="1545">Anticancer</Class><Class id="61">Angiogenesis inhibitor</Class></Class><Technologies><Technology id="180">Antibody fragment</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="128">Cell culture technique</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="596">Injectable formulation</Technology><Technology id="620">Ophthalmic formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="84">Protein fusion</Technology><Technology id="85">Protein recombinant</Technology><Technology id="342">Receptor fusion</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-06-03T00:00:00Z</DateStart><DateChangeLast>2018-06-12T09:15:20Z</DateChangeLast><DateAdded>2017-06-09T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tokyo Women's Medical University ; The department of ophthalmologyof Diabetes Center</Affiliation><Email>ge2s-ktn@asahi-net.or.jp</Email><Name>Kitano Shigehiko</Name><Phone>03-3353-8111</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tokyo Women's Medical University ; The department of ophthalmologyof Diabetes Center</Affiliation><Email>ge2s-ktn@asahi-net.or.jp</Email><Name>Kitano Shigehiko</Name><Phone>03-3353-8111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosed as diabetic retinopathy complicated with diabetic macular edema&lt;/li&gt;&lt;li&gt;Detected retinal nonperfusion area by fluorescein fundus angiography examination&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;In case of receiving intravitreal administration of anti-VEGF drug within 3 months before enrollment&lt;/li&gt;&lt;li&gt;When panretinal or partial retinal photocoagulation was performed for the purpose of treatment against diabetic retinopathy within 3 months before starting participation&lt;/li&gt;&lt;li&gt;During systemic administration of anti-VEGF drug&lt;/li&gt;&lt;li&gt;Pregnant women or potential patients&lt;/li&gt;&lt;li&gt;Patients judged inappropriate as subjects by research managers&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Retinal nonperfusion area in fluorescein fundus angiography after administration of aflibercept</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Best corrected visual acuity, macular retinal thickness measured by optical coherence tomography, number of retinal neovasculature, grade of neovascularization on the optic nerve head, grade of neovascularization on the iris</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to evaluate the effect of intravitreal administration of &lt;ulink linkType="Drug" linkID="53547"&gt;aflibercept&lt;/ulink&gt; on retinal nonperfusion area of diabetic retinopathy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Aflibercept (as gene recombinant) 2 mg (0.05 ml) will be  administered intravitreally three consecutive times once a month. After that, it  will be injected intravitreally once every 2 months, seven times in total until 12 months after the first medication.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Tokyo Women's Medical University</Name><Address1>Tokyo</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Macular edema</Disease><PatientSegments><PatientSegment><PatientSegment id="9522">Subjects with Diabetic Macular Edema(DME)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11392">Subjects with Diabetic Retinopathy(DR)</PatientSegment><SubSegments><SubSegment id="9526">Subjects with proliferative diabetic retinopathy(PDR)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000027618</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Macular edema" id="16462"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Macular edema" id="16465">Other Laboratory assessment</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Macular edema" id="16429"><Endpoint>Assessment of Visual Function</Endpoint><SubEndpoints><SubEndpoint disease="Macular edema" id="16430">Assessment of visual acuity(VA)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Macular edema" id="16434"><Endpoint>Assessment of Structural Changes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Macular edema" id="16444"><Endpoint>Assessment of ocular function</Endpoint><SubEndpoints><SubEndpoint disease="Macular edema" id="16435">Assessment of Retinal Thickness</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Macular edema" id="16462"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Macular edema" id="16465">Other Laboratory assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Macular edema" id="15410"><Criterion>Subjects with Diabetic Macular Edema(DME)</Criterion></Inclusion><Inclusion disease="Macular edema" id="15414"><Criterion>Subjects with Diabetic Retinopathy(DR)</Criterion><SubCriteria><SubCriterion disease="Macular edema" id="15416">Subjects with proliferative diabetic retinopathy(PDR)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Macular edema" id="15440"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Macular edema" id="14063"><Criterion>Subjects with History of/Scheduled for Ocular Therapy</Criterion><SubCriteria><SubCriterion disease="Macular edema" id="14064">Subjects with history of/scheduled for ocular drug</SubCriterion><SubCriterion disease="Macular edema" id="14065">Subjects with history of/scheduled for ocular procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Macular edema" id="14068"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-06-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="317444"><TitleDisplay>Evaluation of Preoperative N-1539 in Colorectal Surgery</TitleDisplay><TitleOfficial>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety and Efficacy of Preoperative N-1539 In Colorectal Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03323385</Identifier><Identifier type="Organisational Study">REC-17-024</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>meloxicam (pain, NanoCrystal), Recro</Name><Drug id="64339">meloxicam (pain, NanoCrystal), Recro</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="64339">meloxicam (pain, NanoCrystal), Recro</Drug><IndicationsPioneer/><Companies><Company><Company id="1043338">Recro Pharma Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1043338" type="Company"><TargetEntity id="5035525689" type="organizationId">Recro Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="1001" type="Action"><TargetEntity id="407" type="Mechanism">Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors</TargetEntity><TargetEntity id="5042" type="Mechanism">Anti-Prostaglandin G/H Synthase 2 (PTGS2; COX-2)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>10</NumberOfSites><CompaniesSponsor><Company id="1043338">Recro Pharma Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1001">Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2946">Analgesic</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="641">Controlled release formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="599">Nanoparticle formulation injectable</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2017-10-24T00:00:00Z</DateStart><DateEnd type="estimated">2018-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:45:32Z</DateChangeLast><DateAdded>2017-11-06T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>smccallum@recropharma.com</Email><Extension>2411</Extension><Name>Stewart McCallum, MD</Name><Phone>484-395-2470</Phone></Contact><Contact type="Public contact"><Email>rmack@recropharma.com</Email><Extension>2406</Extension><Name>Randall Mack</Name><Phone>484-395-2470</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Voluntarily provide written informed consent&lt;/li&gt;&lt;li&gt;Be planned to undergo primary (no repeat procedures) open or laparoscopic colorectal surgery (laparoscopic expected to require a &gt;/= 5 cm incision) with bowel resection and/or anastomosis&lt;/li&gt;&lt;li&gt;ASA physical status category 1, 2 or 3&lt;/li&gt;&lt;li&gt;Female subjects not pregnant or planning/attempting to become pregnant, not lactating or commits to the use of an acceptable form of birth control for the duration of the study&lt;/li&gt;&lt;li&gt;Have a body mass index&amp;lt; 40 kg/m(2)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have a known allergy or hypersensitivity to any study treatment&lt;/li&gt;&lt;li&gt;Planned surgical procedure includes a resection beyond the peritoneal reflection, is related to an acute bout of diverticulitis or is associated with an emergency procedure&lt;/li&gt;&lt;li&gt;Have a history of myocardial infarction within the preceding 12 months&lt;/li&gt;&lt;li&gt;Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation&lt;/li&gt;&lt;li&gt;Have active or recent (within 6 months) gastrointestinal ulceration or bleeding, with exception of events related to an ulcerative colitis diagnosis&lt;/li&gt;&lt;li&gt;Have a known bleeding disorder which may be worsened with the administration of an NSAID&lt;/li&gt;&lt;li&gt;Be currently receiving treatment with oral meloxicam (Mobic) or another NSAID within 48 h prior to surgery&lt;/li&gt;&lt;li&gt;Have previously received N-1539/iv meloxicam or received any investigational product within 30 days before dosing with study medication&lt;/li&gt;&lt;li&gt;Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Evaluation of Safety and Tolerability: evaluate the incidence of adverse events in subjects receiving N-1539 30 mg versus placebo prior to colorectal surgery</Description><Timeframe>Up to 30 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of this study is to evaluate the safety and tolerability of      preoperative dosing of &lt;ulink linkType="Drug" linkID="64339"&gt;N-1539&lt;/ulink&gt; (30 mg) in subjects undergoing colorectal surgery, including      clinical laboratory tests, wound healing evaluation, incidence of anastomotic leaks and      incidence of Adverse Events (AEs) and Serious AEs (SAEs).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study will consist of two arms: &lt;br/&gt;Arm A:  subjects will receive  N-1539 (meloxicam injection for iv use) 30 mg, qd&lt;br/&gt;Arm B:  subjects will receive    once-daily intravenous placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Research Center</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44111</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44195</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Columbus</Address1><Address2>Ohio</Address2><Address3>43210</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Florence</Address1><Address2>Alabama</Address2><Address3>35630</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Jackson</Address1><Address2>Mississippi</Address2><Address3>39202</Address3><CountrySubDivision code="MS">Mississippi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Metairie</Address1><Address2>Louisiana</Address2><Address3>70006</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33136</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Mobile</Address1><Address2>Alabama</Address2><Address3>36605</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19140</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Research Center</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3>33606</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18739">Subjects Undergoing Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03323385</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gastrointestinal disease" id="42921"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other gastrointestinal disease" id="43670"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other gastrointestinal disease" id="44054"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other gastrointestinal disease" id="43393"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="32960"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="34319"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="32955">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gastrointestinal disease" id="34485"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="33019">Subjects who are Pregnant/Lactating</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35171"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="35186">Subjects with protocol specified weight/BMI values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35312"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="35194">Subjects completing/Participating in a specified study</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gastrointestinal disease" id="24021"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24301"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25167">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24468"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24596"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25161"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25163">Subjects with abnormal hematological tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25170"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25189"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25607"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25183">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="26748"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25169">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-10-24T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-11-06T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="322775"><TitleDisplay>The effects of gut microflora on protein-bound uremic toxins based on a peritoneal dialysis cohort: a protocol of placebo-controlled, double-blinded, randomized, crossover trial</TitleDisplay><TitleOfficial>The effects of gut microflora on protein-bound uremic toxins based on a peritoneal dialysis cohort: a protocol of placebo-controlled, double-blinded, randomized, crossover trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR-INR-17013739</Identifier></Identifiers><Indications><Indication id="3251">End stage renal disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="118" role="Therapeutic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="165" role="Therapeutic effect marker" type="Genomic;Proteomic">Beta-2-microglobulin</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="213" role="Therapeutic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="336" role="Therapeutic effect marker" type="Proteomic">Transthyretin</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="3475" role="Therapeutic effect marker" type="Biochemical">Urea</BiomarkerName><BiomarkerName id="4376" role="Therapeutic effect marker" type="Biochemical">Lysine</BiomarkerName><BiomarkerName id="6109" role="Therapeutic effect marker" type="Biochemical">Indoxyl sulfate</BiomarkerName><BiomarkerName id="7895" role="Therapeutic effect marker" type="Physiological">Estimated glomerular filtration rate</BiomarkerName><BiomarkerName id="11071" role="Therapeutic effect marker" type="Biochemical">Fatty acids</BiomarkerName><BiomarkerName id="12516" role="Therapeutic effect marker" type="Proteomic">Urinary protein</BiomarkerName><BiomarkerName id="24126" role="Therapeutic effect marker" type="Biochemical">p-Cresol sulfate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Oligofructose-enriched inulin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1014969" type="Company"><TargetEntity id="5035524727" type="organizationId">Tongji Medical College of Hust</TargetEntity></SourceEntity><SourceEntity id="3251" type="ciIndication"><TargetEntity id="N18.6" type="ICD10"/><TargetEntity id="D007676" type="MeSH"/><TargetEntity id="1890" type="siCondition"/><TargetEntity id="1604" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1014969">Tongji Medical College</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>44</PatientCountEnrollment><DateStart>2018-01-02T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-12-21T05:00:21Z</DateChangeLast><DateAdded>2017-12-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tongji Hospital, Tongji Medical College, Huazhong University Science and Technology</Affiliation><Email>13886010354@163.com</Email><Name>Xuezhi Zuo</Name><Phone>+86 13886010354</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with an estimated glomerular filtration rate (eGFR)&amp;lt; 15 ml/min/1.73 m2, receiving CAPD treatment &gt; 3 months, aged between 18 and 65 years and able to provide informed consent.&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients will be excluded if they meet any of the following criteria:&lt;ul&gt;&lt;li&gt;With a diagnosis of diabetes mellitus&lt;/li&gt;&lt;li&gt;Consumed antibiotic therapy within 1 month of study commencement&lt;/li&gt;&lt;li&gt;Receiving/or have received radiation to the bowel or large bowel resection&lt;/li&gt;&lt;li&gt;Medically diagnosed irritable bowel syndrome, Crohns disease or ulcerative colitis&lt;/li&gt;&lt;li&gt;Severely malnourished (Subjective Global Assessment &gt; 15)&lt;/li&gt;&lt;li&gt;Having had a clinically significant change to their immunosuppressant dose within 6 months (determined by the medical team)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Indoxyl sulfate in serum, dialysate, urine and fecal samples</Description><Timeframe>Pre and post intervention period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A p-cresyl sulfate n serum, dialysate, urine and fecal samples</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Estimate glomerular filtration rate, proteinuria, albuminuria and beta-2 microglobulin in 24-h urine</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Microbiological analysis in stool samples</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Weekly total urea clearance (Kt/V) and weekly total creatinine clearance (Ccr)</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Dietary protein and fiber intake</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Serum albumin, prealbumin,the subjective global assessment score</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Serum including hs-CRP, interleukin6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)</Description><Timeframe>Pre and post intervention period</Timeframe></Measure><Measure><Description>Blood pressure, total cholesterol (TC), total triacylglycerol (TG), Low density lipoprotein (LDL), High density lipoprotein (HDL) and short chain fatty acids (SCFA) and serum carboxy methyl lysine</Description><Timeframe>Pre and post intervention period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aims of the study are to verify its effect on the productions of IS and PCS; demonstrate its effect on gut microflora; explore whether such reduction in toxin concentrations and changes in gut microflora are associated with clinical benefit, like nutrition status and the risk of cardiovascular diseases.  &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive Oligofructose-enriched inulin or maltodextrin (placebo).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>TongJi Medical College Of HuaZhong University Of Science and Technology</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><CountrySubDivision>Hubei</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7704">Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR-INR-17013739</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22544"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22598"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="45223"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22509"><Endpoint>Assessment of Urinary Protein Excretion/Proteinuria</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22511">Assessment of proteinuria/albuminuria/macroalbuminuria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22513"><Endpoint>Assessment of Urine Creatinine</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22521"><Endpoint>Assessment of Biomarkers</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22526">Assessment of interleukin(IL-6/8/10/18)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22532">Assessment of other inflammatory/oxidative stress markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22539"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22540">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22543"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22544"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22559"><Endpoint>Assessment of Nutritional Status</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22560">Assessment of protein status</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22578"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22583">Assessment by Subject Global Assessment (SGA) Questionnaire</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22592"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22515">Assessment of renal clearance</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22598"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="45223"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="46155"><Endpoint>Assessment of Glomerular Filtration Rate (GFR)</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22506">Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17655">Subjects with protocol specified dialysis adequacy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17700"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17703">Subjects with protocol specified other lab findings</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17521"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17524"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17525">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17541"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17545">Subjects with history of/scheduled for immunomodulators</SubCriterion><SubCriterion disease="End stage renal disease" id="17550">Subjects with history of/scheduled for antibiotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17555"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-12-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="336362"><TitleDisplay>A study comparing quickness and quality of recovery from general anesthesia in patients in whom sevoflurane or desflurane are used as inhalational anesthetics for maintenance of general anesthesia</TitleDisplay><TitleOfficial>Comparison of emergence and recovery characteristics after desflurane or sevoflurane in patients undergoing general anesthesia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2018/04/013130</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>desflurane</Name><Drug id="6027">desflurane</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sevoflurane</Name><Drug id="5356">sevoflurane</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5356">sevoflurane</Drug><IndicationsPioneer/><Companies><Company><Company id="1082614">Government Medical College Calicut, Kerala</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6027">desflurane</Drug><IndicationsPioneer/><Companies><Company><Company id="1082614">Government Medical College Calicut, Kerala</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6027" type="Drug"><TargetEntity id="144844" type="siDrug">Desflurane</TargetEntity></SourceEntity><SourceEntity id="5356" type="Drug"><TargetEntity id="90235" type="siDrug">Sevoflurane</TargetEntity></SourceEntity><SourceEntity id="1082614" type="Company"><TargetEntity id="5039680593" type="organizationId">Government Medical College Kozhikode</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1082614">Government Medical College Calicut, Kerala</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1668">General anesthetic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="616">Inhalant formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>110</PatientCountEnrollment><DateStart>2014-12-14T00:00:00Z</DateStart><DateChangeLast>2018-04-17T22:00:55Z</DateChangeLast><DateAdded>2018-04-18T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Government Medical College, Kozhikode</Affiliation><Email>binusajid@gmail.com</Email><Name>Binu Sajid</Name><Phone>9447324632</Phone></Contact><Contact type="Public contact"><Affiliation>Government Medical College Kozhikode</Affiliation><Email>drramyathangavelu@gmail.com</Email><Name>Ramya T</Name><Phone>7736386676</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;ASA status I or II &lt;/li&gt;&lt;li&gt;Surgery duration within 2 h&lt;/li&gt;&lt;li&gt;BMI 25 to 30 &lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with significant Cardiovascular dysfunction,hepatic, renal dysfunction,endocrinal disturbances, neurological, psychiatric disorder&lt;/li&gt;&lt;li&gt;Pregnant and breastfeeding females&lt;/li&gt;&lt;li&gt;Patients who underwent anaesthesia within previous 7 days  &lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Emergence, Early recovery, Delayed recovery</Description><Timeframe>5 min, every 15 min</Timeframe></Measure><Measure><Description>Post anesthetic patient recovery profile</Description><Timeframe>1 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a cohort study, comparing the emergence, early recovery and delayed recovery between &lt;ulink linkType="Drug" linkID="5356"&gt;sevoflurane&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6027"&gt;desflurane&lt;/ulink&gt; inhalational anesthetic in patients undergoing general anaesthesia for surgery lasting less than 2 h in 110 patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who received desflurane or sevoflurane will be observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Govt. Medical College, Kozhikode</Name><Address1>Kozhikode</Address1><Address2>KERALA</Address2><CountrySubDivision>KERALA</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2018/04/013130</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="337657"><TitleDisplay>Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study</TitleDisplay><TitleOfficial>Follow-up of phase I/II study of CaspaCide T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR alpha-beta + T cells in pediatric patients affected by hematological disorders</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2016-003226-16</Identifier><Identifier type="Secondary Organisational">BP-404</Identifier><Identifier type="Other">NCT03733249</Identifier></Identifiers><Indications><Indication id="142">Hematological disease</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="616">Graft versus host disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rimiducid</Name><Drug id="7484">rimiducid</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rivogenlecleucel</Name><Drug id="69455">rivogenlecleucel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="69455">rivogenlecleucel</Drug><IndicationsPioneer/><Companies><Company><Company id="1023406">Bellicum Pharmaceuticals Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="7484">rimiducid</Drug><IndicationsPioneer/><Companies><Company><Company id="1023406">Bellicum Pharmaceuticals Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="7484" type="Drug"><TargetEntity id="270609" type="siDrug">Rimiducid</TargetEntity></SourceEntity><SourceEntity id="69455" type="Drug"><TargetEntity id="698093" type="siDrug">Rivogenlecleucel</TargetEntity></SourceEntity><SourceEntity id="1023406" type="Company"><TargetEntity id="5000448724" type="organizationId">Bellicum Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="142" type="ciIndication"><TargetEntity id="10061590" type="MEDDRA"/><TargetEntity id="D006402" type="MeSH"/><TargetEntity id="-1796155433" type="omicsDisease"/><TargetEntity id="987" type="siCondition"/></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"/><TargetEntity id="D019337" type="MeSH"/><TargetEntity id="-105358819" type="omicsDisease"/><TargetEntity id="1328" type="siCondition"/></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"/><TargetEntity id="10018651" type="MEDDRA"/><TargetEntity id="D006086" type="MeSH"/><TargetEntity id="39812" type="ORPHANET"/><TargetEntity id="-1437372564" type="omicsDisease"/><TargetEntity id="1129" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1023406">Bellicum Pharmaceuticals Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="17039">CASP9 gene stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1596">Immunomodulator</Class><Class id="396">Immunosuppressant</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="570">Cell therapy</Technology><Technology id="140">Gene expression regulation</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>175</PatientCountEnrollment><DateStart>2017-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2036-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-11-09T07:06:43Z</DateChangeLast><DateAdded>2018-05-02T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sponsor GmbH</Affiliation><Name>Bellicum Pharmaceuticals Clinical Development</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Signed written informed consent by the patient or the patient's guardian for children who are minors&lt;/li&gt;&lt;li&gt;Enrolled on&lt;ulink linkType="Protocol" linkID="174070"&gt;BP-004&lt;/ulink&gt; protocol, received BPX-501 infusion and completed 6 months of active treatment&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Lack of parents'/guardian's informed consent for children who are minors&lt;/li&gt;&lt;li&gt;Loss of allograft prior to 6 months&lt;/li&gt;&lt;li&gt;Progression of malignant disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of disease-free survival in both malignant and non-malignant patients at one and two years</Description><Timeframe>Up to two years post-transplant</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Long-term safety for a total of 15 years from BPX-501 administration</Description><Timeframe>15 years</Timeframe></Measure><Measure><Description>Number of patients with replication competent retrovirus : presence of replication competent retrovirus in patient peripheral blood mononuclear cells measured by quantitative PCR</Description><Timeframe>Every 6 months after rivogenlecleucel infusion for 5 years and yearly thereafter for another 10 years</Timeframe></Measure><Measure><Description>Vector copy number: copy number of integrated retroviruses in patient peripheral blood mononuclear cells measured by quantitative PCR</Description><Timeframe>Every 6 months after rivogenlecleucel infusion for 5 years and yearly thereafter for another 10 years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Main objective of the trial:&lt;br/&gt;To evaluate the long-term safety of the infusion of BPX-501 gene modified T cells (&lt;ulink linkType="Drug" linkID="69455"&gt;CaspaCide&lt;/ulink&gt;) and to evaluate disease-free survival at one and two years. &lt;/para&gt;&lt;para&gt;Secondary objectives of the trial:&lt;br/&gt;Long-term safety for a total of 15 years from BPX-501 administration.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects enrolled on the &lt;ulink linkType="Protocol" linkID="174070"&gt;BP-004&lt;/ulink&gt; study who have completed 6 months active treatment with BPX-501 T-cells (rivogenlecleucel) will be requested to enroll on this long-term follow up protocol. Long term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.&lt;/para&gt;&lt;para&gt;Patients will receive infusion of BPX-501 gene modified T cells. &lt;ulink linkType="Drug" linkID="7484"&gt;Rimiducid&lt;/ulink&gt; will be given at 0.4 mg/kg weight (intravenous infusion) who have received rivogenlecleucel.&lt;br/&gt;Patients who received rivogenlecleucel in the BP-004 study will  be evaluated for long-term safety and efficacy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Great North Children's Hospital</Name><Address1>Newcastle Upon Tyne</Address1><Address3>NE1 4LP</Address3><Contacts/></Site><Site><Name>Institute of Child Health &amp; Great Ormond Street Hospital</Name><Address1>London</Address1><Address3>WC1N 1EH</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Contacts><Contact type="Facility contact backup"><Email>mfrench@bellicum.com</Email><Name>Martha French</Name><Phone>018323841119</Phone></Contact></Contacts></Site><Site><Name>IRCCS Ospedale Pediatrico Bambino Gesù</Name><Address1>Rome</Address1><Address3>00161</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Saudi Arabia"><Sites><Site><Name>King Abdullah International Medical Research Center (KAIMRC)</Name><Address1>Riyadh</Address1><Address3>11426</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Bellicum Pharmaceuticals, Inc</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other hematological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18261">Subjects with specific disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier>NCT03733249</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2016-003226-16</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other hematological disease" id="42900"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hematological neoplasm" id="43296"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hematological neoplasm" id="45543"><Endpoint>Assessment of Survival</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other hematological disease" id="42900"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hematological neoplasm" id="43296"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other hematological disease" id="33056"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Hematological neoplasm" id="33080"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other hematological disease" id="34317"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other hematological disease" id="33114">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other hematological disease" id="35075"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hematological neoplasm" id="25526"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="25612"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other hematological disease" id="24612">Subjects unable/unwilling to give informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hematological neoplasm" id="27845"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="27915"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-11-02T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="3378"><TitleDisplay>Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus</TitleDisplay><TitleOfficial>A Phase III, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naive Patients With Type 2 Diabetes Mellitus</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">9630</Identifier><Identifier type="Secondary Organisational">H7U-MC-IDAY</Identifier><Identifier type="NCT">NCT00391209</Identifier><Identifier type="Other">2006-002999-17</Identifier><Identifier type="Trial Acronym">IDAY</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="808" role="Toxic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1906" role="Therapeutic effect marker" type="Physiological">Carbon monoxide diffusing capacity</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>insulin (inhaled, AIR), Alkermes/Lilly</Name><Drug id="31753">insulin (inhaled, AIR), Alkermes/Lilly</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="31753">insulin (inhaled, AIR), Alkermes/Lilly</Drug><IndicationsPioneer/><Companies><Company><Company id="14005">Alkermes plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="17810">Eli Lilly &amp; Co</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="31753" type="Drug"><TargetEntity id="297084" type="siDrug">Inhaled insulin</TargetEntity></SourceEntity><SourceEntity id="14005" type="Company"><TargetEntity id="4295905472" type="organizationId">Alkermes Inc</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>42</NumberOfSites><CompaniesSponsor><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSponsor><CompaniesCollaborator><Company id="14005">Alkermes plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="38211">Human insulin fast acting product</Class><Class id="38215">Human insulin long acting product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="616">Inhalant formulation</Technology><Technology id="80">Peptide</Technology><Technology id="618">Powder formulation inhalant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>379</PatientCountEnrollment><PatientCountEvaluable>382</PatientCountEvaluable><DateStart>2006-10-31T00:00:00Z</DateStart><DateEnd type="actual">2008-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-29T12:23:52Z</DateChangeLast><DateAdded>2007-08-07T11:09:16Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 2 diabetes mellitus for at least 6 months&lt;/li&gt;&lt;li&gt;Have a HbA1c &gt; 7.0% and&amp;lt;/=  10.5% at screening&lt;/li&gt;&lt;li&gt;Diffusing capacity of the lung for carbon monoxide (DLCO) &gt;70% of predicted&lt;/li&gt;&lt;/ul&gt;Forced expiratory volume in 1 s (FEV1) = forced vital capacity(FVC) greater than lower limit of normal&lt;ul&gt;&lt;li&gt;FEV1 &gt; 70% predicted&lt;/li&gt;&lt;li&gt;Patients who have been treated with all of  the following regimen:&lt;ul&gt;&lt;li&gt;One or more oral anti-hyperglycemic medications on a stable dose for at least 6 weeks (12 weeks for thiazolidinediones [TZDs])&lt;/li&gt;&lt;li&gt;Have been on insulin for 14 days or less throughout life and have not taken insulin within 6 months&lt;/li&gt;&lt;li&gt;Are candidates for insulin therapy, in the opinion of the investigator&lt;/li&gt;&lt;li&gt;Are nonsmokers for &gt; 6 months before the study (serum cotinine&amp;lt; 20 ng/ml at screening)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Are investigative site personnel directly affiliated with the study, and/or their immediate families.&lt;/li&gt;&lt;li&gt;Patients are Lilly employees or are employed by Alkermes. Immediate family of Lilly or Alkermes employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at a Lilly facility&lt;/li&gt;&lt;li&gt;Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry&lt;/li&gt;&lt;li&gt;Patients who have previously received any form of inhaled insulin, or have completed or discontinued from this study&lt;/li&gt;&lt;li&gt;Patients who are taking a TZD dose greater than what is indicated in combination with insulin according to the TZD label in the respective country. In countries where the combination of the TZD and insulin is not approved, patients taking any TZD at study entry will be excluded&lt;/li&gt;&lt;/ul&gt;Patients who have had more than two episodes of severe hypoglycemiaduring the 6 months prior to study entry &lt;ul&gt;&lt;li&gt;Patients who have had more than one hospitalization or emergency room visit due to poor diabetic control during the 6 months prior to study entry&lt;/li&gt;&lt;li&gt;Patients who have had pneumonia in the 3 months prior to screening, on clinical or radiologic grounds&lt;/li&gt;&lt;li&gt;Patients who have received systemic glucocorticoid therapy within the 3 months prior to study entry (topical preparations, nasal preparations, intra-articular administration, as well as physiologic replacement for Addison’s Disease and hypopituitarism are permitted),&lt;/li&gt;&lt;li&gt;Patients who have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransaminase/serum glutamic pyruvic transaminase (ALT/SGPT) greater than three times the upper limit of the reference range&lt;/li&gt;&lt;li&gt;Patients who have a history of renal transplantation, are currently receiving renal dialysis, or have a serum creatinine &gt; 2.0 mg/dl (177 micromol/l) if not on metformin; or if on metformin at study entry, have a serum creatinine above what is contraindicated in the metformin label in the respective country (for example, in the United States, &gt;/= 1.5 mg/dl [132 micromol/l] for males or &gt;/= 1.4 mg/dl [123 micromol/l] for females)&lt;/li&gt;&lt;li&gt;Patients who have a history of angina, myocardial infarction (MI), or Functional Capacity Class III/IV cardiac disease (as defined by the New York Heart Association within the 6 months prior to study entry&lt;/li&gt;&lt;li&gt;Patients who have an active or untreated malignancy, or have been in remission from a clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) for&amp;lt; 5 years&lt;/li&gt;&lt;li&gt;Patients who have a current or past history of lung cancer&lt;/li&gt;&lt;li&gt;Patients who have a history of lung transplantation&lt;/li&gt;&lt;li&gt;Patients who have a current or past history of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, or other clinically relevant pulmonary disease that, in the opinion of the investigator, would preclude participation in the study due to safety concerns, or confound data interpretation&lt;/li&gt;&lt;li&gt;Patients who are taking or have taken exenatide (Byetta) or other incretin mimetics that are not approved for use with insulin during the prior 8 weeks&lt;/li&gt;&lt;li&gt;Patients who have any other condition (including reported drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol&lt;/li&gt;&lt;li&gt;Patients who fail to satisfy the investigator of suitability to participate for any other reason&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Demonstrate that a simple approach for adding AIR Inhaled Insulin to oral antihyperglycemic medication can achieve within 6 months glycemic control similar to a more aggressive approach</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean change in HbA1c from baseline to various endpoints</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Patient safety (safety was evaluated by hypoglycemia ie, rate, incidence, nocturnal, and severity, treatment-emergent adverse events (TEAEs), inhaler reliability, pulmonary function changes, and body weight changes)</Description><Timeframe>Throughout the study</Timeframe></Measure><Measure><Description>Patient reported outcome from W-BQ12</Description><Timeframe>Screening, baseline, month 6</Timeframe></Measure><Measure><Description>Treatment satisfaction</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Insulin dose</Description><Timeframe>Throughout the study</Timeframe></Measure><Measure><Description>8-point SMBG profiles</Description></Measure><Measure><Description>Proportion of patients who achieve A1C &lt;/= 6.5% and &lt; 7.0%</Description></Measure><Measure><Description>Patient reported outcome from DSC-R</Description><Timeframe>Screening, baseline, month 6</Timeframe></Measure><Measure><Description>Patient reported outcome from DTSQS</Description><Timeframe>Screening, baseline, month 6</Timeframe></Measure><Measure><Description>Patient reported outcome from IDSQ</Description><Timeframe>Months 1, 2 and 6</Timeframe></Measure><Measure><Description>Patient reported outcome from 'Expectations About Insulin Therapy Questionnaire'</Description><Timeframe>Screening, baseline, month 6</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in May 2009. A total of 23 patients experienced one or more serious adverse events (SAEs), 11 patients in the Algorithm A group and 12 patients in the Algorithm B group. A total of 6 patients in the Algorithm A group and no patients in the Algorithm B group had a TEAE that resulted in study discontinuation. One event of bronchiolitis, one event of grand mal convulsion, and one event of allergic dermatitis were considered to be related to study drug, study device, and/or study procedures. Overall, 118 (61.8%) and 120 (63.2%) patients in the Algorithm A and B groups, respectively, experienced at least one TEAE during the study. There were statistically significant differences between the two algorithms in the SOC psychiatric disorders (p = 0.037) with one patient in the Algorithm A group reporting seasonal affective disorder versus a total of seven patients in the Algorithm B group reporting events for this SOC with three patients reporting anxiety, two reporting depression, and two reporting insomnia. In the Algorithm B group, the rate of hypoglycemia per 30 days was significantly greater from randomization through endpoint (p &amp;lt; 0.001). There were statistically significant differences between the treatment groups at  any time points during the study for rate or incidence of both hypoglycemia and nocturnal hypoglycemia. The incidence of severe hypoglycemic episodes was 8.7% in the Algorithm A group and 14.4% in the Algorithm B group; however, the difference between groups did not meet the threshold for statistical significance (p= 0.105) [&lt;ulink linkType="Reference" linkID="1280161"&gt;1280161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, data showed that ihe incidence of patients with one or more treatment emergent adverse events (TEAEs) did not differ significantly between simplified (118 of 191) and intensive (120 of 190) algorithms (p = 0.83). The most common adverse event was cough in the simplified (27 of 191) and intensive algorithms (28 of 190 )  (p = 0.88). In patients receiving the simplified algorithm, 11  serious TEAEs were reported of which 1 was due to hypoglycemia and  in patients receiving the intensive algorithm there were 12 serious TEAEs of which 2 were due to hypoglycemia. During simplified treatment, there were lower rates of hypoglycemia compared to intensive insulin treatment  at  week  4 (1.53 +/- 2.7 versus 3.03 +/- 4.69, respectively; p &amp;lt; 0.001), week 8 (1.7 +/- 3.0 versus 4.42 +/- 7.19, respectively; p &amp;lt; 0.001), week 12 (1.84 +/- 3.23 versus 5.62 +/- 8.73, respectively; p &amp;lt; 0.001), and  week 24  (1.29 +/-  2.35 versus 2.92 +/- 3.94, respectively; p &amp;lt; 0.001). Incidence of severe hypoglycemia  was similar for  simplified and intensive treatment algorithms (p = 0.11). During intensive treatment, there were higher rates of nocturnal hypoglycemia (episodes per patient per 30 days) compared to the simplified insulin treatment at  week 8  (0.68 +/-1.50 versus 0.35 +/- 1.08, respectively; p = 0.015) and week 12 (1.21 +/- 3.29 versus 0.39 +/- 1.2, respectively; p &amp;lt; 0.001) [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This randomized, multicenter, open-label, active-comparator, two-arm, parallel-group, 6-month study was designed to compare the efficacy of two treatment regimens (algorithm A versus algorithm B) in insulin-naive patients with type 2 diabetes not optimally controlled by one or more oral anti-hyperglycemic medications.&lt;/para&gt;&lt;para&gt;The secondary objectives of the study are:&lt;br/&gt;To compare the two dose titration algorithm groups with respect to the following: mean change in HbA1c from baseline to 2 and 3 months, daily insulin dose requirements, time to maximum dose; time to 90% maximum dose and time to achievement of 75% of SBGM targets, the proportion of patients achieving HbA1c &amp;lt; 7% and, in a separate analysis, achieving HbA1c &amp;lt;/= 6.5%, 8-point SBGM profile, 4-point SBGM profile, and total number of blood glucose measurements per week,  hypoglycemia, patient-reported energy; fatigue and cognitive distress symptoms; diabetes treatment satisfaction; and evaluation of the insulin delivery system,  treatment-emergent adverse events, safety as assessed by insulin antibody levels; pulmonary function testing (PFT) &lt;br/&gt;and diffusing capacity of the lung for carbon monoxide (DLCO); Pulmonary Symptoms Questionnaire (PSQ); body weight.&lt;br/&gt;To assess inhaler reliability.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in May 2009. The noninferiority of a simplified dosing regimen was not demonstrated. The overall difference (Algorithm A – Algorithm B) in the change in HbA1c between algorithms was 0.24%. Patients in the Algorithm B group were more consistently able to achieve HbA1c values of &amp;lt; 7.0 and ≤6.5% over the course of the study. A statistically significant difference was seen between the treatment algorithm groups during the study and overall (p = 0.005 and 0.022, respectively). There were some statistically but not clinically significant differences between the two treatment algorithm groups for the other parameters  [&lt;ulink linkType="Reference" linkID="1280161"&gt;1280161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, results were published.  In the simplified and intensive titration algorithms, the change from baseline A1C to last observation carried forward (LOCF) end point in the ITT population (least squares mean [LSM] standard error [SE])  was -1.36 +/- 0.09 and -1.60 +/- 0.09, respectively. There was no non-inferiority  between the two algorithms (p = 0.02). There was a greater drop in A1C in the intensive treatment algorithm, which  was superior in controlling A1C compared  with the simplified treatment algorithm (p &amp;lt; 0.05; 8 and 12 weeks and LOCF).  In the per-protocol population, the upper limit of the two-sided 95% CI  was 0.41 (p = 0.09). In the simplified and intensive algorithms, the number of patients with A1C &amp;lt; 7.0% and  A1C &amp;lt;/= 6.5% at 24-week LOCF was [75  and 102  (p = 0.005)] and [48  and 69  (p = 0.022)], respectively  [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results were published in june 2010. With greater self-efficacy, increasingly positive expectations were significantly associated with greater self-efficacy; with greater positive expectations, shorter diabetes duration, less symptom distress, greater well-being, self-efficacy and diabetes treatment satisfaction greater levels of positive experiences were significantly associated.Overall, patients' experiences were significantly more positive than their expectations with inhaled insulin therapy: 58, 29, 13% patient's experiences exceeded expectations, experiences met expectations and experiences did not meet expectations respectively. Among these groups, post hoc tests indicated that treatment satisfaction scores differed (all p &amp;lt; 0.01) [&lt;ulink linkType="Reference" linkID="1530024"&gt;1530024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;For the simplified  and the intensive algorithms, the change from baseline to LOCF end point for fasting blood glucose (LSM-SE) were similar, based on eight-point SMBG reported (average across three 2-h postprandial meal times and then averaged over 3 days of eight-point SMBG in IFCC plasma) in the patient diaries (simplified [-43.24 +/- 3.42 mg/dl {-2.40 +/- 0.19 mmol/l}; n = 145] and the intensive [-47.2 +/- 3.42 mg/dl {-2.62+/- 0.19 mmol/l}; n = 153] algorithms [p = 0.24]).    For overall 2-h postprandial blood glucose, the change from baseline at LOCF end point was not statistically different between both the algorithms (p = 0.33). For bedtime blood glucose, the change from baseline at LOCF end point was -69.54 +/- 4.5 mg/dl for the simplified algorithm and -69.18 +/- 4.32 mg/dl for the intensive algorithm (p = 0.93).  In the evening  prandial glucose levels there were statistically significant treatment differences, in change from baseline to LOCF. The estimate was -43.06 +/- 3.96 mg/dl for the simplified algorithm and -51.7 +/- 3.78 mg/dl for the intensive algorithm (p = 0.039). At LOCF end point, insulin- specific antibody titer (median) was 0.20% (n = 141) for the simplified  and 0.20% (n = 138) for the intensive insulin treatment cohort. There were no statistically significant treatment differences seen between simplified and intensive algorithms for FEV1 and DLCO. Mean changes from baseline to LOCF end point for DLCO (-0.38 ml/min/torr and -0.07 ml/min/torr for simplified and intensive algorithms, respectively) and  FEV1 (-0.09  and -0.08 l for simplified and intensive algorithms, respectively)   were not considered clinically significant and were small [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;According to A1C (&amp;lt;/= 8.5 and &amp;gt; 8.5%), insulin secretagogue use, and country, patients were randomized using a computer-generated system to one of two treatment algorithms: a simplified diabetes management regimen and an intensive diabetes management regimen. Laboratory tests  and patients performed pulmonary function tests (PFTs) were performed. Patients  were given study diaries for recording self-monitored blood glucose (SMBG) values, any changes in medication, and adverse events, at randomization. On prestudy doses of OAMs, patients remained throughout the study unless it was  not safe for them  [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;For the simplified algorithm (Algorithm A), &lt;ulink linkType="Drug" linkID="31753"&gt;AIR insulin&lt;/ulink&gt; was  initiated at 6 U administered within 15 min before meals. The four-point SMBG was monitored before all meals and at bedtime, twice per week for the first month and then once per week until the study ends. Based on blood glucose measurements taken on the previous day  dose, adjustments were made as follows: the morning dose was based on mid-day prandial blood glucose, the mid-day dose was based on evening prandial blood glucose, and the evening dose was based on bedtime blood glucose. Dose adjustments were also made twice per week for the first month and once per week for the remainder of the study, reflecting the previous 1-day SMBG levels. In the increments of 2 U dose, titrations were made  for each meal according to the SMBG results from the day before until the target blood glucose was reached or hypoglycemia occurred. Insulin total dosage should not reach more than 6 U/day  was instructed to patients  [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1280161"&gt;1280161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;For the intensive algorithm (Algorithm B),  based on fasting blood glucose, gender, height, and weight the total daily starting dose of &lt;ulink linkType="Drug" linkID="31753"&gt;AIR insulin&lt;/ulink&gt; was calculated. Daily four-point SMBG  was conducted by patients for the entire study. Based on the average four-point SMBG results from the previous 3 days by &amp;lt;/= 8 U per day insulin dose adjustments were made, until the target blood glucose was reached or hypoglycemia occurred. Every 3 days or twice weekly for the entire duration of  study dose adjustments were made. The greatest prandial blood glucose value determined, which dose to titrate most aggressively, if all three prandial plasma glucose values were &amp;lt;/= 165 mg/dl (&amp;lt;/= 9.2 mmol/l) [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1280161"&gt;1280161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="31753"&gt;AIR insulin&lt;/ulink&gt;  adjusted to plasma glucose ranges  were administered within 15 min before meals.  The targets for pre-midday meal, pre-evening meal, and bedtime  were 85 to 124 mg/dl (4.7 to 6.8 mmol/l). If an episode of hypoglycemia or plasma glucose &amp;lt;/= 75 mg/dl (&amp;lt;/= 4.2 mmol/l) occurred within the previous 3 days, the dose was not increased.  If a stable dose regimen was established and the fasting blood glucose was &amp;gt; 130 mg/dl (&gt; 7.2 mmol/l), from 3 months after randomization, a fourth dose (4 U, adjusted down to 2 U later if needed) and a snack (containing 60 g of carbohydrate) were initiated at bedtime [&lt;ulink linkType="Reference" linkID="1048747"&gt;1048747&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>insulin (inhaled, AIR), Alkermes/Lilly</Name><Drug id="31753">insulin (inhaled, AIR), Alkermes/Lilly</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="1039">Myalgia</Indication></AdverseEvent><AdverseEvent><Indication id="1101">Skin allergy</Indication></AdverseEvent><AdverseEvent><Indication id="1734">Chronic lymphocytic leukemia</Indication></AdverseEvent><AdverseEvent><Indication id="224">Myocardial infarction</Indication></AdverseEvent><AdverseEvent><Indication id="3135">Clonic seizure</Indication></AdverseEvent><AdverseEvent><Indication id="445">Hypoglycemia</Indication></AdverseEvent><AdverseEvent><Indication id="50">Bronchitis</Indication></AdverseEvent><AdverseEvent><Indication id="82">Cough</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Argentina"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Buenos Aires</Address1><Address3>1012</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Austria"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Vienna</Address1><Address3>1090</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Wien</Address1><Address3>A-1030</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Brugge</Address1><Address3>8000</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Brussels</Address1><Address3>1070</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Leuven</Address1><Address3>3000</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Liege</Address1><Address3>4000</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Alcira</Address1><Address3>46600</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Alicante</Address1><Address3>03114</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Granada</Address1><Address3>18014</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>La Coruña</Address1><Address3>15006</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Palma De Mallorca</Address1><Address3>07198</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Requena</Address1><Address3>46340</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>La Coruna</Address1><Address3>15006</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Eli Lilly</Name></Contact></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>La Roche Sur Yon</Address1><Address3>85925</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>La Rochelle</Address1><Address3>17019</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Rouen</Address1><Address3>76031</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Valenciennes</Address1><Address3>59322</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="India"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Ahmedabad</Address1><Address3>380006</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Bangalore</Address1><Address3>560052</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Chennai</Address1><Address3>600116</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Mexico"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Guadalajara</Address1><Address3>44670</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Monterrey</Address1><Address3>64060</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Puerto Rico"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Caguas</Address1><Address3>00726</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Ponce</Address1><Address3>00717-2075</Address3><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Rio Piedras</Address1><Address3>00921</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78731</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Biddeford</Address1><Address2>Maine</Address2><Address3>04005</Address3><CountrySubDivision code="ME">Maine</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Greenville</Address1><Address2>South Carolina</Address2><Address3>29605</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Hollywood</Address1><Address2>Florida</Address2><Address3>33021</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Honolulu</Address1><Address2>Hawaii</Address2><Address3>96813</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Idaho Falls</Address1><Address2>Idaho</Address2><Address3>83404</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55416</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70121</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>New Port Richey</Address1><Address2>Florida</Address2><Address3>34652</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Renton</Address1><Address2>Washington</Address2><Address3>98057</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><Address3>84124</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78229</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Santa Ana</Address1><Address2>California</Address2><Address3>92705</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>South Miami</Address1><Address2>Florida</Address2><Address3>33143</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Stratford</Address1><Address2>New Jersey</Address2><Address3>08084</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Tacoma</Address1><Address2>Washington</Address2><Address3>98405</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20010</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="100">Subjects on Treatment/Requiring &gt;1  Antidiabetic Agent</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="101">Subjects on Treatment/Requiring Insulin</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="103">Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="145">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="172">Insulin Naive Type 2 Diabetes Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00391209</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2006-002999-17</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1350">Self monitoring of blood glucose (SMBG)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1359">Change in HbA1c</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1624"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="33857"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33885">Diabetes symptom checklist(DSC-R) questionnaire</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33887">Diabetes treatment and satisfaction questionnaire(DTSQ)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33890">Well-being questionnaaire(WBQ)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33927">Insulin treatment satisfaction questionnaire</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33946">Other patient reported outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1515">Severe/major hypoglycemia</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1517">Hypoglycemia rate (Rate of hypoglycemic events)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="1624"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1633">Assessment of neuropsychiatric adverse events</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1634">Assessment of serious adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="1626"><Endpoint>Assessment of Adverse Events</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1627">Adverse drug reaction (ADR)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1503">Assessment of body weight</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="6756"><Endpoint>Assessment of Antibodies</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="6760">Insulin antibodies</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="6761">Insulin autoantibodies (IAA)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="670"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="676">Subjects on/treated with thiazolidinediones</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="680">Subjects on treatment/requiring  insulin</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="905">Subjects on/agreeing to maintain stable dose of oral hypoglycemic agents</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="1047"><Criterion>Treatment Naive Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1048">Insulin naïve subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="607">Subjects with Poor/Inadequate Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="845">Post-renal transplant subjects</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="925"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="948">Subjects on/treated with incretin mimetics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="959"><Criterion>Conditions Altering Blood Glucose Levels</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="961">Subjects on glucocorticoid/steroid therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="979"><Criterion>Subjects with Hypoglycemia/Hypoglycemia Unawareness</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5072"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="26284"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="982">Subjects with history/scheduled to undergo organ transplantation</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-05-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2007-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>14.03 Months</EnrollmentPeriod><EnrollmentRate>27.01 Patients/Month</EnrollmentRate><DateFirstReceived>2006-10-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-08-07T11:09:16Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="340333"><TitleDisplay>Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer</TitleDisplay><TitleOfficial>Phase II, Non-Randomized, Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03532737</Identifier><Identifier type="Organisational Study">HNIT 01</Identifier></Identifiers><Indications><Indication id="623">Head and neck tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>intensity modulated radiotherapy (66 to 70 Gy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cetuximab</Name><Drug id="10388">cetuximab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>pembrolizumab</Name><Drug id="70667">pembrolizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10388">cetuximab</Drug><IndicationsPioneer/><Companies><Company><Company id="1118814">Kuwait Cancer Control Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="70667">pembrolizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="1118814">Kuwait Cancer Control Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="10388" type="Drug"><TargetEntity id="230562" type="siDrug">Cetuximab</TargetEntity></SourceEntity><SourceEntity id="70667" type="Drug"><TargetEntity id="729094" type="siDrug">Pembrolizumab</TargetEntity></SourceEntity><SourceEntity id="1118814" type="Company"><TargetEntity id="5049432659" type="organizationId">Kuwait Cancer Control Center</TargetEntity></SourceEntity><SourceEntity id="623" type="ciIndication"><TargetEntity id="C76.0" type="ICD10"/><TargetEntity id="10067821" type="MEDDRA"/><TargetEntity id="D006258" type="MeSH"/><TargetEntity id="-545944758" type="omicsDisease"/><TargetEntity id="1148" type="siCondition"/></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1118814">Kuwait Cancer Control Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="67136">Programmed cell death protein 1 inhibitor</Action><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="2946">Analgesic</Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class><Class id="7761">T-lymphocyte stimulator</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="852">Intravesical formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="167">Monoclonal antibody murine</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Medical procedure</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2018-10-07T00:00:00Z</DateStart><DateEnd type="estimated">2022-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-22T05:21:42Z</DateChangeLast><DateAdded>2018-05-24T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>mustafashawki@yahoo.com</Email><Name>Mustafa S El-Sherify, MD</Name><Phone>+965 554 66285</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kuwait Cancer Control Center</Affiliation><Name>Mustafa S El-Sherify, MD</Name></Contact></Contacts><MeasuresOutcome><MeasuresPrimary><Measure><Description>Dose Limiting Toxicity (DLT): a pembrolizumab attributable, dose-limiting toxicity (DLT) will be defined as follows: 1) Any &gt;/= grade 3 adverse event (CTCAE, version 4) that is related to pembrolizumab that does not resolve to grade 1 or less within 28 days; 2) A delay in radiotherapy of &gt; 2 weeks due to toxicity related to pembrolizumab; 3) Inability to complete radiotherapy due to toxicity related to pembrolizumab; 4) Inability to receive an adequate dose (&gt;/= 70%) of cisplatin or cetuximab due to toxicity definitely related to pembrolizumab</Description><Timeframe>From the first dose of pembrolizumab to 28 days after the completion of radiation therapy</Timeframe></Measure><Measure><Description>Response Rate: response rates according to irRECIST criteria</Description><Timeframe>Three years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Locoregional control rates: number of local disease progression events</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Overall survival: number of cancer-related deaths</Description><Timeframe>Five years initially (longer follow up will be done)</Timeframe></Measure><Measure><Description>Progression free survival: number of local or distant disease progression events</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Patients Quality of life (QoL): QoL assessment by the patients</Description><Timeframe>Five years initially</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This will be a phase II, non-randomized trial to define safety      and efficacy of combining the PD-1 inhibitor &lt;ulink linkType="Drug" linkID="70667"&gt;pembrolizumab&lt;/ulink&gt; given concomitantly with the usual      standard of care chemoradiation/bioradiation for locally advanced non-nasopharyngeal head and neck cancer (HNC).      Primary end point will be assessment of toxicity and tolerability while the secondary end      points will be response rates (RR) and progression free survival (PFS).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In the current trial, Investigators are trying to fill this gap by testing the      efficacy and safety of pembrolizumab with radical chemoradiation in all cases of locally advanced head and neck cancer (LAHNC).&lt;/para&gt;&lt;para&gt;All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor. Chemotherapy: cisplatin: 100 mg/m2 q21d D1, D22, D43. or &lt;ulink linkType="Drug" linkID="10388"&gt;cetuximab&lt;/ulink&gt; loading dose 400 mg/m2, 1 week before radiation then maintenance dose 250 mg/m2 qw, D8, D15, D22, D29, D36, D43. Pembrolizumab 200 mg will be administered as an intravenous infusion over 30 min q3w 21 days prior to radiation, then Day 1 of radiation and then q21d for total six doses. Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66 to 70 Gy/30 to 35 Fr over 6 to 7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB).&lt;/para&gt;&lt;para&gt;Post-treatment evaluations will start 4 weeks after completion of      radiation therapy. The  week 4 post-treatment evaluations will consist of a physical      examination, hematology and biochemistry profiles, tumor assessments (by palpation) and an      objective assessment of adverse events which may have occurred since completing treatment.      Radiological assessment of response will be done 8 to 10 weeks post treatment. Responses will be      reported according to irRECIST criteria.&lt;/para&gt;&lt;para&gt;Subsequent Follow-up evaluations will commence after the 8 week post-treatment, every 4      weeks (+/- 1 week) for years one and every 8 weeks for year two, and then, every 4 months (+/-  2      weeks) for year three to five. The evaluations in the first year will consist of a physical      examination, hematology and chemistry profiles, Quality of Life, imaging/diagnostic      assessments, and tumor assessments. Evaluations in year two to five  will consist of a physical      examination, imaging/diagnostic, and tumor assessments.&lt;/para&gt;&lt;para&gt;Statistical methods and consideration.&lt;br/&gt;Statistical package for social sciences (SPSS) version 16. Quantitative variables will           be summarized using mean and standard deviation (SD), median minimum and maximum values.           Qualitative data will be summarized using frequencies and percentage.&lt;br/&gt;Overall survival will be calculated from the date of histological diagnosis.&lt;br/&gt;Progression free survival (PFS) will be calculated from the date of starting of           treatment till disease progression and death whichever comes first.&lt;br/&gt;Survival analysis will be done using Kaplan- Meier, comparisons will be done using           Log-rank test.&lt;br/&gt;Differences will be considered significant when p was 0.05 and highly significant when p           0.01.&lt;br/&gt;Patients lost for follow up with disease will be considered as dead.&lt;br/&gt;At the time of data analysis stratification of the patients according to sub sites,           prognostic and risk factors including HPV status will be done.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Kuwait"><Sites><Site><Name>Kuwait Cancer Control Center</Name><Address1>Kuwait</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Mustafa El-Sherify</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Head and neck tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3764">Subjects with Laryngeal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3775">Subjects with Locally Advanced Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3777">Subjects with Specific Histological Sub-type of HNC</PatientSegment><SubSegments><SubSegment id="3778">Subjects with squamous cell carcinoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3784">Subjects with Unresectable Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7278">Subjects with Oral Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7281">Subjects with Pharyngeal Cancer</PatientSegment><SubSegments><SubSegment id="7283">Subjects with oropharyngeal cancer</SubSegment><SubSegment id="7284">Subjects with hypopharyngeal cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="10289">Subjects with TNM Stage III Head and Neck Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10290">Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment><SubSegments><SubSegment id="10291">Subjects with TNM stage IVa HNC</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03532737</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Head and neck tumor" id="7263"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7285"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7290">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7311"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7313">Assessment of dose limiting toxicity</SubEndpoint><SubEndpoint disease="Head and neck tumor" id="7316">Assessment of grade 3 toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7312"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Head and neck tumor" id="7352"><Endpoint>Assessment of compliance/adherence</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Head and neck tumor" id="7244"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7256"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7277"><Endpoint>Assessment of Disease Control</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7278">Assessment of loco-regional control</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="7331"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Head and neck tumor" id="26070"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Head and neck tumor" id="7285"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7290">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Head and neck tumor" id="7299"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Head and neck tumor" id="7308"><Endpoint>Assessment of Physical Examination</Endpoint></OtherEndpoint><OtherEndpoint disease="Head and neck tumor" id="7335"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Head and neck tumor" id="7347"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="7346">Assessment of hematological status</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Head and neck tumor" id="45203"><Endpoint>Clinical Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Head and neck tumor" id="4359"><Criterion>Subjects with Oral Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4370"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4371">Subjects with measurable disease as per RECIST criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4373"><Criterion>Subjects with Non-measurable Disease</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4385"><Criterion>Subjects with TNM Stage III Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4386"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4387">Subjects with TNM stage IV A HNC</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4390"><Criterion>Subjects with Unresectable Head and Neck Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4396"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4403">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4407"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4414"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4416">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Head and neck tumor" id="4417">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4455"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4458">Protocol specified inclusion criteria for females</SubCriterion><SubCriterion disease="Head and neck tumor" id="5240">Subjects recovered from prior therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4793"><Criterion>Subjects with Specific Histological Sub-type of Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4794">Subjects with squamous cell head and neck carcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="7087"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="7093"><Criterion>Subjects with Pharyngeal Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4362">Subjects with oropharyngeal cancer</SubCriterion><SubCriterion disease="Head and neck tumor" id="4363">Subjects with hypopharyngeal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="7094"><Criterion>Subjects with Laryngeal Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="34017"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4419">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="34137"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4459">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="34360"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4460">Subjects willing/able to provide informed consent/assent</SubCriterion><SubCriterion disease="Head and neck tumor" id="5213">Subjects included based on discretion of investigator</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="34809"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4457">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Head and neck tumor" id="5738"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5744"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5751"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="5752"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5758">Subjects with abnormal pulmonary functions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5771"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5772">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion><SubCriterion disease="Head and neck tumor" id="5773">Subjects with hypersensitivity/contraindication to biological therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5777"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5779">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="5781">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Head and neck tumor" id="5784">Subjects with history of targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5792"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5791">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="25523"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5793">Subjects unable/unwilling to give informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="26365"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5755">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Head and neck tumor" id="5757">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="26437"><Criterion>Subjects with Evidence of Metastasis</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="26697"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="26885"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5782">Subjects with history of surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="27118"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5774">Subjects with hypersensitivity/contraindication to radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="27355"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Head and neck tumor" id="27843"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="6478">Subjects unable to comply with protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="28294"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-05-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-10-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="354093"><TitleDisplay>9-ING-41 in Patients With Advanced Cancers</TitleDisplay><TitleOfficial>Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3 beta) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematological Malignancies or Solid Tumors</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03678883</Identifier><Identifier type="Organisational Study">1801</Identifier><Identifier type="Other">Actuate 1801</Identifier></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="759">Central nervous system tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>9-ING-41</Name><Drug id="96541">9-ING-41</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>9-ING-41</Name><Drug id="96541">9-ING-41</Drug></Intervention><Intervention type="InterventionPrimary"><Name>carboplatin</Name><Drug id="44383">carboplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>lomustine</Name></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Name><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Name><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug><IndicationsPioneer/><Companies><Company><Company id="1121663">Actuate Therapeutics</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159247">Developmental Therapeutics Consortium, UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="29016">paclitaxel (albumin-bound nanoparticle, intravenous), Celgene</Drug><IndicationsPioneer/><Companies><Company><Company id="1121663">Actuate Therapeutics</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159247">Developmental Therapeutics Consortium, UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer/><Companies><Company><Company id="1121663">Actuate Therapeutics</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159247">Developmental Therapeutics Consortium, UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44383">carboplatin</Drug><IndicationsPioneer><Indication id="2054">Hematological neoplasm</Indication></IndicationsPioneer><Companies><Company><Company id="1121663">Actuate Therapeutics</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159247">Developmental Therapeutics Consortium, UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="96541">9-ING-41</Drug><IndicationsPioneer><Indication id="1069">Metastasis</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="759">Central nervous system tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1121663">Actuate Therapeutics</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159247">Developmental Therapeutics Consortium, UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="96541">9-ING-41</Drug><IndicationsPioneer><Indication id="1069">Metastasis</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="759">Central nervous system tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1121663">Actuate Therapeutics</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1159247">Developmental Therapeutics Consortium, UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44383" type="Drug"><TargetEntity id="125568" type="siDrug">Carboplatin</TargetEntity></SourceEntity><SourceEntity id="29016" type="Drug"><TargetEntity id="289351" type="siDrug">nab-paclitaxel</TargetEntity><TargetEntity id="289351" type="siDrug">nab-paclitaxel</TargetEntity></SourceEntity><SourceEntity id="1121663" type="Company"><TargetEntity id="5046715668" type="organizationId">Actuate Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1159247" type="Company"><TargetEntity id="5035854911" type="organizationId">Developmental Therapeutics Consortium Ltd</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"/><TargetEntity id="D009362" type="MeSH"/><TargetEntity id="-1423187778" type="omicsDisease"/><TargetEntity id="618" type="siCondition"/></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"/><TargetEntity id="D019337" type="MeSH"/><TargetEntity id="-105358819" type="omicsDisease"/><TargetEntity id="1328" type="siCondition"/></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"/><TargetEntity id="D005909" type="MeSH"/><TargetEntity id="360" type="ORPHANET"/><TargetEntity id="-1357419475" type="omicsDisease"/><TargetEntity id="678" type="siCondition"/></SourceEntity><SourceEntity id="759" type="ciIndication"><TargetEntity id="10007958" type="MEDDRA"/><TargetEntity id="D016543" type="MeSH"/></SourceEntity><SourceEntity id="4360" type="Action"><TargetEntity id="1869" type="Mechanism">Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1121663">Actuate Therapeutics</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1159247">Developmental Therapeutics Consortium, UK</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4360">Glycogen synthase kinase-3 beta inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2576">Microtubule stabilizer</Class><Class id="50">Anticancer alkylating agent</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="599">Nanoparticle formulation injectable</Technology><Technology id="756">Pharmaceutical carrier</Technology><Technology id="207">Protein conjugated</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="745">Suspension</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>250</PatientCountEnrollment><DateStart>2019-01-04T00:00:00Z</DateStart><DateEnd type="estimated">2022-11-30T00:00:00Z</DateEnd><DateChangeLast>2019-05-22T02:04:30Z</DateChangeLast><DateAdded>2018-09-24T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Actuate Therapeutics</Affiliation><Name>Francis J Giles, MD</Name></Contact><Contact type="Public contact"><Email>fgiles@actuatetherapeutics.com</Email><Name>Francis J Giles, MD</Name><Phone>+12817961852</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient:&lt;ul&gt;&lt;li&gt;Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures&lt;/li&gt;&lt;li&gt;Is aged &gt;/=  18 years&lt;/li&gt;&lt;li&gt;Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:&lt;ul&gt;&lt;li&gt;Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition&lt;/li&gt;&lt;li&gt;Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit&lt;/li&gt;&lt;li&gt;Malignancy has relapsed after standard therapy&lt;/li&gt;&lt;li&gt;Malignancy for which there is no standard therapy that improves survival by at least 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Has evaluable tumor(s) by standard radiological and/or laboratory assessments as applicable to their malignancy - in Part 3, patients with solid tumors must have least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI). In the case of patients with glioblastoma multiforme (GBM) or other central nervous system (CNS) tumors, the tumor must be measurable, defined as a clearly enhancing tumor with at two perpendicular diameters at entry equal or superior to 1 cm&lt;/li&gt;&lt;li&gt;Has laboratory function within specified parameters (may be repeated):&lt;ul&gt;&lt;li&gt;Adequate bone marrow function: absolute neutrophil count (ANC) &gt;/= 1,000/ml; hemoglobin &gt;/= 8.5 g/dl, platelets &gt;/= 75,000/ml&lt;/li&gt;&lt;li&gt;Adequate liver function: transaminases (aspartate aminotransferase/ alanine aminotransferase, AST/ALT) and alkaline phosphatase&amp;lt;/= 3 (&amp;lt;/= 5 x the upper limit of normal [ULN] in the setting of liver metastasis or infiltration with malignant cells) x ULN; bilirubin &amp;lt;/= 1.5 x ULN 3. Adequate renal function: creatinine clearance &gt;/= 60 ml/min (Cockcroft and Gault) &lt;/li&gt;&lt;li&gt;Adequate blood coagulation: international normalized ratio (INR)&amp;lt;/= 2.3 &lt;/li&gt;&lt;li&gt;Serum amylase and lipase&amp;lt;/=  1.5 x ULN &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG) PS 0 to 1&lt;/li&gt;&lt;li&gt;Has received the final dose of any of the following treatments/ procedures with the specified minimum intervals before first dose of study drug (unless in the opinion of the investigator and the study medical coordinator the treatments/ procedures will not compromise patient safety or interfere with study conduct and with IDMC agreement):&lt;ul&gt;&lt;li&gt;Chemotherapy, immunotherapy, or systemic radiation therapy - 21 days or &gt;/= 5 half-lives (whichever is shorter)&lt;/li&gt;&lt;li&gt;Focal radiation therapy - 7 days&lt;/li&gt;&lt;li&gt;Systemic and topical corticosteroids - 7 days&lt;/li&gt;&lt;li&gt;Surgery with general anesthesia - 7 days&lt;/li&gt;&lt;li&gt;Surgery with local anesthesia - 3 days&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;May continue endocrine therapies (eg, for breast or prostate cancer) and/or anti-human epidermal growth factor (Her2) therapies while on this study&lt;/li&gt;&lt;li&gt;Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 h of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment&lt;/li&gt;&lt;li&gt;Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence&lt;/li&gt;&lt;li&gt;Must not be receiving any other investigational medicinal product&lt;/li&gt;&lt;li&gt;For study Parts 2 and 3, must have received prior therapy for the same malignancy including the same potential partner agent(s) as that/those being considered for administration on study in combination with 9-ING-41&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Is pregnant or lactating&lt;/li&gt;&lt;li&gt;Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation&lt;/li&gt;&lt;li&gt;Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as&amp;lt;/= CTCAE) Version 4.03 &lt;/li&gt;&lt;li&gt;Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening&lt;/li&gt;&lt;li&gt;Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41 or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator or study medical coordinator&lt;/li&gt;&lt;li&gt;Has known symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable asymptomatic brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug&lt;/li&gt;&lt;li&gt;Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, eg, a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major)&lt;/li&gt;&lt;li&gt;Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation&lt;/li&gt;&lt;li&gt;Has received an investigational anti-cancer drug in the 21-day period before the first dose of study drug (or within five half-lives if longer) or is currently participating in another interventional clinical trial&lt;/li&gt;&lt;li&gt;Has had a previous (within two years) or has a current malignancy other than the target cancer with the exception of curatively treated local tumors including carcinoma in situ of the breast or cervix, basal or squamous cell carcinoma of the skin, or prostate cancer with Gleason Grade&amp;lt; 6 and prostate-specific antigen within normal range&lt;/li&gt;&lt;li&gt;Is considered to be a member of a vulnerable population (for example, prisoners)&lt;/li&gt;&lt;li&gt;For Study Parts 2 and 3, must not have developed persistent (&amp;gt; 28 days) clinically significant Grade 3/4 toxicities attributable to same prior chemotherapy agent as that being considered for administration on this study in combination with 9-ING-41 &lt;/li&gt;&lt;li&gt;During Parts 1 and 2 of the study, patients taking strong inhibitors of CYP2C19, CYP3A4, and CYP1A2 or strong inducers of CYP3A4 should not be entered into the study protocol; this will be reviewed by the IDMC prior to Part 3 of the study opening to recruitment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Parts 1/2: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03: the standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint</Description><Timeframe>3 months to three years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The &lt;ulink linkType="Company" linkID="1121663"&gt;Actuate&lt;/ulink&gt;, 1801,      phase I/II study was designed to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="96541"&gt;9-ING-41&lt;/ulink&gt;, a potent GSK-3 beta      inhibitor, as a single agent and in combination with cytotoxic agents, in patients with      refractory cancers [&lt;ulink linkType="Reference" linkID="2152899"&gt;2152899&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The 1801 study would  have three parts:&lt;br/&gt;Part 1 (9-ING-41 as monotherapy): The standard 3+3 dose escalation design would be applied to all dose cohorts until the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) was identified.&lt;br/&gt;Part 2: 9-ING-41 combined with standard anticancer agents: The 3+3 dose escalation study design would be used for 6 chemotherapy combination regimens (9-ING-41 plus gemcitabine, doxorubicin, lomustine, carboplatin, nab-paclitaxel plus gemcitabine, paclitaxel plus carboplatin) to identify the MTD/RP2D of each regimen. Part 2 would be started after a maximum of 3 dose escalations of 9-ING-41 as a single agent in Part 1. The starting dose level in Part 2 of 9-ING-41 within the six combination regimens would be the 3rd dose level of single agent 9-ING-41 (or lower if the IDMC so recommends). Dose escalations of 9-ING-41 as a single agent in Part 1 would continue in parallel with dose escalations of 9-ING-41 in combination treatments in Part 2.&lt;br/&gt;Part 3: assessment of activity of 9-ING-41 based combination regimens: The primary objective for Study Part 3 was to assess the clinical benefit of each of the six 9-ING-41-based combination regimens. Secondary objectives would include the assessment of other efficacy variables, including progression-free survival (PFS), duration of tumor response, time to treatment failure, 1-year survival rate and overall survival (OS) as well as additional evaluation of toxicities. The Simon's 2-stage design would be employed for Study Part 3 for the six 9-ING-41-based combination regimens.&lt;br/&gt;Patients would be assigned into seven arms:&lt;br/&gt;Arm 1: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min.&lt;br/&gt;Arm 2: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min and &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; 1250 mg/m2 as a 30-min iv infusion on Days 1 and 8 of a 21-day cycle.&lt;br/&gt;Arm 3: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min and doxorubicin 75 mg/m2, iv bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.&lt;br/&gt;Arm 4: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min and lomustine 30 mg/m2 orally as a single-dose, weekly for 12 weeks. &lt;br/&gt;Arm 5: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; AUC 6 intravenously over 1 h on Day 1 of a 21-day cycle.&lt;br/&gt;Arm 6: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min and nb-paclitaxel (&lt;ulink linkType="Drug" linkID="29016"&gt;Abraxane&lt;/ulink&gt;) 125 mg/m2 iv on Days 1, 8 and 15 of a 28-day cycle. &lt;br/&gt;Arm 7: patients would receive starting dose of-9-ING-41 (1 mg/kg iv) would be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 would be administered over 60 min and carboplatin AUC 6 intravenously over 1 h on Day 1 of a 21-day cycle. &lt;ulink linkType="Drug" linkID="3803"&gt;Paclitaxel&lt;/ulink&gt; 175 mg/m2 iv over 3 h on Day 1 of a 21-day cycle.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Developmental Therapeutics Consortium</Name><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Mayo Clinic</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3>55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Ma.Wen@mayo.edu</Email><Name>Wen Wee Ma, M.B.B.S.</Name></Contact></Contacts></Site><Site><Name>Miami Cancer Institute</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33176</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>LudimilaC@baptisthealth.net</Email><Name>Ludimila Cavalcante, MD</Name></Contact></Contacts></Site><Site><Name>Rhode Island Hospital</Name><Address1>Providence</Address1><Address2>Rhode Island</Address2><Address3>02903</Address3><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Benedito.Carneiro@Lifespan.org</Email><Name>Benedito Carneiro, MD</Name></Contact></Contacts></Site><Site><Name>Sanford Research</Name><Address1>Sioux Falls</Address1><Address2>South Dakota</Address2><Address3>57105</Address3><CountrySubDivision code="SD">South Dakota</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Steven.Powell@SanfordHealth.org</Email><Name>Steven Powell, MD</Name></Contact></Contacts></Site><Site><Name>UCSF Helen Diller Family Comprehensive Cancer Center</Name><Address1>San Francisco</Address1><Address2>California</Address2><Address3>94115</Address3><CountrySubDivision code="CA">California</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Pmunster@medicine.ucsf.edu</Email><Name>Pamela Munster, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hematological neoplasm</Disease><PatientSegments><PatientSegment><PatientSegment id="19122">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="19068">Subjects With Advanced Hematological Malignancies</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Glioblastoma</Disease><PatientSegments><PatientSegment><PatientSegment id="7988">Subjects with Relapse/Recurrent Glioblastoma Multiforme</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7998">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12012">Subjects with Advanced Glioblastoma Multiforme</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7961">Subjects with Advanced/Metastatic Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7966">Subjects with Relapsed/Recurrent Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7967">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9673">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9674">Subjects with Recurrent/Relapsed CNS Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12019">Subjects with Advanced CNS Neoplasms</PatientSegment><SubSegments><SubSegment id="20172">Subjects with Stage IV Central Nervous Cell Tumor</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03678883</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Glioblastoma" id="13208"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Glioblastoma" id="13211">Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Glioblastoma" id="13210"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13551"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13554">Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Central nervous system tumor" id="13553"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15288">Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15287"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hematological neoplasm" id="43296"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Glioblastoma" id="13118"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Glioblastoma" id="13126"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Glioblastoma" id="13129"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Glioblastoma" id="13136">Assessment of duration of tumor response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Glioblastoma" id="13208"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13472"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13477"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13480"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13487">Assessment of duration of tumor response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="13551"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15199"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15207"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15211"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15218">Assessment of duration of tumor response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hematological neoplasm" id="43296"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hematological neoplasm" id="43630"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="44881"><Endpoint>Assessment of Survival</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Glioblastoma" id="44882"><Endpoint>Assessment of Survival</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="44887"><Endpoint>Assessment of Survival</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hematological neoplasm" id="45543"><Endpoint>Assessment of Survival</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Central nervous system tumor" id="46106"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13479">Assessment of Time-to-Treatment Failure (TTF)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Glioblastoma" id="46108"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Glioblastoma" id="13128">Assessment of Time-to-Treatment Failure (TTF)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="46116"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15210">Assessment of Time-to-Treatment Failure (TTF)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Glioblastoma" id="7984"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Glioblastoma" id="7990"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="7991">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8001"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8002">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Glioblastoma" id="8003">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8012"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8013">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Glioblastoma" id="8016">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Glioblastoma" id="8017">Subjects with history of surgery/procedure for Glioblastoma Multiforme</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8018"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Glioblastoma" id="8019"><Criterion>Subjects with Refractory Glioblastoma Multiforme</Criterion></Inclusion><Inclusion disease="Glioblastoma" id="8021"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8022">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Glioblastoma" id="8023">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="8028"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8034">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13033"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13035">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13045"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13046">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13047">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13056"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13057">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13060">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13061">Subjects with history of surgery/procedure for CNS Tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13062"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13063"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13064"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13065"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13066">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13067">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13069">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13072"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13096"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13098"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13100">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13102"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13105">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13109"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13110">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Solid tumor" id="13111">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13120"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13121">Subjects with chemotherapy for solid tumors</SubCriterion><SubCriterion disease="Solid tumor" id="13124">Subjects with hormonal therapy for solid tumors</SubCriterion><SubCriterion disease="Solid tumor" id="13126">Subjects with surgery/procedure for solid tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13127"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13128"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13129"><Criterion>Subjects with Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13130"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13131">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Solid tumor" id="13132">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13137"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13143">Protocol specified inclusion criteria for females</SubCriterion><SubCriterion disease="Solid tumor" id="13147">Subjects with ability to discontinue concomitant/required medication</SubCriterion><SubCriterion disease="Solid tumor" id="14851">Subjects with history of any other investigational agent therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13155"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Glioblastoma" id="22406"><Criterion>Subjects with Advanced Glioblastoma Multiforme</Criterion></Inclusion><Inclusion disease="Hematological neoplasm" id="33080"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Solid tumor" id="33912"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13125">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34030"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13133">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="34035"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13068">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="34040"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8024">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="34109"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13082">Subjects with adequate contraception</SubCriterion><SubCriterion disease="Central nervous system tumor" id="35511">Non Pregnant/Non lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34117"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13144">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="34122"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8035">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="34416"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13076">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34423"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13138">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="34429"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8029">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="34888"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13078">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34896"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13140">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Glioblastoma" id="34903"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="8031">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hematological neoplasm" id="35119"><Criterion>Subjects With Advanced Hematological Malignancies</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="35505"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="35506">Subjects with Stage IV Central Nervous Cell Tumor</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Glioblastoma" id="9554"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="9555"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="9565"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9572">Subjects with abnormal radiological findings</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="9582"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9588">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="9590"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="9592"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9595">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Glioblastoma" id="9601">Vulnerable population</SubCriterion><SubCriterion disease="Glioblastoma" id="9602">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10640"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10641"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10651"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10658">Subjects with abnormal radiological findings</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10660"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10661">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10668"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10675">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="10677"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="10680"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10683">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10689">Vulnerable population</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10690">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10714"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10721">Subjects with abnormal radiological findings</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10723"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10724">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10740"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10743"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10746">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Solid tumor" id="10752">Vulnerable population</SubCriterion><SubCriterion disease="Solid tumor" id="12314">Subjects who did not recover from previous therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="12316"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="23396"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="24270"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="24575"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="25453"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10684">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Central nervous system tumor" id="10685">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="25513"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9596">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Glioblastoma" id="9597">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hematological neoplasm" id="25526"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Solid tumor" id="25667"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10747">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Solid tumor" id="10748">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hematological neoplasm" id="25703"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Solid tumor" id="26347"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10717">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Central nervous system tumor" id="26348"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="10654">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="26357"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Glioblastoma" id="9568">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hematological neoplasm" id="26438"><Criterion>Subjects with Evidence of Metastasis</Criterion></Exclusion><Exclusion disease="Solid tumor" id="26453"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10761">Subjects with brain/CNS metastasis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Glioblastoma" id="26954"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Solid tumor" id="26970"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="26971"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="27192"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="27299"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="27349"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="27357"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Solid tumor" id="27478"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Central nervous system tumor" id="27544"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Glioblastoma" id="27585"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="27589"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Solid tumor" id="27666"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="27717"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="27845"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Hematological neoplasm" id="28295"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2022-11-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-09-15T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-21T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="374376"><TitleDisplay>Breast Cancer Diet Intervention Study</TitleDisplay><TitleOfficial>The Effects of Insulin and Insulin-Related Characteristics, and Short-Term Low-Glycemic and High-Glycemic Carbohydrate Intervention on Breast Cancer Biomarkers and Survival</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03886389</Identifier><Identifier type="Organisational Study">59</Identifier><Identifier type="Trial Acronym">BCDIS</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="5" role="Disease marker" type="Genomic;Proteomic">Estrogen receptor</BiomarkerName><BiomarkerName id="6" role="Therapeutic effect marker" type="Genomic;Proteomic">Progesterone receptor</BiomarkerName><BiomarkerName id="159" role="Therapeutic effect marker" type="Biochemical">Lactic Acid</BiomarkerName><BiomarkerName id="378" role="Therapeutic effect marker" type="Genomic;Proteomic">Insulin-like growth factor binding protein 3</BiomarkerName><BiomarkerName id="379" role="Therapeutic effect marker" type="Genomic;Proteomic">Insulin-like growth factor 1</BiomarkerName><BiomarkerName id="425" role="Therapeutic effect marker" type="Proteomic">C-peptide</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="4058" role="Therapeutic effect marker" type="Biochemical">Glycine</BiomarkerName><BiomarkerName id="4753" role="Therapeutic effect marker" type="Biochemical">Choline</BiomarkerName><BiomarkerName id="11071" role="Therapeutic effect marker" type="Biochemical">Fatty acids</BiomarkerName><BiomarkerName id="24539" role="Therapeutic effect marker" type="Biochemical">Lipoproteins</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>carbohydrate intake</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Standard preoperative fasting procedure</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1018537" type="Company"><TargetEntity id="4298294965" type="organizationId">Helse Stavanger HF</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1018537">Helse Stavanger HF</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>80</PatientCountEnrollment><DateStart>2009-06-12T00:00:00Z</DateStart><DateEnd type="actual">2017-07-07T00:00:00Z</DateEnd><DateChangeLast>2019-05-15T06:33:54Z</DateChangeLast><DateAdded>2019-03-25T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Helse Stavanger HF; Stavanger University Hospital</Affiliation><Name>Svein Skeie, PhD</Name></Contact><Contact type="Scientific contact"><Affiliation>Helse Stavanger HF</Affiliation><Name>Haavard Soiland</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All consecutive operable patients in 2009 to 2010, with a clinical and/or radiologic and/or cytologic diagnosis of primary breast cancer, unless the exclusion criteria apply&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Non-operable patients (ie, patients with T3-4 [&amp;gt;5 cm] disease or distant metastases at the time of operation)&lt;/li&gt;&lt;li&gt;All patients who refuse to participate&lt;/li&gt;&lt;li&gt;All patients with DCIS, micro-invasive cancer&amp;lt;2 mm diameter or tumors with histologic poor-quality material&lt;/li&gt;&lt;li&gt;Co-morbidity (insulin dependent diabetes mellitus, Cushing syndrome, previous or concurrent cancers except CIN and non-melanomatous skin cancer)&lt;/li&gt;&lt;li&gt;Mental inability to participate&lt;/li&gt;&lt;li&gt;Persons allergic to one of the compounds in any of the two diets&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mitotic Activity Index (MAI): proliferation in invasive front in tumor</Description><Timeframe>Trough completion of surgery of all included patients, an average of one, five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Breast Cancer Specific Survival: time from surgery to dead of disease or all other causes of death</Description><Timeframe>Eight years follow-up (97 months of follow up)</Timeframe></Measure><Measure><Description>High Resolution Magnetic Resonance Spectroscopy (HR-MRS) profiling of specific metabolites: metabolic profiling in the primary tumor and in the serum samples; measure content of lactate, glycine, choline,fatty acids and lipoproteins</Description><Timeframe>Immediately after surgery: tumor is fresh frozen; High Resolution Magnetic Resonance Spectroscopy (HR-MRS) will be done in the fresh frozen tumor and deep frozen serum samples (as for insulin characteristics)</Timeframe></Measure><Measure><Description>Relapse free survival: time from surgery to a relapse (loco-regional, contralateral and systemic) is experienced</Description><Timeframe>Until eight years (97 months of follow up)</Timeframe></Measure><Measure><Description>S-IGF1: measure of insulin growth factor type 1; unit, nM (nano molar)</Description><Timeframe>Analyzed in serum samples at 5 time points; at inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</Timeframe></Measure><Measure><Description>S-IGFBP3: measure of insulin growth factor binding protein 3; unit mg/l</Description><Timeframe>Analyzed in serum samples at 5 time points; at inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</Timeframe></Measure><Measure><Description>S-insulin: secretion of insulin into serum; unit, mIE/l (milli international units per l)</Description><Timeframe>Analyzed in serum samples at 5 time points; at inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</Timeframe></Measure><Measure><Description>S-insulin c-peptide: measure of total insulin secreted; unit, nM (nano molar)</Description><Timeframe>Analyzed in serum samples at 5 time points; at inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30)</Timeframe></Measure><Measure><Description>Well being after surgery: patient reported outcome measures (questionaire)</Description><Timeframe>Day 1, 2, 3, 4, 5, 6 and 7 after surgery</Timeframe></Measure><Measure><Description>PR: expression of Progesteron Receptor in the primary tumor</Description><Timeframe>Trough completion of surgery of all included patients, an average of one, five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose was to study whether 18 and 2 to 4 h pre-operative per-oral carbohydrate loading      (often given in gastrointestinal surgery, ie, enhanced recovery after surgery = ERAS)      influences proliferation in the tumor, serum insulin characteristics, metabolic profile and      survival.&lt;/para&gt;&lt;para&gt;The aim was to study:&lt;br/&gt;The inter-patient variation in insulin and insulin-related characteristics in the blood           taken just before the operation from breast cancer patients, on a usual pre-operative           fasting schedule.&lt;br/&gt;The influence of the variation in insulin and insulin-related characteristics on           proliferation and other cell biological features in the breast cancers of these           patients.&lt;br/&gt;Whether 4 and 18-h pre-operative hyperglycemic glucose loading (to reduce           postoperative insulin resistance) would influence proliferation (Mitotic Activity Index [MAI]           and other cell biological features) in breast cancer.&lt;br/&gt;The influence of the short-term effect of a pre-operative low-glycemic carbohydrate           isocaloric diet on proliferation and other cell biological features of the primary           breast cancer cells (low-glycemic isocaloric diet intervention study).&lt;br/&gt;Epidemiological risk factors: the correlation between epidemiological risk factors,           insulin and insulin-related characteristics, proliferation, cell biological features and           other biomarkers in breast cancer patients.&lt;br/&gt;Estrogen receptor positive tumors would be analyses separately.&lt;br/&gt;Relapse free survival.&lt;br/&gt;Breast cancer specific survival.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The Short-term effect of carbohydrates would be assessed in a randomized intervention study,      where 30 patients receive oral carbohydrates 18 and 4 h before surgery and 30 patients      receive fasting procedure/water. The primary outcome was proliferation in the tumor as measured by MAI. &lt;br/&gt;Secondary outcomes included: serum insulin characteristics (S-insulin, S-insulin c-peptide, S-IGF and S-IGFBP3) would be measured at various peri-surgical timepoints; changes in metabolic &lt;br/&gt;profile in the   tumor and in serum samples; patient reported outcome measures (PROM) on well being; relapse free survival; breast cancer specific survival; metabolic profile assessed by high resolution magnetic resonance spectroscopy (HR-MRS) in the tumor and in serum samples.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Norway"><Sites><Site><Name>Helse Stavanger HF</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3930">Subjects with Hormone Receptor Positive Breast Cancer</PatientSegment><SubSegments><SubSegment id="3931">Estrogen receptor positive (ER+) breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3955">Subjects with Resectable/Operable Breast Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03886389</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="37159"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Breast tumor" id="45566"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8739"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8740">Assessment of time to recurrence</SubEndpoint><SubEndpoint disease="Breast tumor" id="8743">Assessment of local relapses</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8754"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8757">Assessment of time to all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8759"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8813"><Endpoint>Assessment of Oncogenes/Oncoproteins</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8822">Assessment of growth factors and receptors</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8971"><Endpoint>Assessment of Hormone Levels</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9028">Blood insulin levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="9017"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="9310"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9312">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="37159"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="37161"><Endpoint>Assessment of Tumor Related Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9119">Assessment of tumor metabolism</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="45149"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8718">Assessment of Relapse/Recurrence Free Survival</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Breast tumor" id="8902"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4807"><Criterion>Subjects with Hormone Receptor Positive Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4808">Estrogen receptor positive (ER+) breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4924"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="33170">Subjects with a cytological diagnostic and/or pathology of breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="22398"><Criterion>Subjects with Resectable Tumor</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6215"><Criterion>Subjects with Other forms of Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6906">Inoperable breast cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6415"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26375"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6227">Subjects with ductal carcinoma in situ (DCIS)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26428"><Criterion>Subjects with Evidence of Metastasis</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26710"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Breast tumor" id="26752"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6418">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="27116"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-07-07T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-03-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="added"><Date>2019-04-10T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-04-10T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="updated"><Date>2019-05-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-05-15T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-05-15T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-05-15T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-05-15T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-05-15T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="374582"><TitleDisplay>Clinical Comparison of DDT2 Contact Lens and a Daily Disposable Contact Lens - Study 1</TitleDisplay><TitleOfficial>Clinical Comparison of DDT2 Contact Lens and a Daily Disposable Contact Lens - Study 1</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03888469</Identifier><Identifier type="Organisational Study">CLE383-C007</Identifier></Identifiers><Indications><Indication id="2006">Myopia</Indication></Indications><BiomarkerNames><BiomarkerName id="18315" role="Therapeutic effect marker" type="Physiological">Visual acuity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>1-DAY ACUVUE MOIST</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>DDT2</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1006151" type="Company"><TargetEntity id="4297268694" type="organizationId">Alcon Research Ltd</TargetEntity></SourceEntity><SourceEntity id="2006" type="ciIndication"><TargetEntity id="H52.1" type="ICD10"/><TargetEntity id="10028651" type="MEDDRA"/><TargetEntity id="D009216" type="MeSH"/><TargetEntity id="-1211815872" type="omicsDisease"/><TargetEntity id="790" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1006151">Alcon Research Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>92</PatientCountEnrollment><DateStart>2019-05-03T00:00:00Z</DateStart><DateEnd type="actual">2019-06-24T00:00:00Z</DateEnd><DateChangeLast>2019-06-27T08:40:12Z</DateChangeLast><DateAdded>2019-03-27T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able to understand and sign an informed consent form that has been approved by an Institutional review board&lt;/li&gt;&lt;li&gt;Willing and able to attend all scheduled study visits as required per protocol&lt;/li&gt;&lt;li&gt;Successful wear of spherical soft contact lenses for distance correction in both eyes during the past 3 months for a minimum of 5 days per week and 8 h per day&lt;/li&gt;&lt;li&gt;Manifest cylinder of&amp;lt;/= 0.75 diopter (D) in each eye&lt;/li&gt;&lt;li&gt;Best corrected visual acuity (VA) of 20 / 25 or better in each eye&lt;/li&gt;&lt;li&gt;Able to wear contact lenses within a range of sphere power from -1.00 to -6.00 D (0.25 D steps) and VA of 20/25 or better in each eye with fitting set lenses&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any anterior segment infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear&lt;/li&gt;&lt;li&gt;Any use of systemic or ocular medications for which contact lens wear could be contraindicated&lt;/li&gt;&lt;li&gt;History of ocular or intraocular surgery, including refractive surgery and/or irregular cornea&lt;/li&gt;&lt;li&gt;Biomicroscopy findings at baseline that are moderate (grade 3) or higher and/or corneal vascularization that is mild (grade 2) or higher&lt;/li&gt;&lt;li&gt;Current or history of pathologically dry eye in either eye that would preclude contact lens wear&lt;/li&gt;&lt;li&gt;Eye injury in either eye within 12 weeks immediately prior to enrollment for this trial&lt;/li&gt;&lt;li&gt;Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least one night per week) over the last 3 months prior to enrollment&lt;/li&gt;&lt;li&gt;Any use of topical ocular medications and artificial tear or rewetting drops that would require instillation during contact lens wear&lt;/li&gt;&lt;li&gt;Previous or current habitual wearers of ACUVUE MOIST or DAILIES TOTAL1 contact lenses. Other protocol-specified criteria may apply&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Visual acuity at distance: visual acuity will be recorded in logarithm minimum angle of resolution (logMAR) for each eye individually</Description><Timeframe>Day 8, each product</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate visual acuity at distance when wearing DDT2 contact      lenses compared to Acuvue Moist contact lenses.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be expected to attend three study visits and wear study lenses for approximately 14      to 20 days (7 to 10 days for each product).&lt;br/&gt;Patients would receive DDT2, then 1DAVM verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality or 1DAVM, then DDT2 etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Alcon Investigative Site</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32256</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Alcon Investigative Site</Name><Address1>Maitland</Address1><Address2>Florida</Address2><Address3>32751</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Alcon Investigative Site</Name><Address1>Orlando</Address1><Address2>Florida</Address2><Address3>32803</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Alcon Investigative Site</Name><Address1>Powell</Address1><Address2>Ohio</Address2><Address3>43065</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03888469</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other ocular disease" id="43240"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other ocular disease" id="43440"><Endpoint>Assessment of Visual Function</Endpoint><SubEndpoints><SubEndpoint disease="Other ocular disease" id="43441">Assessment of visual acuity(VA)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other ocular disease" id="32980"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other ocular disease" id="24053"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="24421">Subjects with systemic diseases/disorders</SubCriterion><SubCriterion disease="Other ocular disease" id="24648">Subjects with infectious diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other ocular disease" id="24306"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="24416"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="24417">Subjects undergoing planned intraocular surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other ocular disease" id="24645"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="24993"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="25619"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="27243"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Other ocular disease" id="27920"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="24644">Subjects with inability to comply with study protocol and/or follow up procedures</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2019-06-24T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-06-10T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>1.26 Months</EnrollmentPeriod><EnrollmentRate>73.02 Patients/Month</EnrollmentRate><DateFirstReceived>2019-03-22T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-05-13T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-07-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-07-01T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-07-01T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="374764"><TitleDisplay>Dienogest for Treatment of Adenomyotic Uteri</TitleDisplay><TitleOfficial>Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03890042</Identifier><Identifier type="Organisational Study">DAD</Identifier></Identifiers><Indications><Indication id="3835">Adenomyosis</Indication></Indications><BiomarkerNames><BiomarkerName id="12008" role="Therapeutic effect marker" type="Structural (imaging)">Uterus</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dienogest</Name><Drug id="11378">dienogest</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ultrasound examination</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>gestodene + estrogen (oral), Bayer Schering</Name><Drug id="47516">gestodene + estrogen (oral), Bayer Schering</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>ultrasound examination</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11378">dienogest</Drug><IndicationsPioneer><Indication id="3835">Adenomyosis</Indication></IndicationsPioneer><Companies><Company><Company id="1025024">Assiut University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="11378" type="Drug"><TargetEntity id="90248" type="siDrug">Dienogest</TargetEntity></SourceEntity><SourceEntity id="1025024" type="Company"><TargetEntity id="5035537586" type="organizationId">Assiut University</TargetEntity></SourceEntity><SourceEntity id="3835" type="ciIndication"><TargetEntity id="10056268" type="MEDDRA"/><TargetEntity id="D062788" type="MeSH"/><TargetEntity id="-2137714712" type="omicsDisease"/><TargetEntity id="2129" type="siCondition"/></SourceEntity><SourceEntity id="624" type="Action"><TargetEntity id="559" type="Mechanism">Progesterone Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1025024">Assiut University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="536">Estradiol agonist</Action><Action id="624">Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class></Class><Technologies><Technology id="175">Drug combination</Technology><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>90</PatientCountEnrollment><DateStart>2019-03-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-03-29T12:01:04Z</DateChangeLast><DateAdded>2019-03-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Assiut University</Affiliation><Email>m_khairy2001@yahoo.com</Email><Name>Mohammed Khairy Ali, Lecturer</Name><Phone>+201005537951</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Women aged 20 to 40 years&lt;/li&gt;&lt;li&gt;Women with ultrasonographical evidence of adenomyosis&lt;/li&gt;&lt;li&gt;Woman complains of vaginal bleeding or pelvic pain related to adenomyosis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Women with a history of malignancy or histological evidence of endometrial hyperplasia&lt;/li&gt;&lt;li&gt;Any adnexal abnormality on ultrasound&lt;/li&gt;&lt;li&gt;Undiagnosed vaginal&lt;/li&gt;&lt;li&gt;Contraindication to receive Vissane or Gynera&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of women who will improved from the pelvic pain measured by Visual Analog Scale</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Uterine volume (cm3) measure by ultrasound</Description><Timeframe>6 month</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study aim is to use &lt;ulink linkType="Drug" linkID="11378"&gt;dienogest&lt;/ulink&gt; (Visanne) versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be receiving either dienogest (Visanne) 2 mg tablet qd (dienogest group) or  &lt;ulink linkType="Drug" linkID="47516"&gt;ethinylestradiol + gestodene&lt;/ulink&gt; (Gynera) tablet once daily (Gynera group). Both the groups will undergo ultrasound assessment of uterine volume and Visual Analogue Scale for assessment of pain.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Egypt"><Sites><Site><Name>Women Health Hospital - Assiut university</Name><Address1>Assiut</Address1><Address3>71111</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>m_khairy2001@yahoo.com</Email><Name>Mohammed K ALi, MD</Name><Phone>+201005537951</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other genitourinary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18253">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="17480">Subjects with adenomyosis</SubSegment><SubSegment id="17481">Subjects with pelvic pain</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03890042</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other genitourinary disease" id="43688"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other genitourinary disease" id="43690">Assessment of Pain by Visual Analog Scale (VAS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other genitourinary disease" id="49074"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other genitourinary disease" id="43587"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other genitourinary disease" id="49067"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other genitourinary disease" id="33052"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other genitourinary disease" id="33112"><Criterion>Subjects with adenomyosis</Criterion></Inclusion><Inclusion disease="Other genitourinary disease" id="35814"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other genitourinary disease" id="24057"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other genitourinary disease" id="24302"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other genitourinary disease" id="24607"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Other genitourinary disease" id="24608">Subjects with Hypersensitivity/Contraindication to hormones</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other genitourinary disease" id="27742"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-03-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="376755"><TitleDisplay>Fingerprint Characterization of Sorafenib Treated HCC</TitleDisplay><TitleOfficial>Prospective Evaluation of Image and Molecular Fingerprint Characterization to Guide Treatment With Sorafenib in Hepatocellular Carcinoma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">DRKS00015917</Identifier><Identifier type="Secondary Organisational">729/2018BO1</Identifier><Identifier type="Other">NCT03958669</Identifier><Identifier type="Other">e:Med-HCC-2</Identifier><Identifier type="Trial Acronym">HCC fingerprint/HCC-e:Med2</Identifier></Identifiers><Indications><Indication id="1767">Hepatocellular carcinoma</Indication></Indications><BiomarkerNames><BiomarkerName id="52234" role="Disease marker" type="Genomic">Circulating microRNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>MR spectroscopy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>comprehensive image</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>liquid biopsy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>magnetic resonance imaging</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>molecular fingerprint</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>multi-phase CT scan</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sorafenib</Name><Drug id="29831">sorafenib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ultrasound elastography</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="29831">sorafenib</Drug><IndicationsPioneer/><Companies><Company><Company id="1004516">Deutsche Forschungsgemeinschaft (DFG)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039403">German Federal Ministry of Education and Research</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039869">University Hospital Tubingen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23358">Eberhard Karls Universität Tübingen</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="29831" type="Drug"><TargetEntity id="301618" type="siDrug">Sorafenib</TargetEntity></SourceEntity><SourceEntity id="1004516" type="Company"><TargetEntity id="5035524398" type="organizationId">Deutsche Forschungsgemeinschaft eV</TargetEntity></SourceEntity><SourceEntity id="1039403" type="Company"><TargetEntity id="5035527185" type="organizationId">Federal Ministry of Education and Research</TargetEntity></SourceEntity><SourceEntity id="1039869" type="Company"><TargetEntity id="5035542805" type="organizationId">Universitaetsklinikum Tuebingen</TargetEntity></SourceEntity><SourceEntity id="23358" type="Company"><TargetEntity id="4298339902" type="organizationId">University of Tuebingen</TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="1722" type="Action"><TargetEntity id="1103" type="Mechanism">VEGFR Inhibitors</TargetEntity><TargetEntity id="1619" type="Mechanism">Anti-VEGF</TargetEntity><TargetEntity id="1788" type="Mechanism">Vascular Endothelial Growth Factor (VEGF) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="4542" type="Action"><TargetEntity id="1212" type="Mechanism">Raf Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4548" type="Action"><TargetEntity id="2892" type="Mechanism">Raf kinase B Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4550" type="Action"><TargetEntity id="2963" type="Mechanism">Raf kinase C Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity><SourceEntity id="948" type="Action"><TargetEntity id="1072" type="Mechanism">PDGFR Family Inhibitors</TargetEntity><TargetEntity id="1789" type="Mechanism">Platelet-Derived Growth Factor (PDGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039869">University Hospital Tubingen</Company><Company id="23358">Eberhard Karls Universität Tübingen</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1004516">Deutsche Forschungsgemeinschaft (DFG)</Company><Company id="1039403">German Federal Ministry of Education and Research</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1722">VEGF receptor antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="4542">Raf protein kinase inhibitor</Action><Action id="4548">Raf B protein kinase inhibitor</Action><Action id="4550">Raf 1 protein kinase inhibitor</Action><Action id="48492">PDGF receptor beta antagonist</Action><Action id="948">PDGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2019-07-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-07-01T00:00:00Z</DateEnd><DateChangeLast>2019-06-20T02:05:22Z</DateChangeLast><DateAdded>2019-04-12T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>ursula.koppenhoefer@med.uni-tuebingen.de</Email><Extension>2984457</Extension><Name>Ursula Koppenhofer, Dipl biol</Name><Phone>+497071</Phone></Contact><Contact type="Scientific contact"><Affiliation>University Hospital, Eberhard Kars University Tübingen</Affiliation><Name>Michael Bitzer, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>University Hospital, Eberhard Kars University Tübingen</Affiliation><Name>Nisar P Malek, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;HCC patients with indication for the treatment with sorafenib, irrespective of previous systemic therapies&lt;/li&gt;&lt;li&gt;If prior systemic therapies had been applied, progression has to be documented prior to the start of treatment with sorafenib&lt;/li&gt;&lt;li&gt;Male or female &gt;/= 18 years and written informed consent&lt;/li&gt;&lt;li&gt;Histological confirmed advanced stage hepatocellular carcinoma, BCLC class B or C&lt;/li&gt;&lt;li&gt;Child-Pugh class A or B. Only patients with Child-Pugh index class B of not &gt; 7 will be included. Patients with untreatable ascites or hepatic encephalopathy&amp;gt; grade 1 are excluded (see exclusion criteria)&lt;/li&gt;&lt;li&gt;ECOG performance status 0, 1 or 2&lt;/li&gt;&lt;li&gt;Life expectancy of 12 weeks or more&lt;/li&gt;&lt;li&gt;At least one measurable lesion without previous local therapy and that is suitable for accurate repeated measurements as per mRECIST guidelines&lt;/li&gt;&lt;li&gt;Adequate hematological parameters, as demonstrated by:&lt;ul&gt;&lt;li&gt;Hemoglobin &gt;/= 9.0 g/dl (SI units: 5.6 mmol/l)&lt;/li&gt;&lt;li&gt;WBC &gt;/= 2.5 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 60 x 10(9)/l&lt;/li&gt;&lt;li&gt;Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)&amp;lt;/= 5 times upper limit of normal range (ULNR)*Bilirubin &amp;lt;/= 3 mg/dl&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.5 mg/dl (SI units: 132 micromol/l)&lt;/li&gt;&lt;li&gt;Prothrombin Time (PT) international normalized ratio (INR)&amp;lt;/= 1.5&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Renal failure requiring hemo- or peritoneal dialysis&lt;/li&gt;&lt;li&gt;Patients with no adequate treatment for gastrointestinal bleeding and esophagus varices within 14 days prior to study entry&lt;/li&gt;&lt;li&gt;Child-pugh index class B in combination with more than slight ascites or hepatic encephalopathy&amp;gt; grade I&lt;/li&gt;&lt;li&gt;Altered mental status precluding understanding of the informed consent process&lt;/li&gt;&lt;li&gt;Pregnancy or breastfeeding mother&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To prospectively evaluate clinically available image and/or molecular fingerprint analysis of HCC tumor tissue to predict therapy responses</Description></Measure><Measure><Description>To prospectively evaluate image fingerprint analysis of HCC tumor tissue to predict therapy responses: MRI and CT scan, including radiomics analysis</Description><Timeframe>6 months after therapy initiation</Timeframe></Measure><Measure><Description>To prospectively evaluate molecular fingerprint analysis of HCC tumor tissue to predict therapy responses: multiscale analysis of exome, transcriptome and metabolic tumor characteristics</Description><Timeframe>6 months after therapy initiation</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Time needed to determine parameter based prediction of therapy outcome for single parameters and for multiscale modelling: days needed for prediction of therapy outcome by image, molecular and metabolic analysis</Description><Timeframe>At baseline and between week 3 and 6 after treatment initiation</Timeframe></Measure><Measure><Description>Progression free survival (PFS): months</Description><Timeframe>Between 3.5 and 5.5 months</Timeframe></Measure><Measure><Description>Radiologically determined time to tumor progression (TTP): months</Description><Timeframe>Between 3.5 and 5.5 months</Timeframe></Measure><Measure><Description>Objective response rate (ORR) as measured by the sum of partial and complete responders: percentage of all treated patients</Description><Timeframe>Within 6 months after treatment initiation</Timeframe></Measure><Measure><Description>Duration of tumor stabilization (CR, PR, SD): days of duration of CR, PR or SD after diagnosis of best response</Description><Timeframe>Through study completion, up to 18 months</Timeframe></Measure><Measure><Description>Overall survival (OS): months</Description><Timeframe>Approximately 12 months</Timeframe></Measure><Measure><Description>To prospectively assess patient-reported outcome of HCC patients under treatment with sorafenib: EORTC QLQ-C30 questionnaire</Description><Timeframe>Through study completion, up to 18 months</Timeframe></Measure><Measure><Description>Distribution of sorafenib adverse drug reactions: CTCAE criteria</Description><Timeframe>Through study completion during sorafenib treatment, up to 18 months</Timeframe></Measure><Measure><Description>Feasibility of circulating miRNA Analysis, radiomics analysis and ultrasound elastography: change of miRNA detection in peripheral blood sample between baseline and after treatment initiation; collection of radiomics features of tumor tissue at baseline and after treatment initiation; determination of ultrasound elastography of tumor tissue at baseline and after treatment initiation</Description><Timeframe>Baseline and between week 3 and 6 after treatment initiation</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this prospective, observational clinical study is to validate prognostic parameters for the treatment with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; that have been identified in a separate patient cohort with HCC (study title 'fingerprint characterization of advanced HCC to optimize treatment decisions and enable an early prediction of therapy resistance', ClinicalTrials.gov Identifier &lt;ulink linkType="Protocol" linkID="376792"&gt;NCT02372162&lt;/ulink&gt;, ethical approval 601/2014B01 by the ethical commission of the medical faculty Tubingen).&lt;br/&gt;Based on the previous findings, pre-defined parameters that have been found to correlate with therapy responses will be determined for the patients in this observational trial.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who receive sorafenib will be observed. Study results will not lead to an alteration of the drug treatment. However, the characterization of the tumor on multiple levels will provide information that might influence the current or future treatments.&lt;br/&gt;The parameters will be used to predict therapy outcome, which will be determined at the earliest possible point in time. This prediction will be prospectively compared to the clinical outcome under treatment with sorafenib. Furthermore new hypothesis generating parameters will be investigated in this patient cohort (circulating miRNA, liquid biopsy of predefined genetic alterations, ultrasound elastography of liver tumor areas).&lt;br/&gt;Patients with hepatocellular carcinoma and treatment with sorafenib receive a comprehensive image and molecular tumor characterization ('image and molecular fingerprint').&lt;/para&gt;&lt;para&gt;This study is a prospective evaluation of a multiscale prediction model for the treatment with sorafenib in HCC. Patients with HCC that qualify for systemic treatment with sorafenib will be included. At baseline, prior to sorafenib treatment, molecular and image fingerprints are collected (fingerprint -1). Further fingerprint investigations will be performed after a short treatment period at week 4 (fingerprint -2) and optional at tumor progression (Fingerprint -3). Based on previous findings from a preceding trial the fingerprint diagnostics 1 and 2 will be used to determine a prediction for treatment outcome at the earliest possible point in time ('therapy prediction'). This prediction will be compared to the prospectively determined outcome of the treated patients in this study (validation cohort; primary study endpoint). Fingerprint -3 will be optional to generate hypothesis for treatment failure.&lt;/para&gt;&lt;para&gt;Diagnostic procedures include an image fingerprint (MRI and multi-phase CT scan of tumor manifestations, radiomics analysis of defined tumor areas, ultrasound elastography and a molecular fingerprint with exome and transcriptome sequencing from tumor tissue, liquid biopsy for circulating tumor DNA and miRNA, MR spectroscopy for metabolomics analysis of blood and urine. These parameters at baseline will be used to predict therapy outcome, which will be prospectively compared to the clinical outcome under treatment with sorafenib. A second fingerprint will be collected at 4 weeks treatment and optional at tumor progression. New hypothesis generating parameters will be investigated in this patient cohort (circulating miRNA, liquid biopsy of predefined genetic alterations, ultrasound elastography of liver tumor areas).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Universitatsklinikum Tubingen</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatobiliary system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8059">Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8067">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11994">Treatment Naive Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18937">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16345">Subjects with hepatocellular carcinoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier>NCT03958669</Identifier></Identifiers></Registry><Registry><Name id="1019">German Clinical Trials Register (DRKS)</Name><Identifiers><Identifier type="Secondary Organisational">DRKS00015917</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatobiliary system tumor" id="12101"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hepatobiliary system tumor" id="12231"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12048"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12051"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12055"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Hepatobiliary system tumor" id="12056">Assessment of objective/overall response rate (ORR)</SubEndpoint><SubEndpoint disease="Hepatobiliary system tumor" id="12057">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Hepatobiliary system tumor" id="12058">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Hepatobiliary system tumor" id="12059">Assessment of Stable Disease</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12070"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12101"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12107"><Endpoint>Assessment of Clinical Response</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12114"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Hepatobiliary system tumor" id="12115">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12118"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12131"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="12231"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatobiliary system tumor" id="44930"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Hepatobiliary system tumor" id="12133">Assessment of Feasibility</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatobiliary system tumor" id="7830"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7832"><Criterion>Liver Cancer Subjects with Specific Child-Pugh Score</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="13159">Subjects with Child-Pugh class A liver function</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="13160">Subjects with Child-Pugh class B liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7851"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7853">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7856"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7859">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7863"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7864">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="7865">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="7866">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7881"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7882"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7883">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="7884">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7889"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7908"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="13396"><Criterion>Liver Cancer Subjects with Specific Barcelona Clinic Liver Cancer (BCLC) Staging</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="13398">Subjects with BCLC stage B HCC</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="13399">Subjects with BCLC stage C HCC</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="22382"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="34021"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7885">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="34259"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="32046">Subjects with hepatocellular carcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="34412"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7891">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatobiliary system tumor" id="9390"><Criterion>Liver Cancer Subjects with Specific Child-Pugh Score</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9412"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9447"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9451"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="9455">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="9458">Subjects failing to meet protocol specified criteria</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="9462">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="25535"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="9453">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="26350"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="9424">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="26979"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="29329"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-30T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change><Change type="added"><Date>2019-05-30T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-05-30T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change><Change type="added"><Date>2019-05-30T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="382645"><TitleDisplay>Effects of Periodontal Therapy in Patients with Metabolic Syndrome (MetS)</TitleDisplay><TitleOfficial>Effects of Periodontal Therapy on Local and Systemic Markers of Inflammation in Patients With Metabolic Syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03960216</Identifier><Identifier type="Organisational Study">12/206 CEIC HOSPITAL CLÍNICO</Identifier></Identifiers><Indications><Indication id="2360">Periodontitis</Indication><Indication id="3294">Metabolic syndrome X</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="177" role="Therapeutic effect marker" type="Genomic;Proteomic">Fibrinogen</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="364" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-1 beta</BiomarkerName><BiomarkerName id="438" role="Therapeutic effect marker" type="Genomic;Proteomic">Alpha-1-antitrypsin</BiomarkerName><BiomarkerName id="554" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-8</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Scaling and root planning</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ultrasonic scaler, Minipiezon Electromedical Systems EMS, Nyon, Switzerland</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>azithromycin</Name><Drug id="2587">azithromycin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>chlorhexidine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Supragingival Prophylaxis</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>chlorhexidine</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2587">azithromycin</Drug><IndicationsPioneer><Indication id="3294">Metabolic syndrome X</Indication></IndicationsPioneer><Companies><Company><Company id="15519">Colgate-Palmolive Co</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20556">Universidad Complutense de Madrid</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2587" type="Drug"><TargetEntity id="128642" type="siDrug">Azithromycin</TargetEntity></SourceEntity><SourceEntity id="15519" type="Company"><TargetEntity id="4295903113" type="organizationId">Colgate-Palmolive Co</TargetEntity></SourceEntity><SourceEntity id="20556" type="Company"><TargetEntity id="5001203672" type="organizationId">Complutense University of Madrid</TargetEntity></SourceEntity><SourceEntity id="2360" type="ciIndication"><TargetEntity id="10034539" type="MEDDRA"/><TargetEntity id="D010518" type="MeSH"/><TargetEntity id="-408856592" type="omicsDisease"/><TargetEntity id="1114" type="siCondition"/></SourceEntity><SourceEntity id="3294" type="ciIndication"><TargetEntity id="E88.81" type="ICD10"/><TargetEntity id="10052066" type="MEDDRA"/><TargetEntity id="D024821" type="MeSH"/><TargetEntity id="-65628361" type="omicsDisease"/><TargetEntity id="512" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20556">Universidad Complutense de Madrid</Company></CompaniesSponsor><CompaniesCollaborator><Company id="15519">Colgate-Palmolive Co</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="15187">Systemic dermatological antibacterial product</Class><Class id="1538">Bacterial protein synthesis inhibitor</Class><Class id="1540">Macrolide antibiotic</Class><Class id="1594">Antibacterial</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2012-11-28T00:00:00Z</DateStart><DateEnd type="actual">2018-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-31T06:23:45Z</DateChangeLast><DateAdded>2019-05-31T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University Complutense of Madrid</Affiliation><Name>Mariano Sanz</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of metabolic syndrome according to the IDF definition&lt;/li&gt;&lt;li&gt;At least sixteen teeth&lt;/li&gt;&lt;li&gt;At least eight sites with probing pocket depth (PPD) &gt;/= 6 mm and four sites with clinical attachment loss &gt;/= 5 mm, distributed in at least two different quadrants (Koromantzos et al, 2012)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;They are not medically controlled for obesity and cardiovascular risk factors at the start of the study. For ethical reasons, patient inclusion must be delayed at least 3 months when begins a pharmacological treatment&lt;/li&gt;&lt;li&gt;They had history of kidney disease with Cr&amp;gt; 1.2, CKD-EPI &amp;lt; 70 ml/min, or proteinuria &amp;gt; 300 mg/24 h or 0.3 mg/g Cr in isolated sample&lt;/li&gt;&lt;li&gt;They had history of chronic lung disease, or acute disease during the previous 3 months&lt;/li&gt;&lt;li&gt;They had history of stroke during the previous 3 months, myocardial infarction or revascularization during the previous 6 months, or recent angor pectoris history&lt;/li&gt;&lt;li&gt;They had history of known peripheral artery disease, or chronic heart failure&lt;/li&gt;&lt;li&gt;They had surgical treatment during the previous 3 months&lt;/li&gt;&lt;li&gt;They had any disease that conditions compliance along the study, such as alcoholism or psychiatric disorder&lt;/li&gt;&lt;li&gt;They had a history of systemic antibiotic usage over the previous 3 months&lt;/li&gt;&lt;li&gt;They had non-surgical periodontal treatment during the previous 6 months; or surgical periodontal treatment over the previous 12 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in C-reactive protein: main outcome variable is the change in concentration of C-reactive protein between baseline and 6 months</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in Bleeding on Probing: examination of bleeding on probing</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in Clinical Attachment Level: examination of clinical attachment level will be determined with a periodontal probe and expressed in mm</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in Plaque Index: examination of plaque index</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in Probing Pocket Depth: examination of probing pocket depth will be determined with a periodontal probe and expressed in mm</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in the % of Glycated hemoglobin: analysis of glycated hemoglobin was determined in the Lab of the University Hospital</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in the concentration of Inflammatory mediators (IL-1beta, IL-6, IL-8 and TNF-alpha) in plasma and gingival crevicular fluid: the inflammatory mediators will be determined by Luminex</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in the presence of selected periodontal pathogens: selected periodontal pathogens: Aggregatibacter actinomycetemcomitans, Tannerella forsythia, P.gingivalis, Prevotella intermedia/nigrescens, Parvimonas micra, Campylobacter rectus and Fusobacterium nucleatum</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in the proportions of selected periodontal pathogens: selected periodontal pathogens: Aggregatibacter actinomycetemcomitans, Tannerella forsythia, P.gingivalis, Prevotella intermedia/nigrescens, Parvimonas micra, Campylobacter rectus and Fusobacterium nucleatum</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure><Measure><Description>Change in the total counts of selected periodontal pathogens: by means of anaerobic culture. Selected periodontal pathogens: Aggregatibacter actinomycetemcomitans, Tannerella forsythia, P.gingivalis, Prevotella intermedia/nigrescens, Parvimonas micra, Campylobacter rectus and Fusobacterium nucleatum</Description><Timeframe>Baseline, 3 and 6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial was to evaluate the effect of intensive periodontal therapy (IPT) in      patients with MetS and severe periodontitis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A 6-month, parallel-arm, investigator-masked, randomized clinical trial would be conducted in patients with MetS and severe periodontitis. Participants would be randomly assigned to an Intensive Periodontal Treatment group (IPT; scaling and root planing and azithromycin capsules 500 mg/24 h/3days) or to a Minimal Periodontal Treatment group (MPT; professional plaque removal and placebo capsules).&lt;/para&gt;&lt;para&gt;Group 1 ( Minimal Periodontal Treatment): once the hopeless teeth have been extracted, randomized patients would receive a periodontal prophylaxis, in the form of supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart. During this week the patients would be prescribed local antiseptics (chlorhexidine rinse, 2 x, 10 days) and, after the last session, placebo capsules (one every 24 h for 3 days). Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.&lt;br/&gt;Group 2 (Intensive Periodontal Treatment ): once the hopeless teeth have been extracted, randomized patients would receive non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia. During this week the patients will be prescribed local antiseptics (chlorhexidine rinse,  2 x, 10 days) and after the last session, systemic antibiotics (&lt;ulink linkType="Drug" linkID="2587"&gt;azithromycin&lt;/ulink&gt; 500 mg, q24h3d). Patients  received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>University Complutense of Madrid</Name><Address1>Madrid</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other mouth disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18265">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16570">Subjects with Periodontitis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03960216</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Metabolic syndrome X" id="21003"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Metabolic syndrome X" id="21014">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other mouth disease" id="46441"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="46443">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Metabolic syndrome X" id="20947"><Endpoint>Assessment of HbA1c levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="20972"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21003"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Metabolic syndrome X" id="21006">Assessment of interleukins</SubEndpoint><SubEndpoint disease="Metabolic syndrome X" id="21012">Assessment of TNF</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21017"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Metabolic syndrome X" id="20998">Assessment of fibrinogen levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21033"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21087"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Metabolic syndrome X" id="21099">Changes in microbiota</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="32676"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="43006"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="46440">Assessment of bleeding</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="43598"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="51379">Assessment of microbiological/serological  parameters</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="43699"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="43700">Assessment of probing pocket depth</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="46441"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="46444">Interleukin-6 (IL-6)</SubEndpoint><SubEndpoint disease="Other mouth disease" id="51364">Assessment of tumor necrosis factor alpha (TNFa)</SubEndpoint><SubEndpoint disease="Other mouth disease" id="51376">Plasma fibrinogen</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="46450"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="46499"><Endpoint>Glycemic Control Analysis</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other mouth disease" id="51362"><Endpoint>Intravascular Ultrasound (IVUS)/Intracoronary Ultrasound (ICUS) Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Other mouth disease" id="51363">Plaque index (PI)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Metabolic syndrome X" id="19348"><Criterion>Subjects with Metabolic Syndrome</Criterion></Inclusion><Inclusion disease="Metabolic syndrome X" id="19447"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other mouth disease" id="33061"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="33118">Dental patients with probing pocket depth of protocol specified values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other mouth disease" id="35078"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Metabolic syndrome X" id="15447"><Criterion>Obese Subjects</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15463"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Metabolic syndrome X" id="15545">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Metabolic syndrome X" id="15468"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Metabolic syndrome X" id="15471">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Metabolic syndrome X" id="15470"><Criterion>Subjects with history of cardiac intervention /coronary revascularization</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15480"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15488"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15489"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15492"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15504"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15524"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15541"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24056"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24305"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24629"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="26101"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="26231"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="26251"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="27033"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Metabolic syndrome X" id="15469">Subjects co-morbid with myocardial infarction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Metabolic syndrome X" id="27053"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Metabolic syndrome X" id="15500">Subjects co-morbid with peripheral vascular disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other mouth disease" id="27640"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="27747"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="27894"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Metabolic syndrome X" id="15567">Subjects unable/unwilling  to comply with study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other mouth disease" id="27917"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="29144"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-05-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-05-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="52217"><TitleDisplay>A phase I, safety and efficacy study of a GM-CSF vaccine for the potential treatment of renal tumors</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="999">Renal tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>GM-CSF vaccine, Johns Hopkins</Name><Drug id="12886">GM-CSF vaccine, Johns Hopkins</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12886">GM-CSF vaccine, Johns Hopkins</Drug><IndicationsPioneer><Indication id="999">Renal tumor</Indication></IndicationsPioneer><Companies><Company><Company id="20596">Johns Hopkins University</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20596" type="Company"><TargetEntity id="5000068265" type="organizationId">Johns Hopkins University</TargetEntity></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"/><TargetEntity id="10038389" type="MEDDRA"/><TargetEntity id="D007680" type="MeSH"/><TargetEntity id="-1866040075" type="omicsDisease"/><TargetEntity id="607" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20596">Johns Hopkins University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="410">GM-CSF receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="386">Vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>17</PatientCountEnrollment><PatientCountEvaluable>17</PatientCountEvaluable><DateStart>1996-12-31T00:00:00Z</DateStart><DateChangeLast>2017-08-05T22:05:01Z</DateChangeLast><DateAdded>2009-04-19T12:38:41Z</DateAdded><Contacts/><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase I study was designed to assess the safety and efficacy of &lt;ulink linkType="Company" linkID="20596"&gt;Johns Hopkins University&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="12886"&gt;GM-CSF vaccine&lt;/ulink&gt; for the potential treatment of renal tumors  [&lt;ulink linkType="Reference" linkID="211269"&gt;211269&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;There was a 4-fold difference in magnitude of the maximal response measured in patients receiving the vaccine. The vaccine had been shown to be safe [&lt;ulink linkType="Reference" linkID="211269"&gt;211269&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-04-19T12:38:41Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="5361"><TitleDisplay>A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men</TitleDisplay><TitleOfficial>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of Darapladib (SB-480848) in Healthy Japanese Male Subjects</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">LPL110077</Identifier><Identifier type="NCT">NCT00551317</Identifier></Identifiers><Indications/><BiomarkerNames><BiomarkerName id="100" role="Therapeutic effect marker" type="Genomic;Proteomic">Platelet-activating factor acetylhydrolase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>darapladib</Name><Drug id="36590">darapladib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="36590">darapladib</Drug><IndicationsPioneer/><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="36590" type="Drug"><TargetEntity id="310455" type="siDrug">Darapladib</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="305" type="Action"><TargetEntity id="473" type="Mechanism">Phospholipase A2 (PLA2) Inhibitors</TargetEntity><TargetEntity id="2660" type="Mechanism">Secretory Phospholipase A2 (sPLA2) Inhibitors</TargetEntity><TargetEntity id="5258" type="Mechanism">Anti-Phospholipase A2 (PLA2-Ib)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="305">Phospholipase A2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2667">Antiarteriosclerotic</Class></Class><Technologies><Technology id="590">Enteric coated formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term><Term>Male</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>18</PatientCountEnrollment><DateStart>2007-07-31T00:00:00Z</DateStart><DateEnd type="actual">2007-09-30T00:00:00Z</DateEnd><DateChangeLast>2017-04-09T11:22:03Z</DateChangeLast><DateAdded>2007-11-05T14:40:09Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact><Contact type="Scientific contact"><Affiliation>GlaxoSmithKline</Affiliation><Name>GSK Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Japanese males, 20 to 64 years of age, inclusive&lt;/li&gt;&lt;li&gt;Body weight&amp;gt; 50 kg&lt;/li&gt;&lt;li&gt;BMI: 18 to 28&lt;/li&gt;&lt;li&gt;Subjects must have lived outside of Japan no more than 10 years&lt;/li&gt;&lt;li&gt;Non-smoker or smokes fewer than 10 cigarettes/day&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses&lt;/li&gt;&lt;li&gt;History of sensitivity to heparin or heparin-induced thrombocytopenia&lt;/li&gt;&lt;li&gt;History of alcohol/drug abuse or dependence within 12 months of the study&lt;/li&gt;&lt;li&gt;Positive syphilis, HIV antibody, hepatitis B, hepatitis C&lt;/li&gt;&lt;li&gt;History of cholecystectomy or biliary tract disease or history of liver disease&lt;/li&gt;&lt;li&gt;Participation in a clinical study within 30 days prior to first dose&lt;/li&gt;&lt;li&gt;Subject has been exposed to more than 4 chemical entities within 12 months&lt;/li&gt;&lt;li&gt;Positive urine drug and alcohol at screening&lt;/li&gt;&lt;li&gt;Subject has any medical history or clinically relevant abnormality that would make the subject ineligible for inclusion due to safety reasons&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety/tolerability of single oral doses of darapladib</Description><Timeframe>4, 24 and 96h post-dose</Timeframe></Measure><Measure><Description>Primary pharmacokinetic parameters of single oral doses of darapladib</Description><Timeframe>pre-dose, 0,5, 1, 2, 3, 4, 6, 9 12, 16, 24, 48, 72h post-dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>PK parameters of SB-553253</Description><Timeframe>Throughout the study</Timeframe></Measure><Measure><Description>Inhibition of Lp-PLA2 activity</Description><Timeframe>Throughout the study</Timeframe></Measure><Measure><Description>Description of plasma concentration-Lp-PLA2 activity inhibition relationship after single oral doses of darapladib</Description><Timeframe>Throughout the study</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was conducted to provide initial safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) data that will allow further studies with &lt;ulink linkType="Drug" linkID="36590"&gt;darapladib&lt;/ulink&gt; in Japanese patients. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive single oral doses of darapladib.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>GSK Investigational Site</Name><Address1>Honolulu</Address1><Address2>Hawaii</Address2><Address3>96813</Address3><CountrySubDivision code="HI">Hawaii</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Atherosclerosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7236">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7245">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7250">Subjects with obesity</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00551317</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Atherosclerosis" id="9860"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Atherosclerosis" id="9869"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Atherosclerosis" id="9860"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Atherosclerosis" id="5693"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="5700">Smoking as a risk factor</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Atherosclerosis" id="5723"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="5728">Subjects co-morbid with obesity</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Atherosclerosis" id="7309"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7318">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7326"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7328">Subjects with history of /current hepatitis B virus infection</SubCriterion><SubCriterion disease="Atherosclerosis" id="7329">Subjects with history of /current hepatitis C virus infection</SubCriterion><SubCriterion disease="Atherosclerosis" id="7330">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="7342"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7351">Hypersensitivity/contraindications to drugs of hematological system</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Atherosclerosis" id="27071"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Atherosclerosis" id="7316">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2007-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2007-10-29T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2007-11-05T14:40:09Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="80491"><TitleDisplay>A phase I study to evaluate the safety and efficacy of S-1 in combination with trastuzumab for human epidermal-growth factor receptor (HER2)-positive metastatic breast cancer (MBC)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="3657">Metastatic breast cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>tegafur + gimeracil + oteracil potassium</Name><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug></Intervention><Intervention type="InterventionPrimary"><Name>trastuzumab</Name><Drug id="6386">trastuzumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><IndicationsPioneer/><Companies><Company><Company id="20653">Osaka University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6386">trastuzumab</Drug><IndicationsPioneer/><Companies><Company><Company id="20653">Osaka University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="6386" type="Drug"><TargetEntity id="198466" type="siDrug">Trastuzumab</TargetEntity></SourceEntity><SourceEntity id="10084" type="Drug"><TargetEntity id="203364" type="siDrug">Tegafur/gimeracil/oteracil</TargetEntity><TargetEntity id="217985" type="siDrug">TS1</TargetEntity></SourceEntity><SourceEntity id="20653" type="Company"><TargetEntity id="4295978160" type="organizationId">Osaka University</TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="3756" type="Action"><TargetEntity id="1223" type="Mechanism">HER2 (erbB2) Inhibitors</TargetEntity><TargetEntity id="1820" type="Mechanism">Anti-HER2/neu/ErbB2</TargetEntity></SourceEntity><SourceEntity id="782" type="Action"><TargetEntity id="512" type="Mechanism">Uracil Dehydrogenase Inhibitors</TargetEntity><TargetEntity id="2868" type="Mechanism">Dihydropyrimidine Dehydrogenase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20653">Osaka University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><Action id="6661">Orotate phosphoribosyltransferase inhibitor</Action><Action id="782">Dihydropyrimidine dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="1589">Apoptosis stimulator</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateStart>2011-09-30T00:00:00Z</DateStart><DateChangeLast>2012-03-19T12:04:22Z</DateChangeLast><DateAdded>2011-09-14T09:45:18Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with HER2-positive MBC&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure><Measure><Description>Recommended phase II dose of S-1 and trastuzumab</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In September 2011, results showed that there were no dose limiting toxicities (DLTs) in the study [&lt;ulink linkType="Reference" linkID="1218550"&gt;1218550&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase I study was to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt; for HER2-positive metastatic breast cancer (MBC) and to determine the recommended phase II dose (RD) [&lt;ulink linkType="Reference" linkID="1218550"&gt;1218550&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2011, results were published. A total of 12 patients were treated at level 1. The overall response  and disease control rates were 33.3 and 83.3%, respectively. The recommended phase II dose was 80 mg/m2 &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; and 4 mg/kg followed by 2 mg/kg &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1218550"&gt;1218550&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients  received &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt; (a  fixed initial dose of 4 mg/kg/day, then 2 mg/kg every week) in combination with  &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; (4 weeks followed by a 2-week rest) every 42 days. The dosage of &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt; was set of three levels (80, 65 , and 50 mg/m2) [&lt;ulink linkType="Reference" linkID="1218550"&gt;1218550&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="197452">tegafur + gimeracil + oteracil potassium</Intervention><Treatments><Treatment><Dose>50 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>65 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>80 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="197451">trastuzumab</Intervention><Treatments><Treatment><Dose>2 milligram/kg</Dose><Route></Route></Treatment><Treatment><Dose>4 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-09-14T09:45:18Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="81467"><TitleDisplay>Safety, Tolerability and Efficacy of BFH-772 in Rosacea Patients</TitleDisplay><TitleOfficial>A Proof-of-concept (PoC) Study to Evaluate the Safety, Tolerability, and Efficacy of 12 Week Administration of BFH-772 Ointment in Rosacea Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CBFH772A2203</Identifier><Identifier type="NCT">NCT01449591</Identifier></Identifiers><Indications><Indication id="2164">Rosacea</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BFH-772</Name><Drug id="64528">BFH-772</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>once-daily topical metronidazole, Dermik</Name><Drug id="17168">once-daily topical metronidazole, Dermik</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="64528">BFH-772</Drug><IndicationsPioneer><Indication id="2164">Rosacea</Indication></IndicationsPioneer><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="64528" type="Drug"><TargetEntity id="679043" type="siDrug">BFH-772</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="2164" type="ciIndication"><TargetEntity id="L71" type="ICD10"/><TargetEntity id="10039218" type="MEDDRA"/><TargetEntity id="D012393" type="MeSH"/><TargetEntity id="-252234910" type="omicsDisease"/><TargetEntity id="444" type="siCondition"/></SourceEntity><SourceEntity id="1722" type="Action"><TargetEntity id="1103" type="Mechanism">VEGFR Inhibitors</TargetEntity><TargetEntity id="1619" type="Mechanism">Anti-VEGF</TargetEntity><TargetEntity id="1788" type="Mechanism">Vascular Endothelial Growth Factor (VEGF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="23137">Novartis AG</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1722">VEGF receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15183">Topical antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="612">Emulsion dermatological</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2011-09-30T00:00:00Z</DateStart><DateEnd type="actual">2012-02-29T00:00:00Z</DateEnd><DateChangeLast>2017-05-15T12:15:51Z</DateChangeLast><DateAdded>2011-10-13T13:19:17Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Novartis Pharmaceuticals</Affiliation><Name>Novartis Pharmaceuticals</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Have persistent facial erythema on the cheeks of at least moderate severity&lt;/li&gt;&lt;li&gt;Women must not be able to bear children&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have &gt; 12 inflammatory lesions on the face&lt;/li&gt;&lt;li&gt;Previous treatment of facial skin with lasers or electrocauterization within 2 months             prior to entering the study&lt;/li&gt;&lt;li&gt;Have facial hair that makes it difficult to evaluate rosacea on the face&lt;/li&gt;&lt;li&gt;Other             protocol-defined inclusion/exclusion criteria may apply&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To assess the effect of BFH-772 treatment compared to vehicle on non-transient facial erythema using the investigator's assessment of facial erythema score</Description><Timeframe>12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate a patient's assessment of flushing frequency via patient reported episodes and facial redness via a patient reported score</Description><Timeframe>12 weeks</Timeframe></Measure><Measure><Description>To measure blood levels of BFH-772 in patients</Description><Timeframe>12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study will evaluate the safety, tolerability and efficacy of 1% &lt;ulink linkType="Drug" linkID="64528"&gt;BFH-772&lt;/ulink&gt; after 12 weeks of      treatment as compared to an active control (&lt;ulink linkType="Drug" linkID="17168"&gt;Noritate&lt;/ulink&gt; 1%) and vehicle in patients with      erythemato-telangiectatic rosacea.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive BFH-772 1% ointment or vehicle ointment or Noritate 1% cream.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Novartis Investigative Site</Name><Address1>Hot Springs</Address1><Address2>Arkansas</Address2><CountrySubDivision code="AR">Arkansas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Ann Abor</Address1><Address2>Michigan</Address2><CountrySubDivision code="MI">Michigan</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Paramus</Address1><Address2>New Jersey</Address2><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Portland</Address1><Address2>Oregon</Address2><CountrySubDivision code="OR">Oregon</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Austin</Address1><Address2>Texas</Address2><CountrySubDivision code="TX">Texas</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Spokane</Address1><Address2>Washington</Address2><CountrySubDivision code="WA">Washington</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01449591</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-09-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-10-13T13:19:17Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="92323"><TitleDisplay>Metabolic Effects of Almond in the Longer-term Study</TitleDisplay><TitleOfficial>Effects of Chronic Almond Consumption at Meals or as Snacks on Appetite, Intake, Body Weight, Glycemia, Insulinemia and Lipids in Healthy Adults</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">055-022</Identifier><Identifier type="NCT">NCT01690936</Identifier><Identifier type="Secondary Organisational">Snacking study</Identifier><Identifier type="Trial Acronym">MEAL</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="7586" role="Therapeutic effect marker" type="Anthropomorphic">Body fat percentage</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Almonds</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1073293" type="Company"><TargetEntity id="5037848282" type="organizationId">Almond Board of California</TargetEntity></SourceEntity><SourceEntity id="20663" type="Company"><TargetEntity id="4296810739" type="organizationId">Purdue University</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20663">Purdue University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1073293">Almond Board of California</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2010-10-31T00:00:00Z</DateStart><DateEnd type="actual">2012-06-30T00:00:00Z</DateEnd><DateChangeLast>2016-07-30T14:30:18Z</DateChangeLast><DateAdded>2012-09-28T13:13:27Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Purdue University</Affiliation><Name>Richard D Mattes, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Not taking any medication known to affect glycemia, lipid metabolism or appetite&lt;/li&gt;&lt;li&gt;Regular breakfast consumers&lt;/li&gt;&lt;li&gt;Eat at least   five meals a day&lt;/li&gt;&lt;li&gt;Weight stable&lt;/li&gt;&lt;li&gt;Either one of the  six conditions&lt;/li&gt;&lt;li&gt;BMI 27 to 35&lt;/li&gt;&lt;li&gt;Family history of diabetes&lt;/li&gt;&lt;li&gt;Fasting glucose between 6.1 to 6.9 mmol/l&lt;/li&gt;&lt;li&gt;The 2 h glucose 7.8 to 11.1 mmol/l&lt;/li&gt;&lt;li&gt;Blood pressure&amp;gt; 130/85 mmHg&lt;/li&gt;&lt;li&gt;Waist&amp;gt; 102 cm (men) and &amp;gt; 88 cm (women)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Nut allergy&lt;/li&gt;&lt;li&gt;Not willing to eat test foods and almonds&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Postprandial glucose, insulin and lipids: responses of these parameters to a standard breakfast and a standard lunch for all participants, plus almonds at designated times according to group randomization</Description><Timeframe>490 min</Timeframe></Measure><Measure><Description>Anthropometric measurements: changes in body weight, BMI, fat mass, waist circumference over 4 weeks</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Fasting blood biochemistries: fasting glucose, insulin and lipids at baseline, weeks 1, 2, 3 and 4</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Dietary intake: dietary intakes were assessed at baseline, weeks 2, and  4 of study</Description><Timeframe>4 weeks</Timeframe></Measure><Measure><Description>Blood pressure: blood pressure measurements at baseline and final week of study</Description><Timeframe>Baseline and week 4</Timeframe></Measure><Measure><Description>Appetite ratings</Description><Timeframe>Baseline, week 2, and week 4</Timeframe></Measure><Measure><Description>Postprandial appetite sensations</Description><Timeframe>490 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was aimed to      examine the effects of almond consumption with meals versus snacks on outcomes such as      appetite, energy intake, body weight, as well as blood glucose, insulin and lipid responses.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Oral glucose tolerance test (OGTT) sessions  would be performed at baseline,here participants would attend a session where a standard OGTT with drinks containing 75      g dextrose    would be performed following an overnight fasting. Serum glucose and insulin      concentrations  would be  measured at 0 and 120 min of the session. During the same session,      height, weight (Tanita), body fat (air displacement plethysmography, BOD POD), waist      circumference, and blood pressure  would be  measured. Participants would also complete a 24 h      dietary recall using a multi-pass interview method and standard questionnaires that would assess      personality, eating behavior and habitual physical activity levels during the OGTT session.      After the completion of this session, participants would be  asked to record their hourly      appetite sensations, measured as 'hunger',  'fullness' and  'desire to eat ' on visual analog      scales, during waking hours for a day before attending the next (clinical) visit.      Participants would repeate this session after 4 weeks of almond consumption.&lt;/para&gt;&lt;para&gt;Acute feeding sessions    would start within a week following the OGTT session, participants would return for an acute-feeding      session, after an overnight fasting of at least 10 h. This session would began between 7:00       and 8:00 am, and lasted for approximately 515 min. Upon arrival, an indwelling arm      catheter would be  placed in the upper arm for blood sample collection. Participants would rest for 15      min after catheter placement, before a baseline blood sample would be  drawn. Immediately      after the first blood sample collection, a standard breakfast  would be served, and participants      would be  instructed to consume the entire portion within 10 min. Subsequent blood samplings      would be  performed at 15, 45, 60, 90, 120, 180, and 240 min after the breakfast, before a      standard lunch would be  provided to the participants. Again, participants would be  given 10 min      to consume the lunch, before blood samples would be taken at similar intervals again (at 265,      295, 310, 340, 370, 430, and 490 min of the session). Participants   randomized into the      BF (breakfast) and LN (lunch) groups would receive 43 g of almonds together with their meals, while the MS and AS      groups would consumed 43 g of almonds 120 min after breakfast and lunch respectively.      Participants would also record  their   'hunger',  'fullness', and  'desire to eat ' sensations when      blood samples would be  taken. During the acute-feeding session, activities that might alter      appetite sensations (eg, sleeping and watching movies containing food cues) would be      prohibited. Postprandial glucose, insulin and triacylglycerol concentrations would be  measured      for all 15 samples collected from each participant. Participants in all almond groups group      would   be   asked to rate their likings for the almonds they ingested using a general label      magnitude scale, and their action responses to almonds using the 'food action rating scale',      a visual analog scale ranging from  'I would eat the almonds only if I were forced to ' to  'I      would eat this food every opportunity I had ' would be anchored to the two extremes. This session would be      repeated again after 4 weeks of almond supplementation.&lt;/para&gt;&lt;para&gt;Weekly follow-upswould be done following the baseline acute-feeding session, participants would be  asked to consume 43 g of      almonds every day at times based on their group randomization. The CL (control) group would be be  instructed      to avoid all nuts and seeds in the diet during the study period. All almonds would be       dry-roasted and lightly salted, and would be  pre-weighed and per-packaged for convenience.      Except for the permission to adjust dietary intake due to almond supplement, participants      would be asked to maintain their dietary intakes and physical activity levels. A ruse (breath      analysis) would be introduced in order to enhance the compliance of participants to consuming      almonds at the designated times of day. Compliance to almond consumption would be  assessed      through fasting plasma alpha-tocopherol. Participants attended weekly visit (week 1, 2 and 3)      after an overnight fasting, during which body weight would be recorded and compliance to study      protocol would be reinforced. During the week 2 visit, participants would  also be  asked to complete a      24 h dietary intake assessment using the multi-pass interview method and appetite      sensation ratings on VAS at every waking hour for a day. On week-4, participants would  returned      for OGTT and acute-feeding sessions as described above. The study protocol would be approved by      the &lt;ulink linkType="Company" linkID="20663"&gt;Purdue University&lt;/ulink&gt; Institutional Review Board. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Purdue University</Name><Address1>West Lafayette</Address1><Address2>Indiana</Address2><Address3>47907</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7738">Subjects with Central (Abdominal) Obesity</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7745">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7743">Overweight/Obese Subjects with Hypertension</SubSegment><SubSegment id="7748">Overweight/obese prediabetics subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01690936</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20413"><Endpoint>Assessment of Insulin Levels</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20409">Assessment of fasting insulin</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20427"><Endpoint>Assessment of Dietary Intake</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20432"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20435">Assessment of postprandial glucose</SubEndpoint><SubEndpoint disease="Obesity" id="20437">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20446"><Endpoint>Assessment of lipid profiles</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20402">Assessment of waist circumference</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20554">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19675">Subjects with Central (Abdominal) Obesity</SubCriterion><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19681">Subjects with BMI&gt;27</SubCriterion><SubCriterion disease="Obesity" id="19688">Subjects with BMI&lt;35</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19697"><Criterion>Subjects with pre-hypertension/hypertension</Criterion></Inclusion><Inclusion disease="Obesity" id="19705"><Criterion>Subjects with High Fasting Glucose</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19706">Subjects with pre-diabetes</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19774"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19693">Subjects with stable body weight</SubCriterion><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15354"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15366">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-09-28T13:13:27Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="9302"><TitleDisplay>Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</TitleDisplay><TitleOfficial>A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC-207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CR011929</Identifier><Identifier type="NCT">NCT00449644</Identifier><Identifier type="Secondary Organisational">TMC207-TIDP13-C208</Identifier><Identifier type="NCT Alias">NCT00614627</Identifier><Identifier type="NCT Alias">NCT00980265</Identifier><Identifier type="Other">2007-004462-40</Identifier></Identifiers><Indications><Indication id="221">Mycobacterium tuberculosis infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bedaquiline</Name><Drug id="51310">bedaquiline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="51310">bedaquiline</Drug><IndicationsPioneer/><Companies><Company><Company id="1003570">Janssen R&amp;D (Ireland)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="51310" type="Drug"><TargetEntity id="386239" type="siDrug">Bedaquiline fumarate</TargetEntity></SourceEntity><SourceEntity id="1003570" type="Company"><TargetEntity id="4298281145" type="organizationId">Janssen R&amp;D Ireland</TargetEntity></SourceEntity><SourceEntity id="221" type="ciIndication"><TargetEntity id="A15" type="ICD10"/><TargetEntity id="10044755" type="MEDDRA"/><TargetEntity id="D014376" type="MeSH"/><TargetEntity id="3389" type="ORPHANET"/><TargetEntity id="-1043612885" type="omicsDisease"/><TargetEntity id="843" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2b Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>16</NumberOfSites><CompaniesSponsor><Company id="1003570">Janssen R&amp;D (Ireland)</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="49687">ATP synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="4855">Antibacterial multidrug resistance inhibitor</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>208</PatientCountEnrollment><PatientCountEvaluable>160</PatientCountEvaluable><DateStart>2007-06-30T00:00:00Z</DateStart><DateEnd type="actual">2012-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-08-10T11:35:30Z</DateChangeLast><DateAdded>2008-04-02T12:41:17Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Janssen Infectious Diseases BVBA</Affiliation><Name>Janssen Infectious Diseases BVBA Clinical Trial</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Females of non-childbearing potential&lt;/li&gt;&lt;li&gt;Patients with newly diagnosed sputum smear-positive pulmonary MDR-TB infection&lt;/li&gt;&lt;li&gt;Patients must consent to HIV-testing&lt;/li&gt;&lt;li&gt;Patients must be willing to discontinue all TB drugs to allow 7 days washout&lt;/li&gt;&lt;li&gt;Patients having normal weight&lt;/li&gt;&lt;li&gt;Patients are willing to be hospitalized per standard of care&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previously having been treated for MDR-TB&lt;/li&gt;&lt;li&gt;Having a significant cardiac arrhythmia that requires medication&lt;/li&gt;&lt;li&gt;For HIV infected patients, having a CD4+ count&amp;lt; 300 cells/microl&lt;/li&gt;&lt;li&gt;Patients with complicated or severe extrapulmonary manifestations of TB or neurological manifestations of TB&lt;/li&gt;&lt;li&gt;Patients who will require surgical procedure for management of their TB&lt;/li&gt;&lt;li&gt;Evidence of chorioretinitis, optic neuritis, or uveitis at screening&lt;/li&gt;&lt;li&gt;Having had a drug susceptibility test performed prior to screening and being not susceptible to at least three of the five classes of TB drugs used to treat MDR-TB&lt;/li&gt;&lt;li&gt;Women who are pregnant and/or breastfeeding&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The time to sputum culture conversion at Week 8 (Stage 1): sputum culture conversion is defined as as having two consecutive negative cultures at least 25 days apart, not followed by a confirmed positive during the considered time period. Participants who discontinue or die during the considered time period are considered as non-responders and censored at their last assessment</Description><Timeframe>Week 8, stage 1</Timeframe></Measure><Measure><Description>The time to sputum culture conversion at Week 24 (Stage 2): sputum culture conversion is defined as as having two consecutive negative cultures at least 25 days apart, not followed by a confirmed positive during the considered time period. Participants who discontinue or die during the considered time period are considered as non-responders and censored at their last assessment</Description><Timeframe>Week 24, stage 2</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The time to sputum culture conversion at Week 72 (Stage 2): sputum culture conversion is defined as as having two consecutive negative cultures at least 25 days apart, not followed by a confirmed positive during the considered time period. Participants who discontinue or die during the considered time period are considered as non-responders and censored at their last assessment</Description><Timeframe>Week 72, stage 2</Timeframe></Measure><Measure><Description>The percentage of participants with sputum culture conversion (Stage 1): sputum culture conversion is defined as as having two consecutive negative cultures at least 25 days apart, not followed by a confirmed positive during the considered time period. Participants who discontinue or die during the considered time period are considered as non-responders</Description><Timeframe>Weeks 8, 24, and 104 (stage 1)</Timeframe></Measure><Measure><Description>The percentage of participants with sputum culture conversion (Stage 2): sputum culture conversion is defined as as having two consecutive negative cultures at least 25 days apart, not followed by a confirmed positive during the considered time period. Participants who discontinue or die during the considered time period are considered as non-responders</Description><Timeframe>Weeks 24, 72, and 120 (stage 2)</Timeframe></Measure><Measure><Description>The time to sputum culture conversion at Week 24 (Stage 1): sputum culture conversion is defined as as having two consecutive negative cultures at least 25 days apart, not followed by a confirmed positive during the considered time period. Participants who discontinue or die during the considered time period are considered as non-responders and censored at their last assessment</Description><Timeframe>Week 24, stage 1</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; was generally well tolerated; adverse events included nausea, dizziness and diarrhea. Grade 3/4 adverse events were similar for &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; (26%) and placebo (21%). No discontinuations due to adverse events, no serious adverse events were reported. The commonly reported events in the  &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt;  and placebo groups, respectively, were bilateral hearing impairment (13 and 21%), extremity pain (17 and 13%), acne (9 and 17%), and non-cardiac chest pain (4 and 17%). Except for resistance to ethambutol and ethionamide, resistance to companion drugs was observed in 4.8 and 21.7% of patients of the  &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt;  and placebo groups, respectively (p = 0.18). Resistance to &lt;ulink linkType="Drug" linkID="52139"&gt;ofloxacin&lt;/ulink&gt; was acquired by 0 and 22% of patients of respective groups (p = 0.066). A total of 44 and 54% of patients of the  &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt;  and placebo groups, respectively, discontinued study prior to its completion. A total of eight patients withdrew for non-compliance or default, and seven withdrew consent owing to rigorous program of investigations for safety and pharmacokinetic monitoring [&lt;ulink linkType="Reference" linkID="956602"&gt;956602&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="950749"&gt;950749&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1126493"&gt;1126493&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1309832"&gt;1309832&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014 results were published. The overall incidence of adverse events in both the groups was found to be similar. Number of deaths in &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; and placebo groups was ten and two, with no causal pattern evident [&lt;ulink linkType="Reference" linkID="1622748"&gt;1622748&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  objective of this study was to demonstrate that the antibacterial activity of &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; is better than placebo when added to a standardized background regimen (BR) for treatment of multi-drug resistant TB (MDR-TB) and also to evaluate safety and tolerability.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2008, data were presented from this phase IIb study. Within the 8-week period, 47.5% of patients treated with &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; became culture negative, compared with 8.7% of patients receiving placebo; culture conversion was also more rapid with the drug . QTcF prolongation was observed with &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="956602"&gt;956602&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="950749"&gt;950749&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2010, data were presented from stage 1 part of the trial at the 50th ICAAC meeting in Boston, MA. An analysis of sputum culture from patients demonstrated 57% of placebo-treated patients to be culture-negative at the end of the trial compared with 81% of subjects treated with &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt;. At that time, data from stage 2 of the trial were expected soon as enrollment had been completed [&lt;ulink linkType="Reference" linkID="1126493"&gt;1126493&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, results were published. There was a significant reduction in time to culture conversion over 24 weeks in  &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt;  group (p = 0.031) [&lt;ulink linkType="Reference" linkID="1309832"&gt;1309832&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014 results were published. Reduction in the median time to culture conversion from 125 to 83 days (HR = 2.44; p &amp;lt; 0.001, by Cox regression analysis) and increase in the rate of culture conversion at 24 (79 versus. 58%, p = 0.008) and 120 weeks (62 versus 44%, p = 0.04) were observed with &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; when compared to placebo. On the basis of World Health Organization outcome definitions for multidrug-resistant tuberculosis, cure rates at 120 weeks for &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; and placebo groups were 58 and 32% (p = 0.003), respectively [&lt;ulink linkType="Reference" linkID="1622748"&gt;1622748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;b&gt;Regulatory Information&lt;/b&gt;&lt;/para&gt;&lt;para&gt;This trial was cited by the FDA in the successful approval (NDA#204384) of Sirturo as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available on 28/12/2012 [&lt;ulink linkType="Reference" linkID="2024766"&gt;2024766&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The trial would be conducted in two consecutive stages, an exploratory (investigative) stage (stage 1) and an efficacy stage (stage 2). During stage 1, a panel of 50 patients would be randomized to receive either &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo for 8 weeks on top of a BR. In stage 2, another panel of 150 patients would be randomized to receive either &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo for 24 weeks on top of a BR.  &lt;/para&gt;&lt;para&gt;When the patients in stage 1 had completed 8 weeks double-blind  treatment with &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo, the primary stage 1 analysis would be performed on all data of the first 8 weeks of treatment. Following the stage 1 analysis, stage 2 would be initiated and a panel of 150 new patients would be enrolled.The primary efficacy analysis would be performed on all stage 2 patients when they had completed the 24-week double-blind treatment with &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo (or have discontinued earlier). After the double-blind treatment phase in both stage 1 and stage 2, patients would continue to receive MDR-TB treatment as per national treatment guidelines. They would be followed for safety, tolerability, pharmacokinetics and microbiological efficacy for 96 weeks after receiving the last dose of &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo. The Data Safety Monitoring Board Committee would review these data on a regular basis.&lt;/para&gt;&lt;para&gt;Patients would  be randomized into two stages:&lt;br/&gt;Stage 1: patients would receive &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo 400 mg (4 tablets) qd for 14 days, 200 mg (2 tablets) tiw for 6 weeks in addition to background regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).&lt;br/&gt;Stage 2: patients would receive &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt; or placebo 400 mg (4 tablets) qd  for 14 days, 200 mg (2 tablets) tiw for 22 weeks in addition to BR for MDR-TB.&lt;/para&gt;&lt;para&gt;Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.&lt;/para&gt;&lt;para&gt;This trial record was relevant for the &lt;b&gt;Accelerated Approval&lt;/b&gt; (NDA #204384) of Sirturo for combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (Mdr-Tb) [&lt;ulink linkType="Reference" linkID="1353290"&gt;1353290&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received a five-drug MDR-TB regimen (plus either placebo or &lt;ulink linkType="Drug" linkID="51310"&gt;TMC-207&lt;/ulink&gt;  for 8 weeks (400 mg qd for 2 weeks followed by 200 mg tiw for 6 weeks) followed by BR for 18 to 24 months of MDR-TB treatment  [&lt;ulink linkType="Reference" linkID="956602"&gt;956602&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="950749"&gt;950749&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1126493"&gt;1126493&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1345192"&gt;1345192&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1622748"&gt;1622748&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>bedaquiline</Name><Drug id="51310">bedaquiline</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication></AdverseEvent><AdverseEvent><Indication id="20">Pain</Indication><CountPatientsAffectedPercentage>17.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication></AdverseEvent><AdverseEvent><Indication id="2434">Vertigo</Indication></AdverseEvent><AdverseEvent><Indication id="3">Acne</Indication><CountPatientsAffectedPercentage>9.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="997">Hearing disorder</Indication><CountPatientsAffectedPercentage>13.0</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="9639">bedaquiline</Intervention><Treatments><Treatment><Dose>200 milligram</Dose><Route></Route></Treatment><Treatment><Dose>400 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><Address1>Rio De Janeiro</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="India"><Sites><Site><Address1>Chennai</Address1><Contacts/></Site><Site><Address1>New Delhi</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Latvia"><Sites><Site><Address1>Stopinu Region</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Peru"><Sites><Site><Address1>Lima</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Philippines"><Sites><Site><Address1>Quezon City</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Address1>Moscow</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Thailand"><Sites><Site><Address1>Chiang Mai</Address1><Contacts/></Site><Site><Address1>Nakhon</Address1><Contacts/></Site><Site><Address1>Nonthaburi</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="South Africa"><Sites><Site><Address1>Bethelsdorp</Address1><Contacts/></Site><Site><Address1>Cape Town</Address1><Contacts/></Site><Site><Address1>Durban</Address1><Contacts/></Site><Site><Address1>George</Address1><Contacts/></Site><Site><Address1>Klerksdorp</Address1><Contacts/></Site><Site><Address1>Sandringham</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Mycobacterium tuberculosis infection</Disease><PatientSegments><PatientSegment><PatientSegment id="8589">Subjects with Pulmonary Tuberculosis</PatientSegment><SubSegments><SubSegment id="8593">Subjects with sputum/smear positive pulmonary tuberculosis</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8606">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="8607">Subjects with multidrug resistant tuberculosis(MDR-TB)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00449644</Identifier><Identifier type="NCT Alias">NCT00614627</Identifier><Identifier type="NCT Alias">NCT00980265</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2007-004462-40</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Mycobacterium tuberculosis infection" id="15041"><Endpoint>Assessment of Microbiological Response</Endpoint><SubEndpoints><SubEndpoint disease="Mycobacterium tuberculosis infection" id="15042">Sputum culture conversion</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Mycobacterium tuberculosis infection" id="15054"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Mycobacterium tuberculosis infection" id="15062"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Mycobacterium tuberculosis infection" id="14260"><Criterion>Subjects with Pulmonary Tuberculosis</Criterion><SubCriteria><SubCriterion disease="Mycobacterium tuberculosis infection" id="14264">Subjects with sputum/smear positive pulmonary tuberculosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Mycobacterium tuberculosis infection" id="14272"><Criterion>Subjects with De Novo Disease Diagnosis</Criterion></Inclusion><Inclusion disease="Mycobacterium tuberculosis infection" id="14282"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Mycobacterium tuberculosis infection" id="14283">Subjects with multidrug resistant tuberculosis(MDR-TB)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Mycobacterium tuberculosis infection" id="11668"><Criterion>Subjects With Extrapulmonary Tuberculosis</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11669"><Criterion>Subjects with Drug Resistant Tuberculosis</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11672"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11681"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11682"><Criterion>Subjects on Prior/Concurrent Anti-tubercular Medications</Criterion></Exclusion><Exclusion disease="Mycobacterium tuberculosis infection" id="11686"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>38.06 Months</EnrollmentPeriod><EnrollmentRate>5.47 Patients/Month</EnrollmentRate><DateFirstReceived>2007-03-16T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-04-02T12:41:17Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="96395"><TitleDisplay>A pilot study to assess the therapeutic effect of intravitreal triamcinolone acetonide (IVTA) injection in the treatment of endothelial graft rejection</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="515">Transplant rejection</Indication></Indications><BiomarkerNames><BiomarkerName id="1005" role="Therapeutic effect marker" type="Genomic;Proteomic">C-X-C motif chemokine 10</BiomarkerName><BiomarkerName id="1651" role="Therapeutic effect marker" type="Genomic;Proteomic">C-X-C chemokine receptor type 3</BiomarkerName><BiomarkerName id="2077" role="Therapeutic effect marker" type="Genomic;Proteomic">C-X-C motif chemokine 9</BiomarkerName><BiomarkerName id="2240" role="Therapeutic effect marker" type="Genomic;Proteomic">C-X-C motif chemokine 11</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ciclosporin, Novartis</Name><Drug id="5999">ciclosporin, Novartis</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>ciclosporin, Novartis</Name><Drug id="5999">ciclosporin, Novartis</Drug></Intervention><Intervention type="InterventionPrimary"><Name>triamcinolone acetonide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5999">ciclosporin, Novartis</Drug><IndicationsPioneer/><Companies><Company><Company id="1045021">Chonnam National University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5999">ciclosporin, Novartis</Drug><IndicationsPioneer/><Companies><Company><Company id="1045021">Chonnam National University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="5999" type="Drug"><TargetEntity id="91277" type="siDrug">Ciclosporin</TargetEntity><TargetEntity id="91277" type="siDrug">Ciclosporin</TargetEntity></SourceEntity><SourceEntity id="1045021" type="Company"><TargetEntity id="5035545190" type="organizationId">Chonnam National University Hospital</TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"/><TargetEntity id="D006084" type="MeSH"/><TargetEntity id="1133" type="siCondition"/></SourceEntity><SourceEntity id="4010" type="Action"><TargetEntity id="1500" type="Mechanism">Calcineurin (PP-2B) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1045021">Chonnam National University Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4010">Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="1669">Emulsion formulation</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="776">Oral gel formulation</Technology><Technology id="80">Peptide</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>24</PatientCountEnrollment><PatientCountEvaluable>24</PatientCountEvaluable><DateStart>2012-10-31T00:00:00Z</DateStart><DateChangeLast>2012-11-01T06:36:20Z</DateChangeLast><DateAdded>2012-11-01T06:36:20Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with acute endothelial graft rejection&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the trial was to evaluate the efficacy of intravitreal injection of triamcinolone acetonide in the treatment of endothelial graft rejection and T-helper type 1 (Th-1) chemokines expression in the aqueous humor [&lt;ulink linkType="Reference" linkID="1335890"&gt;1335890&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2012, results showed that no significant differences were observed in visual acuity, intraocular pressure, and recurrence rate between the two groups. Mean time to improvement was 9.1 +/- 3.9 and 15.4 +/- 5.5 days in groups 1 and 2 (p = 0.04), respectively. Concentrations of CXCL-9, -10, and -11 were 6.7 +/- 6.8 (p &amp;lt; 0.01), 207.5 +/- 209.8 (p &amp;lt; 0.01), and 18.9 +/- 19.5 (p &amp;lt; 0.01) pg/ml, respectively, after treatment and 562.7 +/- 109.4, 30293.1 +/- 12537.1, and 228.3 +/- 80.8 pg/ml, respectively, before treatment. CXCL-10 level was correlated with time to improvement of graft rejection (p = 0.02). Significantly decreased number of CXCR3 and CXCR3CD4 cells were exhibited by flow cytometry in the aqueous humor after treatment [&lt;ulink linkType="Reference" linkID="1335890"&gt;1335890&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study included two groups:&lt;br/&gt;Group 1 (n = 11): patients received intravitreal triamcinolone acetonide injection (4 mg/0.1 ml)  in addition to conventional treatment, including systemic and topical steroids and &lt;ulink linkType="Drug" linkID="5999"&gt;cyclosporine A&lt;/ulink&gt;.&lt;br/&gt;Group 2 (n = 13): patients received conventional treatment only.&lt;br/&gt;In group 1, Th-1 chemokines (CXCL-9, -10, and -11) were evaluated in aqueous humor by enzyme-linked immunosorbent assay and CXCR3 cells were counted by flow cytometry before treatment and at the period of improvement [&lt;ulink linkType="Reference" linkID="1335890"&gt;1335890&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-01T06:36:20Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>